Methods for treating Axl-expressing cancers using anti-Axl antibodies, antibody fragments, and immunoconjugates thereof

JP2023550043A5Inactive Publication Date: 2024-11-12BIOATLA LLC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023528206
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2020-11-12
Filing Date
2021-11-10
Publication Date
2024-11-12
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Current treatments for Axl-expressing cancers, such as soft tissue sarcoma, are palliative and have limited efficacy, with a need for more effective and less toxic options, especially for advanced patients resistant to existing therapies.

Method used

Development of conditionally active anti-Axl antibodies and antibody fragments that exhibit increased binding affinity to Axl in the tumor microenvironment compared to non-tumor environments, allowing for higher doses and more frequent treatments with reduced side effects.

Benefits of technology

Enhances cancer treatment efficacy by targeting Axl-expressing tumors with improved specificity and reduced toxicity, offering a more effective therapeutic option for Axl-expressing cancers like sarcoma and non-small cell lung cancer.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

A method for treating Axl-expressing cancer is provided. The method comprises administering to a subject in need thereof a polypeptide having a heavy chain variable region and / or a light chain variable region that specifically binds to Axl protein, an antibody or antibody fragment comprising the polypeptide, and / or an immunoconjugate thereof. The immunoconjugate compound is a conditionally activated biologic (CAB) anti-Axl antibody linked to one or more drugs via a cleavable linker (CAB-Axl-ADC). The immunoconjugate comprises mAbBA3011-cleavable linker-MMAE. (n) or a pharmaceutically acceptable salt thereof, wherein mAbBA3011 is an antibody or antibody fragment, MMAE is monomethyl auristatin E, and (n) is an integer between 1 and 4. Also provided are immunoconjugates, pharmaceutical compositions, and kits comprising the polypeptides, or antibodies and antibody fragments comprising the polypeptides.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to U.S. Provisional Application No. 63 / 133040, filed November 12, 2020, the entire disclosure of which is specifically incorporated herein by reference. Sequence Listing Reference This application contains a Sequence Listing that has been submitted herewith as a text file entitled "BIAT-1034_Sequence Listing," created on October 14, 2020, and containing 12,000 bytes. The material contained in this text file is hereby incorporated by reference. The present disclosure relates to a method for treating an Axl-expressing cancer, the method comprising administering to a subject in need thereof about 0.3 mg / kg to about 1.8 mg / kg of an anti-Axl antibody, antibody fragment, and / or immunoconjugate of said antibody and antibody fragment once a week. [Background technology]

[0002] Axl proteins (also known as Ark, UFO, and Tyro-7) are receptor tyrosine kinases in the Tyro-3 family of kinases. Tyro-3 receptor kinases are characterized by two immunoglobin-like domains and double fibronectin type III repeats in the extracellular region combined with a cytoplasmic kinase domain. The ligands for Tyro-3 receptor kinase are Gas6 (growth-arrest-specific 6) and Protein S, two vitamin K-dependent proteins that share 43% amino acid sequence identity and similar domain structures. Each protein has an N-terminal Gla domain containing 11 g-carboxyglutamic acid residues, followed by four epidermal growth factor (EGF)-like modules, and a C-terminal sex hormone-binding globin (SHBG)-like structure consisting of two tandem laminin G domains. The SHBG domain is essential and sufficient for Tyro-3 receptor kinase binding and activation, whereas the GIa domain binds negatively charged membrane phospholipids and plays a key role in Tyro-3 kinase-mediated phagocytosis of apoptotic cells.

[0003] Axl activation leads to signaling through PI-3-kinase / Akt (Franke et al., Oncogene, vol. 22, pp. 8983-8998, 2003) and other major pathways, such as Ras / Erk and β-catenin / TCF (Goruppi et al., Mol. Cell. Biol., vol. 21, pp. 902-915, 2001). Axl is weakly expressed in a range of normal tissues, including the brain, heart, skeletal muscle, organ capsules, and connective tissues of several other organs, and is expressed in monocytes but not lymphocytes. Axl-induced Akt phosphorylation has been shown to be upregulated in fibroblasts (Goruppi et al., Mol. Cell. Biol., vol. 17, pp. 4442-4453, 1997), endothelial cells (Hasanbasic et al., Am J Physiol Heart Circ Physiol, vol. 287, H1207-H1213, 2004), vascular smooth muscle cells (Melaragno et al., J. Mol. Cell. Cardiol., vol. 37, pp. 881-887, 2004), and neurons (Allen et al., Mol. Endocrinol., vol. 13, pp. 191-201, 2004). It has been reported that Axl is involved in the survival of platelets (P < 0.05, p < 0.05, 1999). Furthermore, Axl plays a role in cell adhesion and chemotaxis, since Axl knockout animals exhibit impaired platelet aggregate stabilization and thrombus formation as a result of reduced activation of platelet integrin IIb3.

[0004] Dysfunction of Axl or its ligand Gas6 is involved in the pathogenesis of various human cancers. Overexpression of Axl has been demonstrated in various cancer types, such as breast (Meric et al., Clin. Cancer Res., vol. 8, pp. 361-367, 2002; Berclaz et al., Ann.Oncol., vol. 12, pp. 819-824, 2001), colon (Chen et al., Int.J. Cancer, vol. 83, pp. 579-584, 1999; Craven et al., Int.J. Cancer,vol. 60, pp. 791-797, 1995), prostate (Jacob et al., Cancer Detect.Prey., vol. 23, pp. 325-332, 1999), and lung (Wimmel et al., Eur J Cancer, vol. 37, pp. 2264-2274, 2001), stomach (Wu et al., Anticancer Res., vol. 22, pp. 1071-1078, 2002), ovary (Sun et al., Oncology, vol. 66, pp. 450-457, 2004), endometrium (Sun et al., Ann.Oncol., vol. 14, pp. 898-906, 2003), kidney (Sun et al., Ann.Oncol., vol. 14, pp. 898-906, 2003), hepatocyte (Tsou et al., Genomics, vol. 50, pp. 331-340, 1998), thyroid (Ito et al., Thyroid, vol. 12, pp. 971-975, 2002; Ito et al., Thyroid, vol. 9, pp. 563-567, 1999), and also in chronic myeloid leukemia (Janssen et al., Oncogene, vol. 6, pp. 2113-2120, 1991; Braunger et al., Oncogene, vol. 14, pp. 2619-2631, 1997; O'Bryan et al., Mol. Cell. Biol., vol. 11, pp.5016-5031, 1991), acute myeloid leukemia (Rochlitz et al., Leukemia, vol. 13, pp. 1352-1358, 1999), osteosarcoma (Nakano et al., J. Biol. Chem., vol. 270, pp. 5702-5705, 2003), melanoma (van Ginkel et al., Cancer Res., vol. 64, pp. 128-134, 2004), and in head and neck squamous cell carcinoma (Green et al., Br J. Cancer., vol. 94, pp. 1446-5, 2006). .

[0005] Recently, phosphotyrosine signaling profiling has detected activated Axl in approximately 5% of primary tumors of NSCLC (Rikova et al., Cell, vol. 131, pp. 1190-1203, 2007). Axl expression is induced by targeted chemotherapy drugs, and drug-induced Axl expression confers resistance to chemotherapy in acute myeloid leukemia (Hong et al., Cancer Letters, vol. 268, pp. 314-324, 2008). It also conferred resistance to imatinib and lapatinib / Herceptin in gastrointestinal stromal tumors (Mehadevan et al., Oncogene, vol. 26, pp. 3909-3919, 2007) and breast cancer (Liu et al., Cancer Research, vol. 281, pp. 6871-6878, 2009), respectively.

[0006] Furthermore, Axl has been identified as being involved in tumor metastasis, as it is upregulated in invasive breast cancer cell lines compared with non-invasive cells. In vitro, Axl activity was found to be required for migration and invasion, and this activity could be inhibited by antibody treatment (WO 04 / 008147). Similarly, abrogation of Axl activity in vivo via expression of a dominant-negative form of Axl (Vajkoczy, P., et al., Proc. Natl. Acad. Science USA, vol. 103, pp. 5799-5804, 2005) or siRNA-mediated downregulation of Axl (Holland et al., Cancer Res., vol. 65, pp. 9294-9303, 2005) prevented subcutaneous and orthotopic cell growth in mouse xenograft experiments.

[0007] Therefore, anti-Axl monoclonal antibodies have been described for use in cancer treatment.For example, publications relating to anti-Axl antibodies include WO2009 / 063965, WO2009 / 062690, WO2011 / 014457, US2014 / 0227283 and US8,853,369.US2014 / 0227283 discloses monoclonal anti-Axl antibodies and their use in diagnostic and therapeutic methods.WO2009 / 062690 discloses antibodies that can bind to the extracellular domain of Axl protein and at least partially inhibit Axl activity.

[0008] These monoclonal anti-Axl antibodies bind to Axl with similar affinity at any location in a patient's body, such as the location of a tumor intended for treatment. It is predicted that binding of such antibodies to Axl in non-tumor environments may have adverse effects on the normal function of Axl in those environments and thus cause significant side effects. The present invention provides conditionally active anti-Axl antibodies and antibody fragments that have higher binding affinity to Axl in tumor microenvironments compared to their binding affinity to Axl in non-tumor environments. The anti-Axl antibodies and antibody fragments of the present invention are predicted to have comparable or greater anti-cancer efficacy with reduced side effects compared to monoclonal anti-Axl antibodies known in the art. This may also allow for the administration of higher doses or more frequent treatments of anti-Axl antibodies and antibody fragments, thus providing a more effective treatment option.

[0009] Cancer continues to pose a significant health burden worldwide. In the United States (US), it is the second leading cause of death after heart disease, accounting for nearly one in four deaths (American Cancer Society 2011). Treatment of solid tumors presents particular challenges. For example, lung cancer has been the most common cancer worldwide for decades, with an estimated 1.61 million new cases in 2008, accounting for 12.7% of all new cancers. It is also the leading cause of cancer death, accounting for 1.38 million deaths (18.2% of all deaths) (GLOBOCAN 2008). Non-small cell lung cancer (NSCLC) accounts for approximately 80% to 85% of all lung cancer cases. Despite recent advances in immunotherapy (programmed death ligand 1 antibodies) and targeted therapies (e.g., epidermal growth factor receptor and anaplastic lymphoma kinase inhibitors), only a limited proportion of NSCLC patients benefit from these treatments. Summary of the Invention [Problem to be solved by the invention]

[0010] Soft tissue sarcoma (STS) is a cancer of mesenchymal origin that, according to the most recent World Health Organization (WHO) classification (WHO 2013), has over 100 histological subtypes. Furthermore, STS management is challenging, as treatment is primarily palliative and the chances of cure are dramatically reduced. The reported median overall survival is approximately 12–18 months (Cioffi 2012; Martin-Liberal 2014). Unfortunately, despite advances in cancer treatment, there remains an unmet medical need for more effective and less toxic therapies, particularly for patients with advanced disease who do not respond to or who have developed resistance to existing therapies. [Means for solving the problem]

[0011] In one aspect, the present invention provides an isolated polypeptide that specifically binds to an Axl protein, and use of the polypeptide in a method for treating an Axl-expressing tumor comprising administering the polypeptide to a human in need of such treatment.

[0012] The polypeptide of the present invention comprises six complementarity determining regions H1, H2, H3, L1, L2 and L3, the H1 sequence is X1GX2X3MX4 (SEQ ID NO: 1), where X1, X2, X3 and X4 each independently represent an amino acid; X1 is T, A or W; X2 is H or A; X3 is T or I; X4 is N or I; The H2 sequence is LIKX5SNGGTX6YNQKFKG (SEQ ID NO: 2) (X5 and X6 each independently represent an amino acid): X5 is P or N; X6 is S, I, or T; H3 sequence is GX7X8X9X 10 X 11 X 12 X 13 X 14 DYX 15 X 16(SEQ ID NO: 3) (X7, X8, X9, X 10 , X 11 , X 12、 X 13 , X 14 , X 15 and X 16 each independently represents an amino acid) X7 is H or D or E or P or R or W; X8 is Y or N, X9 is E or A or D or F or G or H or I or L or M or N or R or V or Y; X 10 is S or D or M or N or Q, X 11 is Y or C or E or P, X 12 is F or E or N or S or T or V, X 13 is A or D or G or L or Y, X 14 is M, E, or F, X 15 is W or A or D or H or L or N or P or R or T, X 16 is G or H, L1 array is KASQDX 17 X 18 SX 19 VX 20 (SEQ ID NO: 4)(X 17 , X 18 , X 19 , and X 20 each independently represents an amino acid), X 17 is V or D or G or N or W, X 18 is S or V, X 19 is A, L, or M, X 20 is A or D or N or Q, L2 sequence is X21 X 22 X 23 TRX 24 T (SEQ ID NO: 5) (X 21 , X 22 , X 23 , and X 24 each independently represents an amino acid), X 21 is W or F, X 22 is A or I or N or P or Q, X 23 is S or D, X 24 is H or D, L3 array is QEX 25 X 26 SX 27 X 28 X 29 X 30 (SEQ ID NO: 6)(X 25 , X 26 , X 27 , X 28 , X 29 , and X 30 each independently represents an amino acid), X 25 is H or C or F or I or L or Q or S or T or V or Y, X 26 is F or C or D or E or G or N or S, X 27 is T, C, or P, X 28 is P or A or C or D or E or H or K or S or T or V or W, X 29 is L, G, or R, X 30 is T, I, or R, The polypeptides of the present invention exclude parent polypeptides having the following six CDRs: H1 = TGHTMN, H2 = LIKPSNGGTSYNQKFKG, H3 = GHYESYFAMDYWG, L1 = KASQDVSSAVA, L2 = WASTRHT, and L3 = QEHFSTPLT.

[0013] In another embodiment, the present invention provides isolated polypeptides as described above, which have at most one substitution in CDRs H1, H2, and H3 relative to the parent polypeptide, and at most one substitution in CDRs L1, L2, and L3 relative to the parent polypeptide. This includes isolated polypeptides having one substitution in CDRs H1, H2, and H3 relative to the parent polypeptide, isolated polypeptides having one substitution in CDRs L1, L2, and L3 relative to the parent polypeptide, and isolated polypeptides having one substitution in CDRs H1, H2, and H3, and CDRs L1, L2, and L3 relative to the parent polypeptide. Possible combinations of CDRs H1, H2, and H3 are shown in Figure 1A, and possible combinations of CDRs L1, L2, and L3 are shown in Figure 1B.

[0014] In another aspect, the present invention provides an isolated polypeptide that specifically binds to an Axl protein and use of the polypeptide in a method for treating an Axl-expressing tumor comprising administering the polypeptide to a human in need of such treatment, wherein the isolated polypeptide comprises a heavy chain variable region selected from SEQ ID NO: 20 and a light chain variable region selected from SEQ ID NO: 21.

[0015] In yet another aspect, the present invention provides an anti-Axl antibody or antibody fragment, or an immunoconjugate comprising at least one of the above-described isolated polypeptides of the present invention.

[0016] In another aspect, the invention provides methods of using the anti-Axl antibodies or antibody fragments, or immunoconjugates described above for the treatment of Axl-expressing tumors.

[0017] In yet another aspect, the present invention provides an immunoconjugate comprising an antibody or antibody fragment of the present invention, optionally conjugated to an agent selected from a chemotherapeutic agent, a radioactive atom, a cytostatic agent, and a cytotoxic agent, and provides a method for treating an Axl-expressing tumor, comprising administering such an immunoconjugate.

[0018] In one embodiment, the immunoconjugate is an antibody-drug conjugate (ADC) in which a conditionally active active biologic (CAB) anti-Axl antibody is linked to one or more heterologous molecules via a cleavable linker (CAB-Axl-ADC). The CAB-Axl-ADC is composed of mAbBA3011-cleavable linker-MMAE. (n) wherein the heterologous molecule is monomethyl auristatin E (MMAE) and (n) is an integer between 1 and 4, inclusive.

[0019] In yet another aspect, the present invention provides a method for administering mAbBA301-cleavable linker-MMAE to a human subject in need of such treatment. (n) wherein mAbBA301 is an antibody or antibody fragment having a heavy chain variable region comprising hcCDR1 of SEQ ID NO: 14, hcCDR2 of SEQ ID NO: 15, and hcCDR3 of SEQ ID NO: 16, and a light chain variable region comprising lcCDR1 of SEQ ID NO: 17, lcCDR2 of SEQ ID NO: 18, and lcCDR3 of SEQ ID NO: 19; MMAE is monomethyl auristatin E (MMAE), and (n) is an integer between 1 and 4 (inclusive).

[0020] In yet another aspect, the present invention provides a pharmaceutical composition comprising a polypeptide, antibody or antibody fragment, or immunoconjugate of the invention together with a pharmaceutically acceptable carrier.

[0021] In yet another aspect, the present invention provides a diagnostic or therapeutic kit comprising a polypeptide, antibody or antibody fragment, or immunoconjugate of the present invention and instructions for use for diagnosing or treating an Axl-expressing tumor.

[0022] In another aspect, the present invention provides a method for administering mAbBA301 cleavable linker-MMAE to a human subject in need of such treatment. (n) and a pharmaceutically acceptable carrier, wherein the pharmaceutical composition is administered by intravenous infusion on days 1 and 8 every 21 days at a dose of 1.8 mg / kg of human subject body weight. mAbBA301 is an antibody or antibody fragment having a heavy chain variable region comprising an hcCDR1 of SEQ ID NO: 14, an hcCDR2 of SEQ ID NO: 15, and an hcCDR3 of SEQ ID NO: 16, and a light chain variable region comprising an lcCDR1 of SEQ ID NO: 17, an lcCDR2 of SEQ ID NO: 18, and an lcCDR3 of SEQ ID NO: 19; and (n) is an integer between 1 and 4 (inclusive), preferably, (n) is equal to 4.

[0023] In one embodiment, the heavy chain variable region of mAbBA301 comprises SEQ ID NO:20 and the light chain variable region of mAbBA301 comprises SEQ ID NO:21.

[0024] In a further embodiment, the cleavable linker is mc-vc-PAB.

[0025] In a further embodiment, the Axl-expressing tumor is a sarcoma, an adenocarcinoma, or a non-small cell lung cancer, preferably the Axl-expressing tumor is a sarcoma.

[0026] In a further embodiment, the method further comprises administering a programmed death receptor-1 (PD-1) blocking antibody.

[0027] In a further embodiment, the Axl-expressing tumor has a tumor membrane P-score of at least 70.

[0028] In a further embodiment, the method further comprises administering a granulocyte colony-stimulating factor or an analog thereof.

[0029] In a further embodiment, the pharmaceutically acceptable carrier has a pH of 6.0 and comprises 20 mM histidine-HCl, 70 mg / mL sucrose and 0.5 mg / mL polysorbate 80. [Brief explanation of the drawings]

[0030] [Figure 1] 1A-B show sequence alignments of the heavy and light chain variable regions, respectively, of anti-Axl antibodies of the present invention.

[0031] [Figure 2] 2 shows the binding (OD450) of various conditionally active antibodies of the invention to the Axl extracellular domain at pH 6.0 and pH 7.4. These conditionally active antibodies were more active at pH 6.0 than at pH 7.4.

[0032] [Figure 3] Figure 3 shows the selectivity of various conditionally active antibodies of the invention for the Axl extracellular domain, measured as the ratio of the binding affinity for a binding partner at pH 6.0 to the binding affinity for the same binding partner at pH 7.4.

[0033] [Figure 4] FIG. 4 shows a size exclusion chromatogram demonstrating that the conditionally active antibodies of the invention do not aggregate, as described in Example 1.

[0034] [Figure 5] FIG. 5 shows the thermal stability of a conditionally active antibody of the invention before and after heat shock as measured by ELISA assay, as described in Example 1.

[0035] [Figure 6] 6A-B show the selectivity of the conditionally active antibodies of the present invention as measured by the SPR assay in Example 1.

[0036] [Figure 7] FIG. 7 shows the pH-dependent binding profile for the binding of anti-Axl antibodies of the invention to Axl in KREBS buffer.

[0037] [Figure 8] 8A-E show the results of another cell killing assay using A549 cells, in which anti-Axl antibodies of the invention were used for cell killing at pH 6.0 and pH 7.4 at different antibody concentrations.

[0038] [Figure 9] 9A-D show the binding affinity to human Axl and cynomolgus monkey Axl for anti-Axl antibodies of the invention in different buffers and at different pH levels.

[0039] [Figure 10] Figures 10A-H show cell killing of different cell lines at different pH levels by anti-Axl antibodies of the invention conjugated to duomycin.

[0040] [Figure 11] FIG. 11 shows cell killing of A549 cells at different pH levels by anti-Axl antibodies of the invention conjugated to gemcitabine.

[0041] [Figure 12] FIG. 12 shows the effect on tumor volume of treatment of xenografted mice with duomycin-conjugated anti-Axl antibodies of the invention.

[0042] [Figure 13] 13A-B show detection of the presence of duomycin-conjugated anti-Axl antibodies of the invention in the blood of cynomolgus monkeys over time following injection of the conjugate.

[0043] [Figure 14A]FIG. 14A shows the detection of the presence of aspartate transaminase (AST) in the blood of cynomolgus monkeys over time, starting just before injection of the conjugate (Pre (D-3)) and ending 3 days after injection (Post (D-3)).

[0044] [Figure 14B] FIG. 14B shows the detection of the presence of alanine aspartate transaminase (ALT) in the blood of cynomolgus monkeys over time, starting just before injection of the conjugate (Pre (D-3)) and ending 3 days after injection (Post (D-3)).

[0045] [Figure 15] FIG. 15 shows lymphocyte counts over time in the blood of cynomolgus monkeys after injection of the conjugate.

[0046] [Figure 16] 16A-B show the in vivo treatment of mice receiving LCLC103H and DU145, respectively.

[0047] [Figure 17] Figures 17A-D show the antitumor effect of BA3011 in a xenograft mouse model. The antitumor effect of BA3011 was demonstrated in vivo using xenograft tumors derived from human tumor cell lines expressing Axl in immunodeficient animals. NSCLC (LCLC103H; Figure 17A), prostate (DU145; Figure 17B), and pancreatic tumor (MIAPaCa2; Figure 17C) tumor cell lines were tested in this in vivo mouse model system.

[0048] [Figure 18] FIG. 18 is an exemplary dose escalation flow chart.

[0049] [Figure 19] An exemplary dosing schedule is shown in FIG.

[0050] [Figure 20]Figure 20 shows the total change in target lesions in patients treated with BA3011-CAB-Axl-ADC-MMAE at 1.8 mg / kg Q3W or 2 Q3W. AXL cytoplasmic scoring in the tumor membrane percent score (TmPS) is calculated by summing the percentage of intensities that are either ≥1+, ≥2+, or ≥3+. Thus, the score ranges from 0 to 100. Patients with indistinguishable tumor membrane and tumor cytoplasmic scores are excluded.

[0051] [Figure 21] FIG. 21 shows the mean H-score of Axl cell membrane by cancer indication.

[0052] [Figure 22] Figure 22 shows the percent change in total target lesion count (best response) in sarcoma patients with Axl TmPS > 70 from a Phase 1 study of 1.8 mg / kg Q3W (d1) or 2Q3W (d1,8) doses.

[0053] [Figure 23] FIG. 23 shows the percent change in total target lesions (best response) by Axl TmPS category across all doses tested in evaluable sarcoma patients in a Phase 1 study.

[0054] [Figure 24] Figure 24 shows the percent change in total target lesions by visit and Axl TmPS category at all doses tested in evaluable sarcoma patients in the Phase 1 study. DETAILED DESCRIPTION OF THE INVENTION

[0055] definition To facilitate understanding of the examples provided herein, certain frequently used terms are defined herein.

[0056] The term "about," as used herein in connection with a measured quantity, refers to normal variations in the measured quantity that would be expected by one of ordinary skill in the art making and handling the measurement commensurate with the purpose of the measurement and the precision of the measuring device used. Unless otherwise indicated, "about" refers to a + / - 10% variation of the provided value.

[0057] The term "affinity," as used herein, refers to the strength of the sum of non-covalent interactions between a single binding site of a molecule (e.g., an antibody) and its binding partner (e.g., an antigen). Unless otherwise indicated, as used herein, "binding affinity" refers to the intrinsic binding affinity that reflects a 1:1 interaction between members of a binding pair (e.g., an antibody and an antigen). The affinity of molecule X for partner Y can generally be expressed by the dissociation constant (Kd). Affinity can be measured by common methods known in the art, including those described herein. Specific illustrative and exemplary embodiments for measuring binding affinity are described below.

[0058] The term "affinity matured," when used in reference to an antibody, refers to an antibody or antibody fragment with one or more alterations in one or more hypervariable regions (HVRs) compared to a parent antibody or antibody fragment that does not possess the alterations, which alterations result in an improvement in the affinity of the antibody or antibody fragment for an antigen.

[0059] As used herein, the term "amino acid" refers to any organic compound containing an amino group (--NH) and a carboxyl group (--COOH), preferably either as a free group or alternatively after condensation as part of a peptide bond. "The 20 naturally encoded polypeptide-forming α-amino acids" are art-recognized and refer to alanine (ala or A), arginine (arg or R), asparagine (asn or N), aspartic acid (asp or D), cysteine ​​(cys or C), glutamic acid (glu or E), glutamine (gin or Q), glycine (gly or G), histidine (his or H), isoleucine (ile or I), leucine (leu or L), lysine (lys or K), methionine (met or M), phenylalanine (phe or F), proline (pro or P), serine (ser or S), threonine (thr or T), tryptophan (tip or W), tyrosine (tyr or Y), and valine (val or V).

[0060] As used herein, the term "agent" refers to an element, compound, or molecular entity, including, for example, a drug, therapeutic, or pharmacological compound. Agents can be natural or synthetic, or a combination thereof.

[0061] An "anticancer agent" is an agent that, alone or in combination with other agents as part of a treatment regimen, exerts a cytotoxic or cytostatic effect on cancer cells. For example, an anticancer agent is an agent that can inhibit tumor growth, halt tumor growth, and / or cause regression of an existing tumor.

[0062] As used herein, the term "antiangiogenic agent" refers to a compound that blocks or prevents the development of blood vessels to some extent.Antiangiogenic agents can be, for example, small molecules or antibodies that bind to growth factors or growth factor receptors involved in promoting angiogenesis.In one embodiment, the antiangiogenic agent is an antibody or antibody fragment that binds to vascular endothelial growth factor (VEGF), such as bevacizumab (AVASTIN®).

[0063] "Cytotoxic effect" refers to the inhibition of cell proliferation. "Cytotoxic agent" refers to an agent that has a cytotoxic or cytostatic effect on cells, thereby depleting or inhibiting the growth of individual cells in a cell population. As used herein, the term "antibody fragment" refers to a molecule other than an intact antibody that contains a portion of an intact antibody that binds to the antigen bound by the intact antibody. Examples of antibody fragments include, but are not limited to, Fv, Fab, Fab', Fab'-SH, F(ab')2; diabodies; linear antibodies; and single-chain antibody molecules (e.g., scFv). These antibody fragments, which retain some ability to selectively bind to the antigen (e.g., polypeptide antigen) of the antibody from which they are derived, can be generated using methods well known in the art (see, e.g., Harlow and Lane, supra).

[0064] As used herein, the term "antibody" refers to an intact immunoglobulin molecule. Antibodies or antibody fragments can be used to isolate preparative amounts of antigens by immunoaffinity chromatography. Various other uses of such antibodies or antibody fragments are for diagnosing and / or staging diseases (e.g., neoplasia), as well as for therapeutic applications to treat diseases such as neoplasia, autoimmune diseases, AIDS, cardiovascular diseases, infectious diseases, etc. Chimeric, human-like, humanized, or fully human antibodies or antibody fragments are particularly useful for administration to human patients.

[0065] A Fab fragment consists of a monovalent antigen-binding fragment of an antibody molecule and can be produced by digestion of whole antibody molecules with the enzyme papain to yield a fragment consisting of an intact light chain and a portion of the heavy chain.

[0066] Fab' fragments of antibody molecules can be obtained by treating whole antibody molecules with pepsin, followed by reduction, to yield molecules consisting of an intact light chain and a portion of the heavy chain, resulting in two Fab' fragments per antibody molecule so treated.

[0067] The (Fab')2 fragment of an antibody can be obtained by treating whole antibody molecules with the enzyme pepsin without subsequent reduction. The (Fab')2 fragment is a dimer of two Fab' fragments held together by two disulfide bonds.

[0068] An Fv fragment is defined as a genetically engineered fragment containing the variable region of a light chain and the variable region of a heavy chain expressed as two chains.

[0069] As used herein, the terms "anti-Axl antibody," anti-Axl antibody fragment, and "antibody or antibody fragment that binds to Axl" refer to an antibody or antibody fragment that can bind to Axl with sufficient affinity such that the antibody or antibody fragment is useful as a diagnostic and / or therapeutic agent in targeting Axl. In one embodiment, the extent of binding of an anti-Axl antibody or antibody fragment to an unrelated, non-Axl protein is less than about 10% of the binding of the antibody or antibody fragment to Axl, as measured, for example, by radioimmunoassay (RIA). In certain embodiments, an antibody or antibody fragment that binds to Axl has an affinity of ≦1 μM, ≦100 nM, ≦10 nM, ≦1 nM, ≦0.1 nM, ≦0.01 nM, or ≦0.001 nM (e.g., ≦10 -8 M or less, or 10 -8 M~10 -13 M, or 10 -9 M~10 -13 In certain embodiments, the anti-Axl antibody or antibody fragment binds to an epitope of Axl that is conserved among Axl from different species.

[0070] As used herein, the term "angiogenic disorder" refers to any dysfunction of angiogenesis, including both non-neoplastic and neoplastic conditions, including but not limited to those described below (see, e.g., "cancer"). Non-neoplastic diseases include, but are not limited to, unwanted or abnormal hypertrophy, arthritis, rheumatoid arthritis (RA), psoriasis, psoriatic plaque, sarcoidosis, atherosclerosis, atherosclerotic plaque, proliferative retinopathies such as diabetic retinopathy and retinopathy of prematurity, retrolental fibroplasia, neovascular glaucoma, age-related macular degeneration and the like, diabetic macular edema, corneal neovascularization, corneal graft neovascularization, corneal graft rejection, retinal / choroidal neovascularization, corneal neovascularization (rubeosis), ocular neovascular disease, vascular restenosis, arteriovenous malformations (AVM), meningiomas, hemangiomas, angiofibromas, hyperthyroidism (including Grave's disease), corneal and other tissue disorders. Tissue transplant, chronic inflammation, pneumonia, acute lung injury / ARDS, sepsis, primary pulmonary hypertension, malignant pulmonary edema, cerebral edema (e.g., following acute stroke / closed head injury / trauma), synovial inflammation, pannus formation in RA, myositis ossificans, hypertrophic osteogenesis imperfecta, osteoarthritis (OA), refractory ascites, polycystic ovarian disease, endometriosis, third space fluid disorders (pancreatitis, compartment syndrome, burns, bowel disease), uterine fibroids, preterm labor, chronic inflammation such as IBD (Crohn's disease, ulcerative colitis), kidney transplant rejection, inflammatory bowel disease, nephrotic syndrome, unwanted or abnormal tissue mass growth (non-cancerous), hemophilic arthropathy, hypertrophic scarring, and hair growth inhibition Osler-Weber syndrome, pyogenic granulomatous retrolental fibroplasia, scleroderma, trachoma, vascular adhesions, synovitis, dermatitis, preeclampsia, ascites, pericardial effusion (including those associated with pericarditis), pleural effusion.

[0071] As used herein, the term "angiogenesis" refers to all Axl-related processes that contribute to the growth of new blood vessels from existing vessels, particularly, but not limited to, new tumor-supplying vessels. These processes include multiple cellular events, such as proliferation, survival, migration, and sprouting of vascular endothelial cells, attraction and migration of pericytes, and basement membrane formation for vascular stabilization, vascular perfusion, or secretion of angiogenic factors by stromal or neoplastic cells, which are stimulated or mediated by the non-catalytic or catalytic activity of Axl, preferably, for example, Axl phosphorylation and / or Axl-mediated signal transduction.

[0072] As used herein, the term "Axl" refers to any native Axl from any vertebrate source, for example, mammals, such as primates (e.g., humans) and rodents (e.g., mice and rats), unless otherwise specified. This term encompasses "full-length" unprocessed Axl and any form of Axl resulting from processing in cells. This term also encompasses naturally occurring variants of Axl, such as splice variants or allelic variants. The amino acid sequence of human Axl is well known in the art and is available from public databases, such as GenBank.

[0073] As used herein, the term "Axl activation" refers to the activation or phosphorylation of the Axl receptor. Generally, Axl activation results in signal transduction (e.g., caused by the intracellular kinase domain of Axl or the Axl receptor phosphorylating tyrosine residues in a substrate polypeptide). Axl activation can be mediated by the binding of an Axl ligand (Gas6) to the target Axl receptor. Gas6 binding to Axl can activate the kinase domain of Axl, thereby resulting in the phosphorylation of tyrosine residues in Axl and / or the phosphorylation of tyrosine residues in an additional substrate polypeptide.

[0074] As used herein, the term "Axl-mediated anti-apoptosis" refers to any Axl-involved process that prevents human cells, preferably, but not limited to, human cancer cells, from undergoing programmed cell death (apoptosis). In particular, it refers to a process that prevents human cells, preferably, but not limited to, human cancer cells, from undergoing apoptosis via growth factor withdrawal, hypoxia, exposure to chemotherapeutic agents or radiation, or the initiation of Fas / Apo-1 receptor-mediated signaling, and is stimulated or mediated by the non-catalytic or catalytic activity of Axl, preferably, for example, Axl phosphorylation and / or Axl-mediated signaling.

[0075] The term "binding" as used herein refers to the interaction of an antibody variable region or Fv with an antigen, with the interaction being dependent on the presence of a specific structure (e.g., an antigenic determinant or epitope) on the antigen. For example, an antibody variable region or Fv recognizes and binds to a specific protein structure rather than proteins in general. As used herein, the terms "specifically binding" or "binding specifically" mean that an antibody variable region or Fv binds or associates with a particular antigen more frequently, rapidly, for a longer duration, and / or with a higher affinity than with other proteins. For example, an antibody variable region or Fv specifically binds to the antigen with higher affinity, avidity, ease, and / or duration than it binds to other antigens. In another example, an antibody variable region or Fv binds to a cell surface protein (antigen) with substantially higher affinity than the affinity for related proteins or other cell surface proteins or antigens commonly recognized by polyreactive natural antibodies (i.e., natural antibodies known to bind to a variety of antigens naturally found in humans). However, "specifically binds" does not necessarily require exclusive or undetectable binding of another antigen, as is meant by the term "selective binding." In one example, "specific binding" of an antibody variable region or Fv (or other binding region) that binds to an antigen means that the antibody variable region or Fv binds to the antigen with an equilibrium constant (KD) of 100 nM or less, e.g., 50 nM or less, e.g., 20 nM or less, e.g., 15 nM or less, or 10 nM or less, or 5 nM or less, 2 nM or less, or 1 nM or less.

[0076] As used herein, the terms "cancer" and "cancerous" refer to or describe a physiological condition in mammals that is typically characterized by unregulated cell growth / proliferation. Examples of cancer include, but are not limited to, carcinoma, lymphoma (e.g., Hodgkin's and non-Hodgkin's lymphoma), blastoma, sarcoma, and leukemia. More specific examples of such cancer include squamous cell carcinoma, small cell lung cancer, non-small cell lung cancer, lung adenocarcinoma, lung squamous cell carcinoma, peritoneal cancer, hepatocellular carcinoma, gastrointestinal cancer, pancreatic cancer, glioma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, hepatoma, breast cancer, colon cancer, colorectal cancer, endometrial or uterine cancer, salivary gland cancer, kidney cancer, liver cancer, prostate cancer, vulvar cancer, thyroid cancer, liver cancer, leukemia and other lymphoproliferative disorders, and various types of head and neck cancer.

[0077] As used herein, the terms "cell proliferative disorder" and "proliferative disorder" refer to disorders associated with some degree of abnormal cell proliferation. In one embodiment, the cell proliferative disorder is cancer.

[0078] As used herein, the term "chemotherapeutic agent" refers to a chemical compound useful in the treatment of cancer. Examples of chemotherapeutic agents include alkylating agents such as thiotepa and cyclophosphamide (CYTOXAN®); alkylsulfonates such as busulfan, improsulfan, and piposulfan; aziridines such as benzodopa, carboquone, meturedopa, and uredopa; ethylenimines and methylamelamines, including altretamine, triethylenemelamine, triethylenephosphoramide, triethylenethiophosphoramide, and trimethylmelamine; acetogenins, particularly delta-9-tetrahydrocannabinol (dronabinol, MARINOL®); beta-lapachone; lapachol; colchicine; betulinic acid; camptothecins (including synthetic analogs topotecan (HYCAMTIN®), CPT-11 (irinotecan, CAMPTOSAR®), acetylcamptothecin, scopolectin, and 9-aminocamptothecin); bryostatin; kallistatin; CC-1065 (and including synthetic analogs of adozelesin, carzelesin, and bizelesin; podophyllotoxin; podophyllic acid; teniposide; cryptophycins (especially cryptophycin 1 and cryptophycin 8); dolastatins; duocarmycins (including synthetic analogs KW-2189 and CB1-TM1); eluterobin; pancratistatin; sarcodictin; spongistatin; chlorambucil, chlornaphazine, chlorophosphamide, estramustine, ifosfamide, metronidazole, methadone ... nitrogen mustards such as chlorethamine, mechlorethamine oxide hydrochloride, melphalan, novembitine, fenesterine, prednimustine, trofosfamide, uracil mustard; nitrosoureas such as carmustine, chlorozotocin, fotemustine, lomustine, nimustine, and ranimustine; antibiotics such as enediyne antibiotics (e.g., calicheamicin, particularly calicheamicin gamma 11 and calicheamicin omega 11 (see, e.g., Nicolaou et al., Angew. Chem. Intl. Ed. Engl., 33:183-186 (1994)); the oral alpha-4 integrin inhibitor CDP323;Dynemicins, including dynemicin A; esperamicin; and neocarzinostatin chromophores and related chromoprotein enediyne antibiotic chromophores), aclacinomycin, actinomycin, autramycin, azaserine, bleomycin, cactinomycin, carabicin, caminomycin, carzinophilin, chromomycin, dactinomycin, daunorubicin, detorubicin, 6-diazo-5-oxo-L-norleucine, doxorubicin (ADRIAMYCIN®), morpholino-doxorubicin, cyanomorpholino-doxorubicin, 2-pyrrolino-doxorubicin, doxorubicin HCl liposome injection (DOXIL®), liposomal doxorubicin TLC D-99 (MYOCET®), peglylated liposomal doxorubicin (including CAELYX®, and deoxydoxorubicin), mitomycins such as epirubicin, esorubicin, idarubicin, marcelomycin, mitomycin C, mycophenolic acid, nogalamycin, olivomycin, peplomycin, porfiromycin, puromycin, chelamycin, lodorubicin, streptonigrin, streptozocin, tubercidin, ubenimex, zinostatin, zorubicin; antimetabolites such as methotrexate, gemcitabine (GEMZAR®), tegafur (UFTORAL®), capecitabine (XELODA®), epothilones, 5-fluorouracil (5-FU); denopterin, Folic acid analogues such as methotrexate, pteropterin, and trimetrexate; purine analogues such as fludarabine, 6-mercaptopurine, thiamiprine, and thioguanine; pyrimidine analogues such as ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine, and floxuridine; androgens such as calucelone, dromostanolone propionate, epitiostanol, mepitiostane, and testolactone; antiadrenal agents such as aminoglutethimide, mitotane, and trilostane; folic acid supplements such as furoic acid; aceglatone; aldophosphamide glycosides; aminolevulinic acid; eniluracil; amsacrine; bestravcil; bisantrene; edatraxate; defofamine; demecolcine;Diazicon; elformitin; elliptinium acetate; epothilone; etoglucide; gallium nitrate; hydroxyurea; lentinan; lonidynin; maytansinoids such as maytansine and ansamitocin; mitoguazone; mitoxantrone; mopidanmol; nitraelin; pentostatin; phenamet; pirarubicin; losoxantrone; 2-ethylhydrazide; procarbazine; PSK® polysaccharide complex (JHS Natural Products, Eugene, Oreg.); razoxane; rhizoxin; sizofiran; spirogermanium; tenuazonic acid; triazicon; 2,2',2'-trichlorotriethylamine; trichothecenes (especially T-2 toxin, veracrine A, roridin A, anguidine); urethane; vindesine (ELDISINE®, FILDESIN®); dacarbazine; mannomustine; mitobronitol; mitolactol; pipobroman; gacytosine; arabinoside ("Ara-C"); thiotepa; taxoids, such as paclitaxel (TAXOL®), albumin-modified nanoparticle formulation of paclitaxel (ABRAXANE™), and docetaxel (TAXOTERE®); chlorambucil; 6-thioguanine; mercaptopurine; methicone platinum agents such as cisplatin, oxaliplatin (e.g., ELOXATIN®), and carboplatin; vincas that prevent tubulin polymerization to form microtubules, such as vinblastine (VELBAN®), vincristine (ONCOVIN®), vindesine (ELDISINE®, FILDESIN®), and vinorelbine (NAVELBINE®); etoposide (VP-16); ifosfamide; mitoxantrone; leucovorin; novantrone; edatrexate; daunomycin; aminopterin; ibandronate; the topoisomerase inhibitor RFS2000; difluoromethylornithine (DMF®); retinoids such as retinoic acid, including bexarotene (TARGRETIN®);clodronate (e.g., BONEFOS® or OSTAC®), etidronate (DIDROCAL®), bisphosphonates such as NE-58095, zoledronic acid / zoledronate (ZOMETA®), alendronate (FOSAMAX®), pamidronate (AREDIA®), tiludronate (SKELID®), or risedronate (ACTONEL®); troxacitabine (1,3-dioxolane nucleoside cytosine analog); antisense oligonucleotides, particularly those that inhibit the expression of genes in signal transduction pathways involved in abnormal cell proliferation, such as, for example, PKC-α, Raf, H-Ras, and epidermal growth factor receptor (EGF-R); vaccines such as the THERATOPE® vaccine and gene therapy vaccines, for example, the ALLOVECTIN® vaccine, the LEUVECTIN® vaccine, and the VAXID® vaccine; topoisomerase 1 inhibitors (e.g., LURTOTECAN®); rmRH (e.g., ABARELIX®); BAY439006 (sorafenib, Bayer); SU-11248 (sunitinib, SUTENT®, Pfizer); perifosine, COX-2 inhibitors (e.g., celecoxib or etoricoxib), proteosome inhibitors (e.g., PS341); bortezomib (VELCADE®); CCI-779; tipifarnib (R11577); orafenib, ABT510; Bcl-2 inhibitors such as oblimersen sodium (GENASENSE®); pixantro EGFR inhibitors (see definition below); tyrosine kinase inhibitors (see definition below); serine-threonine kinase inhibitors such as rapamycin (sirolimus, RAPAMUNE®); farnesyltransferase inhibitors such as lonafarnib (SCH6636, SARASAR™); and pharmaceutically acceptable salts, acids, or derivatives of any of the above; combinations of two or more of the above, such as CHOP (an abbreviation for cyclophosphamide, doxorubicin, vincristine, and prednisolone combination therapy);and FOLFOX (an abbreviation for a treatment regimen with oxaliplatin (ELOXATIN™) in combination with 5-FU and leucovorin);

[0079] Chemotherapeutic agents, as defined herein, include "antihormonal agents" or "endocrine therapeutic agents" that act to regulate, reduce, block, or inhibit the effects of hormones that may promote cancer growth. They may themselves be hormones, including, but not limited to, antiestrogens with mixed agonist / antagonist profiles, including selective estrogen receptor modulators (SERMs) such as tamoxifen (NOLVADEX®), 4-hydroxytamoxifen, toremifene (FARESTON®), idoxifene, droloxifene, raloxifene (EVISTA®), trioxifene, keoxifene, and SERM3; pure antiestrogens without the agonist properties of fulvestrant (FASLODEX®) and EM800 (agents that may block estrogen receptor (ER) dimerization, inhibit DNA binding, increase ER turnover, and / or suppress ER levels); aromatase inhibitors, including steroidal aromatase inhibitors such as formestane and exemestane (AROMASIN®), as well as anastrazole (ARIMIDEX®), letrozole (FEMARA®). and aminoglutethimide, and other aromatase inhibitors including vorozole (RIVISOR®), megestrol acetate (MEGASE®), fadrozole, and 4(5)-imidazole; luteinizing hormone-releasing hormone agonists including leuprolide (LUPRON® and ELIGARD®), goserelin, buserelin, and triptorelin; progestins such as megestrol acetate and medroxyprogesterone acetate, estrogens such as diethylstilbestrol and premarin, sex steroids including androgens / retinoids such as fluoxymesteron, all-trans retionic acid, and fenretinide; onapristone; antiprogesterones; estrogen receptor downregulators (ERDs); antiandrogens such as flutamide, nilutamide, and bicalutamide; and pharmaceutically acceptable salts, acids, or derivatives of any of the above; and combinations of two or more of the above.

[0080] As used herein, the term "chimeric" antibody refers to an antibody in which a portion of the heavy and / or light chain is derived from a particular source or species, and the remainder of the heavy and / or light chain is derived from a different source or species.

[0081] As used herein, the term "class" of an antibody refers to the type of constant domain or constant region carried by its heavy chain. There are five major antibody classes: IgA, IgD, IgE, IgG, and IgM, several of which can be further divided into subclasses (isotypes), e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2. The heavy chain constant domains corresponding to the different immunoglobulin classes are called α, δ, ε, γ, and μ, respectively.

[0082] As used herein, the terms "conditionally active antibody" and "conditionally active antibody fragment" refer to an antibody or antibody fragment that is active under conditions in a tumor microenvironment compared to different values ​​of the same conditions in a non-tumor microenvironment. When compared to conditions in a non-tumor microenvironment, conditions in a tumor microenvironment can include lower pH, higher concentrations of lactate and / or pyruvate, low oxygen, lower concentrations of glucose, and slightly higher temperatures. For example, in one embodiment, a conditionally active antibody or antibody fragment may be substantially inactive at normal body temperature but active at higher temperatures than can be found in a tumor microenvironment. In yet another embodiment, a conditionally active antibody or antibody fragment may be less active in normal oxygenated blood than in the hypoxic environment that can exist in a tumor microenvironment. Other conditions in the tumor microenvironment known to those skilled in the art may also be selected for use as conditions in the present invention that can induce an anti-Axl antibody or antibody fragment to have different activities under different values ​​of the conditions.

[0083] As used herein, the term "constitutive," when applied to, for example, Axl activity, refers to the continuous signaling activity of receptor kinases that is not dependent on the presence of ligands or other activating molecules. Depending on the nature of the receptor kinase, all of the activity may be constitutive, or the receptor's activity may be further activated by the binding of other molecules (e.g., ligands). Cellular events that lead to receptor kinase activation are well known to those skilled in the art. For example, activation can include oligomerization into higher-order receptor complexes, such as dimerization and trimerization. A complex may contain a single protein species, i.e., a homocomplex. Alternatively, a complex may contain at least two different protein species, i.e., a heterocomplex. Complex formation can be induced, for example, by overexpression of a normal or mutant form of the receptor on the surface of a cell. Complex formation can also be induced by one or more specific mutations in the receptor.

[0084] The term "cytostatic agent" as used herein refers to a compound or composition that arrests cell proliferation either in vitro or in vivo. Thus, a cytostatic agent may significantly reduce the proportion of cells in S phase. Further examples of cytostatic agents include agents that block cell cycle progression by inducing G0 / G1 arrest or M-phase arrest. Trastuzumab (HERCEPTIN®), a humanized anti-Her2 antibody, is an example of a cytostatic agent that induces G0 / G1 arrest. Classical M-phase blockers include vincas (vincristine and vinblastine), taxanes, and topoisomerase II inhibitors (such as doxorubicin, epirubicin, daunorubicin, etoposide, and bleomycin). Certain agents that arrest G1, e.g., DNA alkylating agents such as tamoxifen, prednisone, dacarbazine, mechlorethamine, cisplatin, methotrexate, 5-fluorouracil, and ara-C, also spill over into S-phase arrest. Further information can be found in Mendelsohn and Israel, eds., The Molecular Basis of Cancer, Chapter 1, entitled "Cell cycle regulation, oncogenes, and anticancer drugs" by Murakami et al. (WB Saunders, Philadelphia, 1995), e.g., p. 13. Taxanes (paclitaxel and docetaxel) are anticancer drugs both derived from the yew tree. Docetaxel (TAXOTERE®, Rhone-Poulenc Rorer), derived from the European yew, is a semisynthetic analog of paclitaxel (TAXOL®, Bristol-Myers Squibb). Paclitaxel and docetaxel promote the assembly of microtubules from tubulin dimers and stabilize microtubules by preventing depolymerization, leading to the inhibition of mitosis in cells.

[0085] The term "cytotoxic agent," as used herein, refers to a substance that inhibits or prevents cell function and / or causes cell death or destruction. Cytotoxic agents include, but are not limited to, radioisotopes (e.g., At 211 , I 131 , I 125 , Y 90 ,Re 186 ,Re 188 , Sm 153 , Bi 212 , P 32 , Pb 212 , and radioactive isotopes of Lu), chemotherapeutic agents or drugs (e.g., methotrexate, adriamycin, vinca alkaloids (vincristine, vinblastine, etoposide), doxorubicin, melphalan, mitomycin C, chlorambucil, daunorubicin, or other intercalating agents), growth inhibitory agents, enzymes such as nucleases and fragments thereof, antibiotics, toxins such as small molecule toxins or enzymatically active toxins of bacterial, fungal, plant, or animal origin, including fragments and / or variants thereof, and various anti-tumor or anti-cancer agents disclosed below.

[0086] As used herein, the term "diabody" refers to a small antibody fragment with two antigen-binding sites, which are bound to the same polypeptide chain (V H -V L ) light chain variable domain (V L ) bound to the heavy chain variable domain (V H ). By using a linker that is too short to allow pairing between the two domains on the same chain, the domains are forced to pair with the complementary domains of another chain and create two antigen-binding sites.

[0087] As used herein, the term "detectably labeled" refers to any substance whose direct or indirect detection or measurement by physical or chemical means indicates the presence of CTCs in a sample.Representative examples of useful detectable labels include, but are not limited to, molecules or ions that can be directly or indirectly detected based on light absorption, fluorescence, reflection, light scattering, phosphorescence, or luminescence properties; molecules or ions that can be detected by radioactivity; molecules or ions that can be detected by nuclear magnetic resonance or paramagnetics.For example, among the group of molecules that can be indirectly detected based on light absorption or fluorescence, various enzymes can convert suitable substrates, for example, from non-light-absorbing molecules to light-absorbing molecules, or from non-fluorescent molecules to fluorescent molecules.

[0088] The term "diagnosis" as used herein refers to determining the subject's susceptibility to disease or disorder, determining whether a subject currently suffers from a disease or disorder, prognosing a subject suffering from a disease or disorder (for example, identifying the pre-metastatic or metastatic cancerous state, the stage of cancer, or the response of cancer to a treatment), and determining treatment strategy (for example, monitoring the subject's condition to provide information on the effectiveness or efficacy of a treatment).In some embodiments, the diagnostic method of the present invention is particularly useful for detecting early cancer.

[0089] The term "diagnostic agent" as used herein refers to a molecule that can be detected directly or indirectly and is used for diagnostic purposes. The diagnostic agent may be administered to a subject or a sample. The diagnostic agent may be provided by itself or may be conjugated to a vehicle such as a conditionally active antibody.

[0090] As used herein, the term "effector function" refers to the biological activities attributable to the Fc region of an antibody, which vary depending on the antibody isotype. Examples of antibody effector functions include C1q binding and complement-dependent cytotoxicity (CDC), Fc receptor binding, antibody-dependent cell-mediated cytotoxicity (ADCC), phagocytosis, down-regulation of cell surface receptors (e.g., B cell receptors), and B cell activation.

[0091] As used herein, the term "effective amount" of an agent, e.g., a pharmaceutical formulation, refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired therapeutic or prophylactic result.

[0092] As used herein, the term "Fc region" is used to define the C-terminal region of an immunoglobulin heavy chain containing at least a portion of the constant region. This term includes native-sequence Fc regions and variant Fc regions. In one embodiment, a human IgG heavy chain Fc region extends from Cys226 or Pro230 to the carboxy terminus of the heavy chain. However, the C-terminal lysine (Lys447) of the Fc region may or may not be present. Unless otherwise specified herein, the numbering of amino acid residues in the Fc region or constant region is according to the EU numbering system (also known as the EU index) as described in Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md., 1991.

[0093] As used herein, the term "framework" or "FR" refers to variable domain residues other than hypervariable region (HVR or H1-3 in the heavy chain and L1-3 in the light chain) residues. The FR of a variable domain generally consists of four FR domains: FR1, FR2, FR3, and FR4. Thus, the HVR and FR sequences generally correspond to the V H (or V L ) appears in the following sequence: FR1-H1(L1)-FR2-H2(L2)-FR3-H3(L3)-FR4.

[0094] The terms "full-length antibody," "intact antibody," or "whole antibody" refer to the antigen-binding variable region (V H or V L), as well as a light chain constant domain (CL) and a heavy chain constant domain (CH1, CH2, and CH3). The constant domains may be native-sequence constant domains (e.g., human native-sequence constant domains) or amino acid sequence variants thereof. Depending on the amino acid sequence of the constant domain of their heavy chain, full-length antibodies can be assigned to different "classes." There are five major classes of full-length antibodies: IgA, IgD, IgE, IgG, and IgM, several of which can be further divided into "subclasses" (isotypes), e.g., IgG1, IgG2, IgG3, IgG4, IgA, and IgA2. The heavy chain constant domains corresponding to the different classes of antibodies are called α, δ, ε, γ, and μ, respectively. The subunit structures and three-dimensional configurations of the different classes of immunoglobulins are well known.

[0095] As used herein, the terms "host cell," "host cell line," and "host cell culture" are used interchangeably and refer to cells into which exogenous nucleic acid has been introduced, including the progeny of such cells. Host cells include "transformants" and "transformed cells," and include the primary transformed cell and its derived progeny, regardless of the number of passages. Progeny may not be completely identical in nucleic acid content to the parent cell and may contain mutations. Mutant progeny that have the same function or biological activity as screened or selected for in the originally transformed cell are included herein.

[0096] As used herein, the term "human antibody" refers to an antibody having an amino acid sequence that corresponds to that of an antibody produced by a human or human cell, or an amino acid sequence derived from a non-human source that utilizes the coding sequence of a human antibody repertoire or other human antibody. This definition of a human antibody specifically excludes humanized antibodies that contain non-human antigen-binding residues.

[0097] As used herein, the term "human consensus framework" refers to the human immunoglobulin V L or V HIn selecting framework sequences, the framework represents the most commonly occurring amino acid residues. Generally, the selection of human immunoglobulin VL or VH sequences is from a subgroup of variable domain sequences. Generally, the subgroup of sequences is a subgroup as in Kabat et al., Sequences of Proteins of Immunological Interest, Fifth Edition, NIH Publication 91-3242, Bethesda, Md. (1991), vols. 1-3. In one embodiment, the subgroup for VL is subgroup kappa I as in Kabat et al., supra. In one embodiment, the subgroup for VH is subgroup III as in Kabat et al., supra.

[0098] As used herein, the term "humanized" antibody refers to a chimeric antibody comprising amino acid residues from non-human HVRs and human FRs. In certain embodiments, a humanized antibody comprises substantially all of at least one, typically two, variable domains in which all or substantially all of the HVRs (e.g., CDRs) correspond to those of a non-human antibody and all or substantially all of the FRs correspond to those of a human antibody. A humanized antibody may optionally comprise at least a portion of an antibody constant region derived from a human antibody. A "humanized form" of an antibody, e.g., a non-human antibody, refers to an antibody that has undergone humanization.

[0099] As used herein, the term "hypervariable region" or "HVR" refers to each of the regions of an antibody variable domain that are hypervariable in sequence and / or form structurally defined loops ("hypervariable loops"). Generally, native four-chain antibodies contain six HVRs; H Three of them (H1, H2, H3), and V LHVRs generally comprise three of these (L1, L2, L3). HVRs generally comprise amino acid residues from the hypervariable loops and / or from the "complementarity-determining regions" (CDRs), the latter of which exhibit the greatest sequence variability and / or are involved in antigen recognition. Exemplary hypervariable loops occur at amino acid residues 26-32 (L1), 50-52 (L2), 91-96 (L3), 26-32 (H1), 53-55 (H2), and 96-101 (H3) (Chothia and Lesk, J. Mol. Biol., vol. 196, pp. 901-917, 1987). Exemplary CDRs (CDR-L1, CDR-L2, CDR-L3, CDR-H1, CDR-H2, and CDR-H3) occur at amino acid residues 24-34 of L1, 50-56 of L2, 89-97 of L3, 31-35B of H1, 50-65 of H2, and 95-102 of H3 (Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md. 1991). With the exception of CDR1 in VH, CDRs generally comprise amino acid residues that form hypervariable loops. CDRs also contain "specificity-determining residues," or "SDRs," which are residues that contact the antigen. SDRs are contained within regions of CDRs called truncated CDRs, or a-CDRs. Exemplary a-CDRs (a-CDR-L1, a-CDR-L2, a-CDR-L3, a-CDR-H1, a-CDR-H2, a-CDR-H3) occur at amino acid residues 31-34 of L1, amino acid residues 50-55 of L2, amino acid residues 89-96 of L3, amino acid residues 31-35B of H1, amino acid residues 50-58 of H2, and amino acid residues 95-102 of H3 (See Almagro and Fransson, Front. Biosci., vol. 13, pp. 1619-1633, 2008). Unless otherwise indicated, HVR residues and other residues in the variable domain (e.g., FR residues) are numbered herein according to Kabat et al., supra.

[0100] As used herein, the term "immunoconjugate" is an antibody conjugated to one or more heterologous molecules, including but not limited to, cytotoxic agents.

[0101] As used herein, the term "individual" or "subject" refers to a mammal. Mammals include, but are not limited to, domestic animals (e.g., cows, sheep, cats, dogs, and horses), primates (e.g., humans and non-human primates such as monkeys), rabbits, and rodents (e.g., mice and rats). In certain embodiments, the individual or subject is a human.

[0102] "Adverse event" (AE) (also known as adverse experience) means an untoward and unintended sign (e.g., laboratory abnormality), symptom, or illness temporarily associated with the use of a medicinal product, without any determination of causality. AEs can occur with any use of a medicinal product (e.g., off-label use, concomitant use with other drugs), and with any route of administration, formulation, or dose, including overdose. An AE is considered "serious" if it results in any of the following: - Deaths (excluding deaths due to underlying diseases) - Life-threatening - Requiring hospitalization or prolonging an existing hospitalization. - Persistent or significant inability or substantial impairment in the ability to perform normal life functions - Congenital anomalies / disabilities - Significant Medical Event - A significant medical event that is not fatal, life-threatening, or requires hospitalization is considered serious if, based on sound medical judgment, it endangers the patient and requires medical or surgical intervention to prevent any of the consequences described in this definition.

[0103] As used herein, the terms "inhibit" or "inhibition of" means to reduce by a measurable amount or to prevent completely.

[0104] As used herein, the term "inhibiting cell growth or proliferation" means reducing cell growth or proliferation by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, or 100%, and includes inducing cell death.

[0105] As used herein, the term "isolated" antibody refers to an antibody that has been separated from the components of its natural environment. In some embodiments, the antibody is purified to greater than 95% or 99% purity, as measured, for example, by electrophoresis (e.g., SDS-PAGE, isoelectric focusing (IEF), capillary electrophoresis) or chromatography (e.g., ion exchange or reverse-phase HPLC). For a review of methods for assessing antibody purity, see, for example, Flatman et al., J. Chromatogr. B, vol. 848, pp. 79-87, 2007.

[0106] As used herein, the term "isolated" nucleic acid refers to a nucleic acid molecule that has been separated from a component of its natural environment. Isolated nucleic acid includes a nucleic acid molecule that is contained in a cell that ordinarily contains the nucleic acid molecule, but where the nucleic acid molecule is present extrachromosomally or at a chromosomal location that is different from its natural chromosomal location.

[0107] As used herein, the term "isolated nucleic acid encoding an anti-Axl antibody" refers to one or more nucleic acid molecules encoding antibody heavy and light chains (or fragments thereof), and includes such nucleic acid molecules in a single vector or separate vectors, and such nucleic acid molecules present in one or more locations in a host cell.

[0108] As used herein, the term "ligand-independent," when applied to, for example, receptor signaling activity, refers to signaling activity that is not dependent on the presence of a ligand. A receptor with ligand-independent kinase activity does not necessarily preclude the binding of a ligand to the receptor to produce additional activation of the kinase activity.

[0109] As used herein, the term "metastasis" refers to all Axl-mediated processes that support cancer cell dispersal from a primary tumor, infiltrate into lymphatics and / or blood vessels, circulate via the bloodstream, and grow in distant foci (metastasis) in normal tissues elsewhere in the body. In particular, it refers to cellular events in tumor cells, such as proliferation, migration, anchorage independence, evasion of apoptosis, or secretion of angiogenic factors, that underlie metastasis and are stimulated or mediated by the noncatalytic or catalytic activity of Axl, preferably, for example, Axl phosphorylation and / or Axl-mediated signaling.

[0110] As used herein, the term "microenvironment" refers to any part or region of a tissue or body that has permanent or temporary, physical or chemical differences from other regions of the tissue or body. In the case of tumors, the term "tumor microenvironment" refers to the environment in which the tumor resides, including the acellular regions within the tumor and the regions immediately outside the tumor tissue but not related to the intracellular compartments of the cancer cells themselves. Tumors and the tumor microenvironment are closely related and constantly interact. Tumors can alter their microenvironment, which can affect tumor growth and spread. Typically, tumor microenvironments have a low pH, ranging from 5.8 to 7.0, more commonly from 6.2 to 6.8, and most commonly from 6.4 to 6.8. Normal physiological pH, on the other hand, is typically in the range of 7.2 to 7.8. The tumor microenvironment is also known to have lower concentrations of glucose and other nutrients but higher concentrations of lactate compared to plasma. Furthermore, the tumor microenvironment may have a temperature 0.3 to 1°C higher than normal physiological temperature. The tumor microenvironment is discussed in Gillies et al., "MRI of the Tumor Microenvironment," Journal of Magnetic Resonance Imaging, vol. 16, pp. 430-450, 2002. The term "non-tumor microenvironment" refers to the microenvironment at sites other than the tumor.

[0111] As used herein, the term "monoclonal antibody" refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical and / or bind to the same epitope, but excludes variant antibodies that contain, for example, naturally occurring mutations or that may arise during production of the monoclonal antibody preparation, and such variants are generally present in minor amounts. In contrast to polyclonal antibody preparations, which typically include different antibodies specific for different determinants (epitopes), each monoclonal antibody of a monoclonal antibody preparation is specific for a single determinant on the antigen. Thus, the modifier "monoclonal" indicates the character of the antibody as obtained from a population of substantially homogeneous antibodies and should not be construed as requiring production of the antibody by any particular method. For example, monoclonal antibodies used in accordance with the present invention can be produced by a variety of techniques, including, but not limited to, hybridoma methods, recombinant DNA methods, phage display methods, and methods utilizing transgenic animals containing all or part of the human immunoglobulin loci; such methods and other exemplary methods for producing monoclonal antibodies are described herein.

[0112] As used herein, the term "naked antibody" refers to an antibody that is not conjugated to a heterologous moiety (e.g., a cytotoxic moiety) or a radiolabel. The naked antibody may be present in a pharmaceutical formulation.

[0113] As used herein, the term "native antibody" refers to a naturally occurring immunoglobulin molecule with a variable structure. For example, a native IgG antibody is a heterotetrameric glycoprotein of approximately 150,000 daltons, composed of two identical light chains and two identical heavy chains that are disulfide-bonded. From the N-terminus to the C-terminus, each heavy chain contains a variable region (V), also called a variable heavy chain domain or heavy chain variable domain. H), followed by three constant domains (CH1, CH2, and CH3). Similarly, from the N-terminus to the C-terminus, each light chain contains a variable region (V), also called the variable light domain or light chain variable domain. L ) followed by the constant light chain (C L ) domain. The light chains of antibodies can be assigned to one of two types, called kappa (κ) and lambda (λ), based on the amino acid sequence of their constant domain.

[0114] As used herein, the term "package insert" refers to instructions customarily included in commercial packaging for a therapeutic product, which contain information about the indications, uses, dosages, administration, concomitant therapy, contraindications, and / or warnings regarding the use of such therapeutic product.

[0115] As used herein, the term "percent (%) amino acid sequence identity" with respect to a reference polypeptide sequence is defined as the percentage of amino acid residues in a candidate sequence that are identical to those in a reference polypeptide sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, without considering any conservative substitutions as part of the sequence identity. Alignment for purposes of determining percent amino acid sequence identity can be achieved in a variety of ways within the skill of the art, for example, using publicly available computer software such as BLAST, BLAST-2, ALIGN, or Megalign (DNASTAR) software. Those skilled in the art can determine appropriate parameters for aligning sequences, including any algorithms necessary to achieve maximum alignment across the entire length of the sequences being compared. However, for purposes herein, percent amino acid sequence identity values ​​are generated using the sequence comparison computer program ALIGN-2. The ALIGN-2 sequence comparison computer program was created by Genentech, Inc., and the source code has been submitted, along with user documentation, to the U.S. Copyright Office (Washington, DC, 20559) and is registered under U.S. Copyright Registration No. TXU510087. The ALIGN-2 program is publicly available from Genentech, Inc., South San Francisco, Calif., or can be compiled from the source code. The ALIGN-2 program must be compiled for use on UNIX operating systems, including Digital UNIX V4.0D. All sequence comparison parameters are set by the ALIGN-2 program and do not vary.

[0116] In situations where ALIGN-2 is used for amino acid sequence comparison, the % amino acid sequence identity of a given amino acid sequence A with or to a given amino acid sequence B (alternatively, it can be expressed as a given amino acid sequence A having or containing a particular % amino acid sequence identity with or to a given amino acid sequence B) is calculated as follows: 100 * (X / Y) where X is the number of amino acid residues scored as identical matches by the sequence alignment program ALIGN-2 in that program's alignment of A and B, and Y is the total number of amino acid residues in B. It will be understood that if the length of amino acid sequence A is not equal to the length of amino acid sequence B, the % amino acid sequence identity of A to B will not equal the % amino acid sequence identity of B to A. Unless otherwise specified, all % amino acid sequence identity values ​​used herein are obtained as described in the previous section using the ALIGN-2 computer program.

[0117] As used herein, the term "pharmaceutical formulation" refers to a formulation that is in a form that is effective for the biological activity of the active ingredient contained therein and that does not contain additional ingredients that are unacceptably toxic to the subject to whom the formulation is administered.

[0118] As used herein, the term "pharmaceutically acceptable carrier" refers to an ingredient in a pharmaceutical formulation, other than the active ingredient, that is non-toxic to a subject. Pharmaceutically acceptable carriers include, but are not limited to, buffers, excipients, stabilizers, or preservatives.

[0119] As used herein, the terms "purified" and "isolated" refer to an antibody or nucleotide sequence according to the present invention and indicate that the designated molecule is present in the substantial absence of other biological macromolecules of the same type. As used herein, the term "purified" preferably means that at least 75% by weight of the same biological macromolecules is present, more preferably at least 85% by weight, even more preferably 95% by weight, and most preferably at least 98% by weight. An "isolated" nucleic acid molecule encoding a particular polypeptide refers to a nucleic acid molecule that is substantially free of other nucleic acid molecules that do not encode the polypeptide, although the molecule may contain some additional bases or moieties that do not adversely affect the basic characteristics of the composition.

[0120] As used herein, the term "recombinant antibody" refers to an antibody (e.g., a chimeric, humanized, or human antibody, or an antigen-binding fragment thereof) expressed by a recombinant host cell containing nucleic acid encoding the antibody. Examples of "host cells" for producing recombinant antibodies include the following: Examples of "host cells" for producing recombinant antibodies include: (1) mammalian cells, such as Chinese hamster ovary (CHO), COS, myeloma cells (including Y0 cells and NS0 cells), baby hamster kidney (BHK), Hela cells, and Vero cells; (2) insect cells, such as sf9, sf21, and Tn5; (3) plant cells, such as plants belonging to the genus Nicotiana (e.g., Nicotiana tabacum); (4) yeast cells, such as those belonging to the genus Saccharomyces (e.g., Saccharomyces cerevisiae) or Aspergillus (e.g., Aspergillus niger); and (5) bacterial cells, such as Escherichia coli cells or Bacillus subtilis cells.

[0121] The term "therapeutically effective amount" of an antibody or antibody fragment of the present invention refers to a sufficient amount of the antibody or antibody fragment to treat a disease or disorder at a reasonable benefit / risk ratio applicable to any medical treatment. It will be understood, however, that the total daily usage of the antibodies or antibody fragments and compositions of the present invention will be decided by the attending physician within the scope of sound medical judgment. The specific therapeutically effective dose level for any particular patient will depend on a variety of factors, including the disorder being treated and the severity of the disorder, the activity of the specific antibody or antibody fragment used, the specific composition used, the patient's age, weight, general health, sex, and diet, the time of administration, route of administration, and excretion rate of the specific antibody or antibody fragment used, the duration of treatment, drugs used in combination with or concomitantly with the specific antibody used, and similar factors known in the medical arts. For example, it is known in the art to start administering compounds at levels lower than those required to achieve the desired therapeutic effect and gradually increase the dosage until the desired effect is achieved.

[0122] As used herein, the term "single-chain Fv" ("scFv") refers to a covalently linked V H ::V L A heterodimer, which typically consists of two genes linked by a peptide-encoded linker, V H and V L "dsFv" is a disulfide bond stabilized V H ::V L Divalent and multivalent antibody fragments can form spontaneously by association of monovalent scFvs or can be generated by linking monovalent scFvs with peptide linkers (such as bivalent sc(Fv)2).

[0123] As used herein, the terms "treatment," "treat," or "treating" refer to clinical intervention in an attempt to alter the natural history of the individual being treated and can be performed either for prophylaxis or during the course of clinical pathology. Desirable effects of treatment include, but are not limited to, prevention of disease onset or recurrence, alleviation of symptoms, reduction of any direct or indirect pathological consequences of disease, prevention of metastasis, reduction in the rate of disease progression, remission or palliation of the disease state, and remission or improved prognosis. In some embodiments, the antibodies or antibody fragments of the invention are used to delay disease onset or slow disease progression. In specific embodiments, the antibodies or antibody fragments of the invention are used to prevent the onset or recurrence of tumor growth, alleviate symptoms associated with tumor progression or regression, reduce direct or indirect pathological consequences associated with cancer, prevent tumor metastasis, enhance tumor regression, reduce or inhibit tumor progression, and induce remission or improved prognosis.

[0124] As used herein, the term "tumor" refers to all neoplastic cell growth and proliferation, whether malignant or benign, and all pre-cancerous and cancerous cells and tissues. The terms "cancer," "cancerous," "cell proliferative disorder," "proliferative disorder," and "tumor" are not mutually exclusive as referred to herein.

[0125] As used herein, the term "variable region" or "variable domain" refers to the domains of an antibody heavy or light chain that are involved in binding the antibody to an antigen. The variable domains of the heavy and light chains of a native antibody (V H and V L ) generally have a similar structure, with each domain containing four conserved framework regions (FR) and three hypervariable regions (HVR) (see, e.g., Kindt et al., Kuby Immunology, 6th ed., W.H. Freeman and Co., page 91 (2007)). H or V LThe V domain may be sufficient to confer specificity of antigen binding. Furthermore, an antibody or antibody fragment that binds to a particular antigen may be obtained by isolating the V domain from the antibody that binds to that antigen. H or V L The complementary V domains were isolated using L or V H Libraries of domains can be screened (see, e.g., Portolano et al., J. Immunol., vol. 150, pp. 880-887, 1993; Clarkson et al., Nature, vol. 352, pp. 624-628, 1991).

[0126] As used herein, the term "vector" refers to a nucleic acid molecule capable of propagating another nucleic acid to which it is linked. The term includes vectors as self-replicating nucleic acid structures as well as vectors that integrate into the genome of a host cell into which they are introduced. Certain vectors are capable of directing the expression of nucleic acids to which they are operatively linked. Such vectors are referred to herein as "expression vectors."

[0127] (Detailed description) For illustrative purposes, the principles of the present invention are described with reference to various exemplary embodiments. While certain embodiments of the present invention are specifically described herein, those skilled in the art will readily understand that the same principles are equally applicable to and can be used in other systems and methods. Before describing the disclosed embodiments of the present invention in detail, it should be understood that the present invention is not limited in its application to the details of any particular embodiment shown. In addition, the terminology used herein is for purposes of description and not limitation. Furthermore, although certain methods are described with reference to steps presented herein in a particular order, in many cases these steps can be performed in any order as would be understood by one of ordinary skill in the art, and thus the novel methods are not limited to the particular arrangement of steps disclosed herein.

[0128] It should be noted that as used in this specification and the appended claims, the singular forms "a," "an," and "the" include plural references unless the context clearly dictates otherwise. Additionally, the terms "a" (or "an"), "one or more," and "at least one" may be used interchangeably herein. The terms "comprising," "including," "having," and "constructed from" may also be used interchangeably.

[0129] Unless otherwise indicated, all numbers expressing quantities of ingredients, properties such as molecular weight, percentages, ratios, reaction conditions, and the like used in the specification and claims, whether or not the term "about" is present, should be understood to be modified in all instances by the term "about." Accordingly, unless otherwise indicated, the numerical parameters set forth in the specification and claims are approximations that may vary depending upon the desired properties sought to be obtained by the present disclosure. At the very least, and not as an attempt to limit the application of the doctrine of equivalents to the scope of the claims, each numerical parameter should be construed at least in light of the number of reported significant digits and by applying ordinary rounding techniques. Notwithstanding that the numerical ranges and parameters setting forth the broad scope of the present disclosure are approximations, the numerical values ​​set forth in the specific examples are reported as precisely as possible. Any numerical value, however, inherently contains certain errors necessarily resulting from the standard deviation found in their respective testing measurements.

[0130] It is understood that each component, compound, substituent, or parameter disclosed herein is to be construed as disclosed for use alone or in combination with one or more of each other component, compound, substituent, or parameter disclosed herein.

[0131] Also, each amount / value or amount / value range of each component, compound, substituent, or parameter disclosed herein should be construed as being disclosed in combination with each amount / value or amount / value range disclosed for any other component, compound, substituent, or parameter disclosed herein; thus, for purposes of this description, any combination of amounts / values ​​or amount / value ranges for two or more components, compounds, substituents, or parameters disclosed herein should also be understood to be disclosed in combination with each other.

[0132] It is further understood that each lower limit of each range disclosed herein should be interpreted as a disclosure in combination with each upper limit of each range disclosed herein for the same component, compound, substituent, or parameter. Thus, a disclosure of two ranges should be interpreted as a disclosure of four ranges derived by combining each lower limit with each upper limit of each range. A disclosure of three ranges should be interpreted as a disclosure of nine ranges derived by combining each lower limit with each upper limit of each range, etc. Furthermore, a specific amount / value of a component, compound, substituent, or parameter disclosed in the description or examples should be interpreted as a disclosure of either a lower or upper limit of a range and, therefore, can be combined with any other lower or upper limit or specific amount / value of a range for the same component, compound, substituent, or parameter disclosed elsewhere in this application to form a range for that component, compound, substituent, or parameter. Regions of anti-Axl antibodies or antibody fragments

[0133] In one aspect, the present invention provides an isolated polypeptide that specifically binds to an Axl protein, and use of the polypeptide in a method for treating an Axl-expressing tumor comprising administering the polypeptide to a human in need of such treatment.

[0134] The polypeptide of the present invention comprises six complementarity determining regions H1, H2, H3, L1, L2 and L3, the H1 sequence is X1GX2X3MX4 (SEQ ID NO: 1), where X1, X2, X3 and X4 each independently represent an amino acid; X1 is T, A or W; X2 is H or A; X3 is T or I; X4 is N or I; The H2 sequence is LIKX5SNGGTX6YNQKFKG (SEQ ID NO: 2) (X5 and X6 each independently represent an amino acid), X5 is P or N; X6 is S, I, or T; The H3 sequence is GX7X8X9X 10 X 11 X 12 X 13 X 14 DYX 15 X 16 (SEQ ID NO: 3) (X7, X8, X9, X 10 , X 11 , X 12、 X 13 , X 14 , X 15 and X 16 each independently represents an amino acid, X7 is H or D or E or P or R or W; X8 is Y or N, X9 is E or A or D or F or G or H or I or L or M or N or R or V or Y; X 10 is S or D or M or N or Q, X 11 is Y or C or E or P, X 12 is F or E or N or S or T or V, X 13 is A or D or G or L or Y, X 14 is M, E, or F, X 15is W or A or D or H or L or N or P or R or T, X 16 is G or H, L1 array is KASQDX 17 X 18 SX 19 VX 20 (SEQ ID NO: 4)(X 17 , X 18 , X 19 , and X 20 each independently represents an amino acid), X 17 is V or D or G or N or W, X 18 is S or V, X 19 is A, L, or M, X 20 is A or D or N or Q, L2 sequence is X 21 X 22 X 23 TRX 24 T (SEQ ID NO: 5) (X 21 , X 22 , X 23 , and X 24 each independently represents an amino acid), X 21 is W or F, X 22 is A or I or N or P or Q, X 23 is S or D, X 24 is H or D, L3 array is QEX 25 X 26 SX 27 X 28 X 29 X 30 (SEQ ID NO: 6)(X 25 , X 26 , X 27 , X 28 , X 29 , and X 30 each independently represents an amino acid), X25 is H or C or F or I or L or Q or S or T or V or Y, X 26 is F or C or D or E or G or N or S, X 27 is T, C, or P, X 28 is P or A or C or D or E or H or K or S or T or V or W, X 29 is L, G, or R, X 30 is T, I, or R, The polypeptides of the present invention exclude parent polypeptides having the following six CDRs: H1 = TGHTMN, H2 = LIKPSNGGTSYNQKFKG, H3 = GHYESYFAMDYWG, L1 = KASQDVSSAVA, L2 = WASTRHT, and L3 = QEHFSTPLT.

[0135] In another embodiment, the present invention provides isolated polypeptides as described above, which have at most one substitution in CDRs H1, H2, and H3 relative to the parent polypeptide, and at most one substitution in CDRs L1, L2, and Le relative to the parent polypeptide. This includes isolated polypeptides having one substitution in CDRs H1, H2, and H3 relative to the parent polypeptide, isolated polypeptides having one substitution in CDRs L1, L2, and L3 relative to the parent polypeptide, and isolated polypeptides having one substitution in CDRs H1, H2, and H3, and CDRs L1, L2, and L3 relative to the parent polypeptide. Possible combinations of CDRs H1, H2, and H3 are shown in Figure 1A, and possible combinations of CDRs L1, L2, and L3 are shown in Figure 1B.

[0136] An alignment of the heavy chain variable regions is shown in Figure 1A, with the complementarity determining regions H1, H2, and H3 boxed.

[0137] An alignment of the light chain variable regions is shown in Figure 1B, with the complementarity determining regions L1, L2, and L3 boxed.

[0138] The present invention identifies these isolated heavy and light chain variable region polypeptides from parent antibodies using the methods disclosed in U.S. Patent No. 8,709,755. The heavy and light chain variable regions of the parent antibody (063-hum10F10) are also aligned in Figures 1A-1B to show the mutations in the isolated heavy and light chain variable region polypeptides.

[0139] A mutant antibody library was generated by evolving DNA encoding a wild-type antibody using Comprehensive Positional Evolution (CPE), which randomizes each position in the template antibody one by one. Each mutant antibody in the library has only one single point mutation. The mutant antibodies in the library were generated by simultaneously screening for selective binding affinity to Axl at pH 6.0 compared to pH 7.4 by ELISA. Two dilutions of mutant antibodies were used: 1:3 and 1:9 dilutions. Mutant antibodies with a ratio of binding affinity at pH 6.0 to pH 7.4 of at least 1.5 under either the 1:3 or 1:9 dilution were selected as conditionally active antibodies with the indicated single point mutations in the heavy and light chain variable regions, respectively (Tables 1 and 2). [Table 1] [Table 2]

[0140] In another aspect, the present invention has identified heavy chain variable regions depicted in Figure 1A and light chain variable regions presented in Figure 1B. Some heavy chain variable regions are encoded by DNA sequences having SEQ ID NOS: 11-13. Some light chain variable regions are encoded by DNA sequences having SEQ ID NOS: 7-10. These heavy and light chain variable regions can specifically bind to Axl. An antibody comprising one of these heavy and light chain variable regions was found to have a higher binding affinity for Axl at a pH found in a tumor microenvironment than at a pH found in a non-tumor microenvironment.

[0141] The present invention also includes variants of the heavy and light chain variable regions encoded by the DNA sequences presented in Figures 1A-1B and having SEQ ID NOS: 9-13, which are capable of specifically binding to Axl. To derive these variants, it was determined that the complementarity-determining regions (CDRs) of the heavy chain variable region (H1-H3) and the CDRs of the light chain variable region (L1-L3) should remain intact.

[0142] The process described herein serves as a guide for deriving these variants. These variants of heavy and light chain variable regions can be prepared by introducing appropriate modifications into the nucleotide sequences encoding the heavy and light chain variable regions or by peptide synthesis. Such modifications include, for example, deletions from, and / or insertions into, and / or substitutions of residues within the amino acid sequence of an antibody or antibody fragment. Any combination of deletions, insertions, and substitutions can be made to arrive at the final construct, provided that the final construct retains at least one desired property, such as antigen binding. Substitution, insertion, and deletion variants

[0143] In certain embodiments, antibody or antibody fragment variants are provided that have one or more amino acid substitutions. Sites of interest for substitutional mutagenesis include CDRs and framework regions (FRs). Conservative substitutions are shown in Table 3 under the heading "Conservative Substitutions." More substantial changes are provided in Table 3 under the heading "Exemplary Substitutions," and are further described below with respect to classes of amino acid side chains. Amino acid substitutions can be introduced into the antibody or antibody fragment of interest, and the products can be screened for a desired activity, such as retention / improvement of antigen binding, or reduced immunogenicity. [Table 3]

[0144] Amino acids can be grouped according to common side chain properties: (1) Hydrophobic: Norleucine, Met, Ala, Val, Leu, Ile (2) Neutral hydrophilicity: Cys, Ser, Thr, Asn, Gln (3) Acidic: Asp, Glu (4) Basic: His, Lys, Arg (5) Residues that affect chain orientation: Gly, Pro (6) Aromatic: Trp, Tyr, Phe

[0145] Non-conservative substitutions involve exchanging a member of one of these classes for another class.

[0146] One type of substitutional variant involves substituting one or more hypervariable region residues of a parent antibody (e.g., a humanized or human antibody). Generally, the resulting variant selected for further testing has an altered (e.g., improved) biological property relative to the parent antibody (e.g., increased affinity, decreased immunogenicity) and / or substantially retains a biological property of the parent antibody. An exemplary substitutional variant is an affinity-matured antibody, which can be conveniently generated using, for example, phage-display-based affinity maturation techniques, such as those described herein. Briefly, one or more CDR residues are mutated, and the variant antibodies are displayed on phage and screened for a particular biological activity (e.g., binding affinity).

[0147] For example, modifications (e.g., substitutions) may be made in CDRs to improve antibody affinity. Such modifications can be made in CDR "hot spots," i.e., residues encoded by codons that undergo frequent mutation during the somatic maturation process (see, e.g., Chowdhury, Methods Mol. Biol., vol. 207, pp. 179-196, 2008), and / or in SDRs (a-CDRs), and the resulting variant VH or VL is tested for binding affinity. Affinity maturation by constructing and then reselecting a secondary library is described, for example, in Hoogenboom et al. in Methods in Molecular Biology, vol. 178, pp. 1-37, 2001. In some affinity maturation embodiments, diversity is introduced into the variable genes selected for maturation by any of a variety of methods (e.g., error-prone PCR, chain shuffling, or oligonucleotide-directed mutagenesis). A secondary library is then generated. The library is then screened to identify any antibody variants with the desired affinity. Another method for introducing diversity involves a CDR-specific approach, in which several CDR residues (e.g., 4-6 residues per round) are randomized. CDR residues involved in antigen binding can be specifically identified, for example, using alanine scanning mutagenesis or modeling. CDR-H3 and CDR-L3 are often targeted in particular.

[0148] In some embodiments, substitutions, insertions, or deletions may occur within one or more HVRs, as long as such changes do not substantially reduce the ability of the antibody or antibody fragment to bind to the antigen. For example, conservative modifications (e.g., conservative substitutions provided herein) that do not substantially reduce binding affinity may be made in the CDRs. Such modifications may be outside the "hot spots" of the CDRs or SDRs. Variant V provided above H and V L In certain embodiments of the sequences, each CDR is either unaltered or does not contain one, two, three or more amino acid substitutions.

[0149] A useful method for identifying antibody residues or regions that can be targeted for mutagenesis is called "alanine scanning mutagenesis," as described by Cunningham and Wells, Science, vol. 244, pp. 1081-1085, 1989. In this method, a target residue or group of target residues (e.g., charged residues such as arg, asp, his, lys, and glu) is identified and replaced with neutral or negatively charged amino acids (e.g., alanine or polyalanine) to determine whether the interaction of the antibody or antibody fragment with the antigen is affected. Further substitutions may be introduced at amino acid positions that show functional sensitivity to the initial substitution. Alternatively or additionally, a crystal structure of an antigen-antibody complex identifies contact points between the antibody or antibody fragment and the antigen. Such contact residues and adjacent residues may be targeted as candidates for substitution or may be eliminated. Variants may be screened to determine whether they contain desired properties.

[0150] Amino acid sequence insertions include amino- and / or carboxyl-terminal fusions, ranging in length from one residue to polypeptides containing 100 or more residues, as well as intrasequence insertions of single or multiple amino acid residues. An example of a terminal insertion is an antibody with an N-terminal methionyl residue. Other insertional variants of antibodies include the fusion to the N- or C-terminus of the antibody of an enzyme (e.g., ADEPT) or a polypeptide which increases the serum half-life of the antibody.

[0151] Amino acid sequence modifications of the antibodies described herein are contemplated. For example, it may be desirable to improve the binding affinity and / or other biological properties of the antibody. V of antibodies derived from non-human animals H and V L Only the CDRs in the V region of a human antibody are H and V LIt is known that when a humanized antibody is produced by grafting amino acid residues into the FRs of a non-human antibody, its antigen-binding activity is reduced compared to that of the original antibody derived from a non-human animal. It is believed that some amino acid residues in the VH and VL of a non-human antibody, not only in the CDRs but also in the FRs, are directly or indirectly involved in antigen-binding activity. Therefore, replacing these amino acid residues with different amino acid residues from the VH and VL FRs of a human antibody will reduce the binding activity. To solve this problem, it is necessary to attempt to identify amino acid residues in the amino acid sequences of the VH and VL FRs of a human antibody that are directly involved in binding to the antibody, or that interact with amino acid residues in the CDRs, or that maintain the three-dimensional structure of the antibody and are directly involved in binding to the antigen. The reduced antigen-binding activity can be increased by substituting the identified amino acids with amino acid residues from the original antibody derived from a non-human animal.

[0152] Modifications and changes can be made in the structure of the antibodies of the present invention, and in the DNA sequences that encode them, while still obtaining a functional molecule that encodes an antibody with desired characteristics.

[0153] When making changes to the amino acid sequence, the hydrophilicity index of the amino acids may be taken into consideration. The importance of the hydrophilicity index in conferring interactive biological function on a protein is generally understood in the art. It is accepted that the relative hydrophilicity characteristics of amino acids contribute to the secondary structure of the resulting protein, which in turn defines the interaction of the protein with other molecules, such as enzymes, substrates, receptors, DNA, antibodies, antigens, etc. Each amino acid is assigned a hydrophilicity index based on its hydrophobicity and charge characteristics: isoleucine (+4.5), valine (+4.2), leucine (+3.8), phenylalanine (+2.8), cysteine / cystine (+2.5), methionine (+1.9), alanine (+1.8), glycine (-0.4), threonine (-0.7), serine (-0.8), tryptophan (-0.9), tyrosine (-1.3), proline (-1.6), histidine (-3.2), glutamic acid (-3.5), glutamine (-3.5), aspartic acid (-3.5), asparagine (-3.5), lysine (-3.9), and arginine (-4.5).

[0154] A further object of the present invention also includes function-conservative variants of the antibodies of the invention.

[0155] A "function-conservative variant" is one in which a given amino acid residue in a protein or enzyme is altered without altering the overall conformation and function of the polypeptide, including, but not limited to, the replacement of an amino acid with an amino acid having similar properties (e.g., polarity, hydrogen-bonding potential, acidic, basic, hydrophobic, aromatic, etc.). Amino acids other than those designated as conserved amino acids may vary in a protein, resulting in a change in the percent sequence similarity of protein or amino acid sequences between any two functionally similar proteins, e.g., 70%-99% when similarity is determined according to an alignment scheme such as a clustering method based on the MEGALIGN algorithm. "Function-conservative variants" also include polypeptides having at least 60% amino acid identity, preferably at least 75%, more preferably at least 85%, even more preferably at least 90%, and even more preferably at least 95%, as determined by the BLAST or FASTA algorithm, with the native or parent protein to which it is compared, and possessing the same or substantially similar properties or functions.

[0156] Two amino acid sequences are "substantially homologous" or "substantially similar" if they are more than 80%, preferably more than 85%, preferably more than 90% identical in amino acids over the entire length of the shorter sequence, or are about 90%, preferably more than 95%, similar (functionally identical). Preferably, similar or homologous sequences are identified by alignment using, for example, a GCG (Genetics Computer Group, Program Manual for the GCG Package, Version 7, Madison, Wis.) pileup program, or one of the sequence comparison algorithms such as BLAST or FASTA.

[0157] For example, certain amino acids can be substituted for other amino acids in a protein structure without appreciable loss of activity. Because the interaction capacity and properties of a protein determine its biological functional activity, certain amino acid substitutions can be made in a protein sequence, and of course, in its DNA coding sequence, while still obtaining a protein with similar properties. Thus, it is contemplated that various changes can be made in the sequences of the antibodies or antibody fragments of the present invention, or the corresponding DNA sequences encoding the antibodies or antibody fragments, without significantly impairing their biological activity.

[0158] It is known in the art that certain amino acids may be substituted by other amino acids having a similar hydrophilicity index or score and still result in a protein with similar biological activity, i.e., still resulting in a biologically functional equivalent protein.

[0159] As outlined above, amino acid substitutions are therefore generally based on the relative similarity of the amino acid side-chain substituents, e.g., their hydrophobicity, hydrophilicity, charge, size, etc. Exemplary substitutions that take into account various of the above characteristics are well known to those of skill in the art and include: arginine and lysine; glutamic acid and aspartic acid; serine and threonine; glutamine and asparagine; and valine, leucine and isoleucine. Glycosylation variants

[0160] In certain embodiments, the antibodies provided herein are altered to increase or decrease the extent to which the antibody is glycosylated. Addition or deletion of glycosylation sites to an antibody can be conveniently accomplished by altering the amino acid sequence so that one or more glycosylation sites are created or removed.

[0161] If the antibody contains an Fc region, the carbohydrate attached thereto can be modified. Native antibodies produced by mammalian cells typically contain branched biantennary oligosaccharides, generally N-linked to Asn297 in the CH2 domain of the Fc region. See, for example, Wright et al., TIBTECH, vol. 15, pp. 26-32, 1997. The oligosaccharides can include various carbohydrates, such as mannose, N-acetylglucosamine (GlcNAc), galactose, and sialic acid, as well as fucose attached to GlcNAc in the "stem" of the biantennary oligosaccharide structure. In some embodiments, modifications of the oligosaccharides in the antibodies of the present invention can be made to create antibody variants with improved properties.

[0162] In one embodiment, antibody variants are provided that have carbohydrate structures lacking fucose attached (directly or indirectly) to the Fc region. For example, the amount of fucose in such antibodies can be 1% to 80%, 1% to 65%, 5% to 65%, or 20% to 40%. The amount of fucose is determined by calculating the average amount of fucose in the glycan at Asn297 relative to the sum of all glycans (e.g., complex, hybrid, and high-mannose structures) attached to Asn297, as measured by MALDI-TOF mass spectrometry, for example, as described in WO 2008 / 077546. Asn297 refers to the asparagine residue located at approximately position 297 in the Fc region (Eu numbering of Fc region residues). However, due to slight sequence variations in antibodies, Asn297 may be located approximately plus or minus three amino acids upstream or downstream of position 297, i.e., positions 294 to 300. Such fucosylation variants may have improved ADCC function. See, for example, U.S. Patent Publication Nos. US2003 / 0157108 (Presta, L.) and US2004 / 0093621 (Kyowa Hakko Kogyo Co., Ltd.). Examples of publications related to "defucosylated" or "fucose-deficient" antibody variants include US2003 / 0157108, WO2000 / 61739, WO2001 / 29246, US2003 / 0115614, US2002 / 0164328, US2004 / 0093621, and US2004 / 01321. 40, US2004 / 0110704, US2004 / 0110282, US2004 / 0109865, WO2003 / 085119, WO2003 / 084570, WO2005 / 035586, WO2005 / 035778, WO2005 / 053742, WO2002 / 031140, Okazaki et al. J. Mol. Biol., vol. 336, pp. 1239-1249, 2004, Yamane-Ohnuki et al. Biotech. Bioeng., vol. 87, pp. 614-622, 2004.Examples of cell lines capable of producing defucosylated antibodies include Lec13 CHO cells, which are deficient in protein fucosylation (Ripka et al. Arch. Biochem. Biophys., vol. 249, pp. 533-545, 1986; U.S. Patent Publication No. US2003 / 0157108A; and WO2004 / 056312A1 (especially Example 11)), and knockout cell lines such as α-1,6-fucosyltransferase gene (FUT8) knockout CHO cells (e.g., Yamane-Ohnuki et al. Biotech. Bioeng., vol. 87, pp. 614-622, 2004; Kanda, Y. et al., Biotechnol. Bioeng., vol. 94, pp. 680-688, 2006; and WO2003 / 085107).

[0163] Antibody variants containing biantennary oligosaccharides are also provided, for example, biantennary oligosaccharides attached to the Fc region of the antibody are bisected by GlcNAc. Such antibody variants may have reduced fucosylation and / or improved ADCC function. Examples of such antibody variants are described, for example, in WO2003 / 011878, U.S. Patent No. 6,602,684, and US2005 / 0123546. Also provided are antibody variants having at least one galactose residue in the oligosaccharide attached to the Fc region. Such antibody variants may have improved CDC function. Such antibody variants are described, for example, in WO1997 / 30087, WO1998 / 58964, and WO1999 / 22764. Fc region variants

[0164] In certain embodiments, one or more amino acid modifications can be introduced into the Fc region of an antibody provided herein, thereby generating an Fc region variant. The Fc region variant can comprise a human Fc region sequence (e.g., a human IgG1, IgG2, IgG3, or IgG4 Fc region) containing an amino acid modification (e.g., substitution) at one or more amino acid positions.

[0165] In certain embodiments, the present invention contemplates antibody variants that retain some, but not all, effector functions, making them desirable candidates for applications in which in vivo antibody half-life is important but certain effector functions (such as ADCC) are unnecessary or deleterious. In vitro and / or in vivo cytotoxicity assays can be performed to confirm reduced / depleted CDC and / or ADCC activity. For example, Fc receptor (FcR) binding assays can be performed to ensure that the antibody lacks FcγR binding (and thus likely lacks ADCC activity) but retains FcRn binding ability. NK cells, the primary cells for mediating ADCC, express only FcγRIII, whereas monocytes express FcγRI, FcγRII, and FcγRIII. FcR expression on hematopoietic cells is summarized in Table 5 on page 464 of Ravetch and Kinet, Annu. Rev. Immunol., vol. 9, pp. 457-492, 1991. Non-limiting examples of in vitro assays to assess ADCC activity of a molecule of interest are described in U.S. Pat. No. 5,500,362 (see also, e.g., Hellstrom et al. Proc. Nat'l Acad. Sci. USA, vol. 83, pp. 7059-7063, 1986) and Hellstrom, I et al., Proc. Nat'l Acad. Sci. USA, vol. 82, pp. 1499-1502, 1985; U.S. Pat. No. 5,821,337 (see also, Bruggemann et al., J. Exp. Med., vol. 166, pp. 1351-1361, 1987). Alternatively, non-radioactive assay methods can be used (see, e.g., ACTI™ Non-Radioactive Cytotoxicity Assay for Flow Cytometry (CellTechnology, Inc. Mountain View, Calif.), and CytoTox 96® Non-Radioactive Cytotoxicity Assay (Promega, Madison, Wis.)). Useful effector cells for such assays include peripheral blood mononuclear cells (PBMCs) and natural killer (NK) cells.Alternatively, or additionally, the ADCC activity of the molecule of interest can be assessed in vivo, for example, in an animal model such as that disclosed in Clynes et al. Proc. Nat'l Acad. Sci. USA, vol. 95, pp. 652-656, 1998. A C1q binding assay can also be performed to confirm that the antibody is unable to bind to C1q and therefore lacks CDC activity. See, for example, the C1q and C3c binding ELISAs in WO2006 / 029879 and WO2005 / 100402. To assess complement activation, CDC assays can be performed (see, for example, Gazzano-Santoro et al., J. Immunol. Methods, vol. 202, pp. 163-171, 1996; Cragg, MS et al., Blood, vol. 101, pp. 1045-1052, 2003; and Cragg, MS, and MJ Glennie, Blood, vol. 103, pp. 2738-2743, 2004). FcRn binding and in vivo clearance / half-life determinations can also be performed using methods known in the art (see, for example, Petkova, SB et al., Int'l. Immunol., vol. 18, pp. 1759-1769, 2006).

[0166] Antibodies with reduced effector function include those with substitutions at one or more of Fc region residues 238, 265, 269, 270, 297, 327, and 329 (U.S. Pat. No. 6,737,056). Such Fc variants include Fc variants with substitutions at two or more of amino acid positions 265, 269, 270, 297, and 327, including the so-called "DANA" Fc variant with substitutions of residues 265 and 297 to alanine (U.S. Pat. No. 7,332,581).

[0167] Certain antibody variants with improved or diminished binding to FcRs have been described (see, for example, U.S. Pat. No. 6,737,056; WO2004 / 056312; and Shields et al., J. Biol. Chem., vol. 9, pp. 6591-6604, 2001).

[0168] In certain embodiments, the antibody variant comprises an Fc region with one or more amino acid substitutions that improve ADCC, e.g., substitutions at positions 298, 333, and / or 334 of the Fc region (EU numbering of residues).

[0169] In some embodiments, alterations that result in altered (i.e., improved or diminished) C1q binding and / or complement-dependent cytotoxicity (CDC), such as those described in U.S. Pat. No. 6,194,551, WO 99 / 51642, and Idusogie et al. J. Immunol., vol. 164, pp. 4178-4184, 2000, are made in the Fc region.

[0170] Antibodies with improved binding to the neonatal Fc receptor (FcRn), which is involved in the transfer of maternal IgG to the fetus (Guyer et al., J. Immunol., vol. 117, pp. 587-593, 1976 and Kim et al., J. Immunol., vol. 24, p. 249, 1994), and increased half-lives are described in US2005 / 0014934. These antibodies comprise an Fc region with one or more substitutions therein that improve binding of the Fc region to FcRn. Such Fc variants include variants with substitutions at one or more of the following residues in the Fc region: 238, 256, 265, 272, 286, 303, 305, 307, 311, 312, 317, 340, 356, 360, 362, 376, 378, 380, 382, ​​413, 424, or 434 (e.g., a substitution at residue 434 in the Fc region; U.S. Pat. No. 7,371,826). For other examples of Fc region variants, see also Duncan & Winter, Nature, vol. 322, pp. 738-740, 1988; U.S. Pat. Nos. 5,648,260 and 5,624,821; and WO 94 / 29351. Cysteine ​​Engineered Antibody Variants

[0171] In certain embodiments, it may be desirable to generate cysteine-engineered antibodies, e.g., "thioMAbs," in which one or more residues of an antibody are substituted with cysteine ​​residues. In certain embodiments, the residue substitution occurs at sites accessible to the antibody. By substituting these residues with cysteine, reactive thiol groups are placed at accessible sites on the antibody, allowing the antibody to be conjugated to other moieties, such as drug moieties or linker-drug moieties, to generate immunoconjugates, as further described herein. In certain embodiments, any one or more of the following residues may be substituted with cysteine: V205 (Kabat numbering) of the light chain, A118 (EU numbering) of the heavy chain, and 5400 (EU numbering) of the heavy chain Fc region. Cysteine-engineered antibodies may be generated, for example, as described in U.S. Pat. No. 7,521,541. antibody derivative

[0172] In certain embodiments, the antibodies or antibody fragments provided herein can be further modified to contain additional non-protein moieties that are readily available and known in the art. Suitable moieties for derivatizing antibodies or antibody fragments include, but are not limited to, water-soluble polymers. Non-limiting examples of water-soluble polymers include, but are not limited to, polyethylene glycol (PEG), ethylene glycol / propylene glycol copolymers, carboxymethylcellulose, dextran, polyvinyl alcohol, polyvinylpyrrolidone, poly-1,3-dioxolane, poly-1,3,6-trioxane, ethylene / maleic anhydride copolymers, polyamino acids (either homopolymers or random copolymers), and dextran or poly(n-vinylpyrrolidone), polyethylene glycol, propylene glycol homopolymer, propylene oxide / ethylene oxide copolymer, polyoxyethylated polyols (e.g., glycerol), polyvinyl alcohol, and mixtures thereof. Polyethylene glycol propionaldehyde may have manufacturing advantages due to its stability in water. Polymers can be of any molecular weight and can be branched or unbranched. The number of polymers attached to the antibody or antibody fragment can vary, and when more than one polymer is attached, they can be the same or different molecules. Generally, the number and / or type of polymers used for derivatization can be determined based on considerations including, but not limited to, the particular property or function of the antibody or antibody fragment to be improved, whether the derivative will be used in therapy under certain conditions, etc.

[0173] In another embodiment, a conjugate of an antibody or antibody fragment and a nonproteinaceous moiety is provided that can be selectively heated by exposure to radiation. In one embodiment, the nonproteinaceous moiety is a carbon nanotube (Kam et al., Proc. Natl. Acad. Sci. USA, vol. 102, pp. 11600-11605, 2005). The radiation may be of any wavelength, including but not limited to, wavelengths that do not harm normal cells but heat the nonproteinaceous moiety to a temperature that kills cells in close proximity to the antibody-nonproteinaceous moiety.

[0174] In another aspect, the present invention provides an anti-Axl antibody or antibody fragment comprising an isolated heavy chain variable region polypeptide or an isolated light chain variable region polypeptide. The isolated heavy chain variable region polypeptide comprises the H1, H2, and H3 regions having SEQ ID NOs: 1-3, respectively. The isolated light chain variable region polypeptide comprises the L1, L2, and L3 regions having SEQ ID NOs: 4-6, respectively.

[0175] The anti-Axl antibodies or antibody fragments of the present invention have a higher binding affinity for Axl under conditions in a tumor microenvironment than under conditions in a non-tumor microenvironment. In one embodiment, the conditions in a tumor microenvironment and the conditions in a non-tumor microenvironment are both pH levels. Thus, the anti-Axl antibodies or antibody fragments of the present invention can selectively bind to Axl at a pH of about 5 to about 6.8, but have a lower binding affinity for Axl at a pH of 7.2 to 7.8, which is found in a normal physiological environment. As shown in Examples 3 and 4, the anti-Axl antibodies or antibody fragments have a higher binding affinity at pH 6.0 than at pH 7.4.

[0176] In certain embodiments, the anti-Axl antibody or antibody fragment of the invention has a dissociation constant (Kd) with Axl under conditions in a tumor microenvironment of about ≦1 μM, ≦100 nM, ≦10 nM, ≦1 nM, ≦0.1 nM, ≦0.01 nM, or ≦0.001 nM (e.g., 10 -8 M or less, or 10 -8 M~10 -13 M, or 10 -9M~10 -13 In one embodiment, the ratio of the Kd of the antibody or antibody fragment with Axl at a value under conditions in a tumor microenvironment to the Kd at a different value under the same conditions in a non-tumor microenvironment is at least about 1.5:1, at least about 2:1, at least about 3:1, at least about 4:1, at least about 5:1, at least about 6:1, at least about 7:1, at least about 8:1, at least about 9:1, at least about 10:1, at least about 20:1, at least about 30:1, at least about 50:1, at least about 70:1, or at least about 100:1.

[0177] In one embodiment, Kd is measured by a radiolabeled antigen binding assay (RIA) performed on the antibody of interest and a Fab version of its antigen using the following assay: The solution binding affinity of a Fab for an antigen is determined by binding the Fab to a minimum concentration ( 125 I) Measurements are made by equilibrating with labeled antigen and then capturing the bound antigen using a plate coated with an anti-Fab antibody (see, e.g., Chen et al., J. Mol. Biol. 293:865-881 (1999)). To establish assay conditions, MICROTITER® multiwell plates (Thermo Scientific) are coated overnight with 5 μg / ml of capture anti-Fab antibody (Cappel Labs) in 50 mM sodium carbonate (pH 9.6), followed by blocking with 2% (w / v) bovine serum albumin in PBS for 2-5 hours at room temperature (approximately 23°C). In non-adsorbent plates (Nunc #269620), 100 pM or 26 pM [ 125[I]-antigen is mixed with serial dilutions of the Fab of interest (e.g., consistent with the evaluation of the anti-VEGF antibody Fab-12 in Presta et al., Cancer Res. 57:4593-4599 (1997)). The Fab of interest is then incubated overnight, although incubation may continue for a longer period (e.g., approximately 65 hours) to ensure equilibrium is reached. The mixture is then transferred to a capture plate and incubated at room temperature (e.g., 1 hour). The solution is then removed, and the plate is washed eight times with 0.1% polysorbate 20 (TWEEN-20®) in PBS. Once the plate has dried, 150 μl / well of scintillant (MICROSCINT-20™, Packard) is added, and the plate is counted for 10 minutes in a TOPCOUNT™ gamma counter (Packard). A concentration of each Fab that provides 20% or less of maximum binding is selected for use in competitive binding assays.

[0178] According to another embodiment, Kd is measured at approximately 10 response units (RU) using a surface plasmon resonance assay with a BIACORE®-2000 or BIACORE®-3000 (BIAcore, Inc., Piscataway, NJ) using an immobilized antigen CM5 chip at 25°C. Briefly, a carboxymethylated dextran biosensor chip (CM5, BIACORE, Inc.) is activated with N-ethyl-N'-(3-dimethylaminopropyl)-carbodiimide hydrochloride (EDC) and N-hydroxysuccinimide (NHS) according to the supplier's instructions. The antigen is diluted to 5 μg / ml (approximately 0.2 μM) with 10 mM sodium acetate (pH 4.8) and then injected at a flow rate of 5 μl / min to achieve approximately 10 response units (RU) of coupled protein. After antigen injection, 1 M ethanolamine is injected to block unreacted groups. For kinetic measurements, two-fold serial dilutions of Fab (0.78 nM to 500 nM) are injected in PBS containing 0.05% polysorbate 20 (TWEEN-20™) surfactant (PBST) at a flow rate of approximately 25 μl / min at 25° C. The association rate (kon ) and dissociation rate (k off The equilibrium dissociation constant (Kd) is calculated using a simple one-to-one Langmuir binding model (BIACORE® evaluation software version 3.2) by simultaneously fitting the association and dissociation sensorgrams. off / k on The on-rate is calculated as a ratio. See, for example, Chen et al., J. Mol. Biol. 293:865-881 (1999). When the on-rate is 10 by the surface plasmon resonance assay described above, 6 M -1 s -1 Above 1000 kJ / s, the on-rate can be determined using a fluorescence quenching technique that measures the increase or decrease in fluorescence emission intensity (excitation = 295 nm, emission = 340 nm, 16 nm bandpass) of 20 nM anti-antigen antibody (Fab form) in PBS (pH 7.2) at 25°C with increasing concentrations of antigen, as measured in a spectrometer such as a stopped-flow equipped spectrophotometer (Aviv Instruments) or an 8000 series SLM-AMINCO™ spectrophotometer (ThermoSpectronic) with a stirred cuvette.

[0179] The anti-Axl antibodies of the present invention can be chimeric, humanized, or human. In one embodiment, anti-Axl antibody fragments, such as Fv, Fab, Fab', Fab'-SH, scFv, diabody, triabody, tetrabody, or F(ab')2 fragments and multispecific antibodies formed from antibody fragments, are used. In another embodiment, the antibody is a full-length antibody, as defined herein, such as an intact IgG antibody or other antibody class or isotype. For a review of certain antibody fragments, see Hudson et al. Nat. Med., vol. 9, pp. 129-134, 2003. For a review of scFv fragments, see, e.g., Pluckthuen, in The Pharmacology of Monoclonal Antibodies, vol. 113, Rosenburg and Moore eds., (Springer-Verlag, New York), pp. 269-315 (1994); see also WO 93 / 16185; and U.S. Pat. Nos. 5,571,894 and 5,587,458. For a discussion of Fab and F(ab')2 fragments that contain salvage receptor-binding epitope residues and have increased in vivo half-lives, see U.S. Pat. No. 5,869,046.

[0180] The diabodies of the present invention can be bivalent or bispecific. For examples of diabodies, see, for example, EP 404,097, WO 1993 / 01161, Hudson et al., Nat. Med. 9:129-134 (2003), and Hollinger et al., Proc. Natl. Acad. Sci. USA, vol. 90, pp. 6444-6448, 1993. Examples of triabodies and tetrabodies are also described in Hudson et al., Nat. Med., vol. 9, pp. 129-134, 2003.

[0181] In some embodiments, the invention includes single-domain antibody fragments, comprising all or a portion of a heavy chain variable domain, or all or a portion of a light chain variable domain of an antibody. In certain embodiments, the single-domain antibody is a human single-domain antibody (Domantis, Inc., Waltham, Mass.; see, e.g., U.S. Patent No. 6,248,516 B1).

[0182] Antibody fragments can be produced by various techniques, including, but not limited to, proteolytic digestion of intact antibodies and production by recombinant host cells (e.g., E. coli or phages) as described herein.

[0183] In some embodiments, the anti-Axl antibody of the present invention may be a chimeric antibody. Certain chimeric antibodies are described, for example, in U.S. Patent No. 4,816,567 and Morrison et al., Proc. Natl. Acad. Sci. USA, vol. 81, pp. 6851-6855, (1984). In one example, a chimeric antibody comprises a non-human variable region (e.g., a variable region derived from a mouse, rat, hamster, rabbit, or non-human primate such as a monkey) and a human constant region. In a further example, a chimeric antibody is a "class-switched" antibody in which the class or subclass of the antibody is changed compared to the class or subclass of the parent antibody. Chimeric antibodies include antigen-binding fragments thereof.

[0184] In certain embodiments, the chimeric antibody of the present invention is a humanized antibody. Typically, such non-human antibodies are humanized to reduce immunogenicity to humans while retaining the specificity and affinity of the parent non-human antibody. Generally, a humanized antibody comprises one or more variable domains, in which the CDRs (or portions thereof) are derived from a non-human antibody and the FRs (or portions thereof) are derived from human antibody sequences. Optionally, the humanized antibody may also comprise at least a portion of a human constant region. In some embodiments, some FR residues of the humanized antibody are substituted with corresponding residues from the non-human antibody (e.g., the antibody from which the CDR residues are derived), e.g., to restore or improve the specificity or affinity of the antibody.

[0185] Humanized antibodies and methods for making them are reviewed, for example, in Almagro and Fransson, Front. Biosci., vol. 13, pp. 1619-1633, 2008, and further described, for example, in Riechmann et al., Nature, vol. 332, pp. 323-329, 1988; Queen et al., Proc. Nat'l Acad. Sci. USA, vol. 86, pp. 10029-10033, 1989; U.S. Patent Nos. 5,821,337; 7,527,791; 6,982,321; and 7,087,409; Kashmiri et al. al., Methods, vol. 36, pp. 25-34, 2005 (describing SDR (a-CDR) grafting), Padlan, Mol. Immunol., vol. 28, pp. 489-498, 1991 (describing "resurfacing"), Dall'Acqua et al., Methods, vol. 36, pp. 43-60, 2005 (describing "FR shuffling"), and Osbourn et al., Methods, vol. 36, pp. 61-68, 2005 and Klimka et al., Br. J. Cancer, vol. 83, pp. 252-260, 2000 (describing a "guided selection" approach to FR shuffling).

[0186] Human framework regions that can be used for humanization include, but are not limited to, framework regions selected using the "best-fit" method (see, e.g., Sims et al. J. Immunol., vol. 151, p. 2296, 1993), framework regions derived from consensus sequences of human antibodies of a particular subgroup of light or heavy chain variable regions (see, e.g., Carter et al. Proc. Natl. Acad. Sci. USA, vol. 89, p. 4285, 1992 and Presta et al. J. Immunol., vol. 151, p. 2623, 1993), human mature (somatically mutated) framework regions or human germline framework regions (see, e.g., Almagro and Fransson, Front. Biosci., vol. 13, pp. 1619-1633, 2008), and framework regions derived from screening of FR libraries (see, e.g., Baca et al. al., J. Biol. Chem., vol. 272, pp. 10678-10684, 1997 and Rosok et al., J. Biol. Chem., vol. 271, pp. 22611-22618, 1996).

[0187] In some embodiments, the anti-Axl antibody of the present invention is a multispecific antibody, e.g., a bispecific antibody. A multispecific antibody is a monoclonal antibody that has binding specificities for at least two different sites. In some embodiments, one binding specificity is for Axl and the other is for another antigen. In some embodiments, a bispecific antibody can bind to two different epitopes of Axl. Bispecific antibodies can also be used to localize cytotoxic agents to cells expressing Axl. Bispecific antibodies can be prepared as full-length antibodies or antibody fragments.

[0188] Techniques for producing multispecific antibodies include, but are not limited to, recombinant co-expression of two immunoglobulin heavy chain-light chain pairs with different specificities (see Milstein and Cuello, Nature, vol. 305, pp. 537-540, 1983; WO 93 / 08829; and Traunecker et al., EMBO J., vol. 10, pp. 3655-3659, 1991), and "knob-in-hole" engineering (see, e.g., U.S. Pat. No. 5,731,168). Multispecific antibodies can also be produced by manipulating electrostatic steering effects to create antibody Fc-heterodimeric molecules (WO2009 / 089004A1), cross-linking two or more antibodies or fragments (see, e.g., U.S. Pat. No. 4,676,980, and Brennan et al., Science, vol. 229, pp. 81-83, 1985), using leucine zippers to produce bispecific antibodies (see, e.g., Kostelny et al., J. Immunol., vol. 148, pp. 1547-1553, 1992), using "diabody" technology to create bispecific antibody fragments (see, e.g., Hollinger et al., J. Immunol., vol. 148, pp. 1547-1553, 1992), and using "diabody" technology to generate bispecific antibody fragments (see, e.g., Hollinger et al., J. Immunol., vol. 148, pp. 1547-1553, 1992). al., Proc. Natl. Acad. Sci. USA, vol. 90, pp. 6444-6448, 1993), and by using single-chain Fv (scFv) dimers (see, for example, Gruber et al., J. Immunol., vol. 152, pp. 5368-5374, 1994), as well as by preparing triabodies (see, for example, Tutt et al. J. Immunol., vol. 147, pp. 60-69, 1991).

[0189] Engineered antibodies with three or more functional antigen binding sites are also included herein, including "Octopus antibodies" (see, eg, US2006 / 0025576A1).

[0190] Antibodies or antibody fragments also include "dual acting Fabs" or "DAFs" that contain antigen binding sites that bind to Axl and another, different antigen (see, e.g., U.S. Patent Application Publication No. 2008 / 0069820).

[0191] The anti-Axl antibodies or antibody fragments of the invention can be produced using the recombinant methods and compositions detailed in U.S. Patent Application Publication No. 2016 / 0017040.

[0192] The physical / chemical properties and / or biological activity of the anti-Axl antibodies or antibody fragments of the present invention can be tested and measured by various assays known in the art, some of which are described in U.S. Patent No. 8,853,369. Immunoconjugates

[0193] In another aspect, the present invention also provides an immunoconjugate comprising an anti-Axl antibody herein conjugated to one or more cytotoxic agents, e.g., a chemotherapeutic agent or drug, a growth inhibitory agent, a toxin (e.g., a protein toxin of bacterial, fungal, plant, or animal origin, an enzymatically active toxin, or fragment thereof), or a radioactive isotope.

[0194] In one embodiment, the immunoconjugate is an antibody-drug conjugate (ADC), in which an antibody is conjugated to one or more drugs, including, but not limited to, maytansinoids (see U.S. Pat. Nos. 5,208,020, 5,416,064, and European Patent No. EP 0425235 B1), auristatins such as monomethyl auristatin drug moieties DE and DF (MMAE and MMAF) (U.S. Pat. Nos. 5,635,483 and and 7,498,298), dolastatins, calicheamicin or derivatives thereof (see U.S. Patent Nos. 5,712,374, 5,714,586, 5,739,116, 5,767,285, 5,770,701, 5,770,710, 5,773,001, and 5,877,296; Hinman et al., Cancer Res., vol. 53, pp. 3336-3342, 1993, and Lode et al., Cancer Res., vol. 58, pp. 2925-2928, 1998), anthracyclines such as daunomycin or doxorubicin (Kratz et al., Current Med. Chem., vol. 13, pp. 477-523, 2006; Jeffrey et al., Bioorganic & Med. Chem. Letters, vol. 16, pp. 358-362, 2006; Torgov et al., Bioconj. Chem., vol. 16, pp. 717-721, 2005; Nagy et al., Proc. Natl. Acad. Sci. USA, vol. 97, pp. 829-834, 2000; Dubowchik et al., al., Bioorg. & Med. Chem. Letters, vol. 12, vol. 1529-1532, 2002; King et al., J. Med. Chem., vol. 45, pp. 4336-4343, 2002; and U.S. Patent No. 6,630,579), methotrexate, vindesine, taxanes (such as docetaxel, paclitaxel, larotaxel, tesetaxel, and ortataxel), trichothecenes, and CC1065.In another embodiment, the immunoconjugate comprises an antibody described herein conjugated to an enzymatically active toxin or fragment thereof, including, but not limited to, diphtheria A chain, non-binding active fragment of diphtheria toxin, exotoxin A chain (from Pseudomonas aeruginosa), ricin A chain, abrin A chain, modeccin A chain, alpha-sarcin, Aleurites fordii protein, dianthin protein, Phytolaca americana proteins (PAPI, PAPII, and PAP-S), Momordica charantia inhibitor, curcin, crotin, Sapaonaria officinalis inhibitor, gelonin, mitogellin, restrictocin, phenomycin, enomycin, and the trichothecenes.

[0195] In another embodiment, the immunoconjugate comprises an antibody described herein conjugated to a radioactive atom to form a radioconjugate. A variety of radioisotopes are available for the production of radioconjugates. Examples include At 211 , I 131 , I 125 , Y 90 ,Re 186 ,Re 188 , Sm 153 , Bi 212 , P 32 , Pb 212 and radioactive isotopes of Lu. When a radioconjugate is used for detection, it can contain radioactive atoms for scintigraphy tests, such as tc99m or I123, or spin labels for nuclear magnetic resonance (NMR) imaging (also known as magnetic resonance imaging, mri), such as iodine-123, as well as iodine-131, indium-111, fluorine-19, carbon-13, nitrogen-15, oxygen-17, gadolinium, manganese.

[0196] Conjugates of antibodies and cytotoxic agents can be made using a variety of bifunctional protein coupling agents, such as N-succinimidyl-3-(2-pyridyldithio)propionate (SPDP), succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC), iminothiolane (IT), bifunctional derivatives of imidoesters (such as dimethyl adipimidate HCl), active esters (such as disuccinimidyl suberate), aldehydes (such as glutaraldehyde), bis-azido compounds (such as bis(p-azidobenzoyl)hexanediamine), bis-diazonium derivatives (such as bis-(p-diazoniumbenzoyl)-ethylenediamine), diisocyanates (such as toluene 2,6-diisocyanate), and bis-active fluorine compounds (such as 1,5-difluoro-2,4-dinitrobenzene). For example, ricin immunotoxins can be prepared as described in Vitetta et al., Science, vol. 238, pp. 1098-, 1987. Carbon-14 labeled 1-isothiocyanatobenzyl-3-methyldiethylenetriaminepentaacetic acid (MX-DTPA) is an exemplary chelating agent for conjugating radionucleotides to antibodies. See WO 94 / 11026. The linker can be a "cleavable linker" that facilitates the release of the cytotoxic agent inside the cell. For example, acid-labile linkers, peptidase-sensitive linkers, photolabile linkers, dimethyl linkers, or disulfide-containing linkers (Chari et al., Cancer Res., vol. 52, pp. 127-131, 1992; U.S. Patent No. 5,208,020) can be used.

[0197] Immunoconjugates encompassed herein are expressly contemplated, but include, but are not limited to, commercially available (e.g., from Pierce Biotechnology, Inc., Rockford, Ill., USA) BMPS, EMCS, GMBS, HBVS, LC-SMCC, MBS, MPBH, SBAP, SIA, SLAB, SMCC, SMPB, SMPH, sulfo-EMCS, sulfo-GMBS, sulfo-KMUS, sulfo-MBS, sulfo-SIAB, sulfo-SMCC, and sulfo-SMPB, as well as immunoconjugates prepared with cross-linking reagents including, but not limited to, SVSB (succinimidyl-(4-vinylsulfone)benzoate).

[0198] Exemplary embodiments of ADCs include an antibody (Ab) that targets a tumor cell, a drug moiety (D), and a linker moiety (L) that attaches the Ab to D. In some embodiments, the antibody is linked to the linker moiety (L) via one or more amino acid residues, such as lysine and / or cysteine.

[0199] An exemplary ADC is Ab-(LD) p wherein p is 1 to about 20. In some embodiments, the number of drug moieties that can be conjugated to an antibody is limited by the number of free cysteine ​​residues. In some embodiments, free cysteine ​​residues are introduced into the antibody amino acid sequence by the methods described herein. Exemplary ADCs of Formula I include, but are not limited to, antibodies with one, two, three, or four engineered cysteine ​​amino acids (Lyon et al., Methods in Enzym., vol. 502, pp. 123-138, 2012). In some embodiments, one or more free cysteine ​​residues are already present in the antibody without modification, in which case the existing free cysteine ​​residues can be used to conjugate the antibody to a drug. In some embodiments, the antibody is exposed to reducing conditions to generate one or more free cysteine ​​residues prior to antibody conjugation.

[0200] The present invention encompasses antibody-drug conjugates (ADCs) comprising a conditionally active biologic (CAB) anti-Axl antibody (CAB-Axl-ADC) linked to at least one drug moiety via a cleavable linker and their use for the treatment of Axl-expressing tumors. Such ADCs are preferably delivered to a subject in need of treatment in a pharmaceutical composition or kit. In some embodiments, the drug moiety is at least one cytotoxic agent, such as monomethyl uristatin drug moieties DE and DF (MMAE and MMAF). The CAB-Axl antibody can be chemically conjugated to cysteines in the heavy and light chains of the antibody via a cleavable peptide linker coupled with MMAE (a synthetic analog of the antitubulin agent dolastatin 10), resulting in a drug-to-antibody ratio (DAR) close to 4. In some embodiments, the antibody-drug conjugate comprising the anti-Axl antibody is covalently linked to MMAE via a vc-PAB linker. After binding, the CAB-Axl-ADC is internalized into tumor cells, where the peptide linker is cleaved by a protease, releasing MMAE. By specifically delivering MMAE to Axl-expressing tumor cells, it is expected to suppress further tumor cell proliferation and shrink tumors.

[0201] In some embodiments, the antibody drug conjugate is delivered to the subject as a pharmaceutical composition.

[0202] In some embodiments, the CAB-Axl-ADC is Ab-cleavable linker-MMAE(n), where MMAE is monomethyl auristatin E (MMAE), and (n) is an integer between 1 and 4, inclusive. An exemplary CAB-Axl-ADC of the invention has the following chemical structure: [ka] or a pharmaceutically acceptable salt thereof, wherein Ab is an anti-Axl antibody and S is a sulfur atom of the antibody.

[0203] In some embodiments, a CAB-Axl-ADC comprises several different moieties, including a mAb as the Ab portion, a cysteine-linked maleimide (MC), and a cleavable peptide linker containing valine and citrulline (vc) followed by MMAE. For example, a CAB-Axl-ADC can be constructed using the mAb-cleavable linker-MMAE. (n) The preferred antibody-drug conjugate is mAbBA3011-MC-vc-PAB-MMAE, a conditionally active biologic (CAB) anti-Axl humanized monoclonal antibody (mAb) (immunoglobulin IgG1) conjugated to monomethyl auristatin E (MMAE) via a cleavable linker containing the dipeptide valine-citrulline (vc), which in turn is conjugated to para-aminobenzyl alcohol (PAB) (a self-degrading moiety) (CAB-Axl-ADC). The antibody moiety (mAb), BA3011, is linked to MC-vc-PAB-MMAE via a sulfhydryl bond and is specific for Axl tyrosine kinase growth factor inhibitors. It specifically and reversibly binds Axl under conditions found within the tumor microenvironment (TME), with reduced binding to Axl outside the TME, conferring a selectivity advantage for tumors over normal cells.

[0204] Antibody-drug conjugates (ADCs), for example, conjugating potent cytotoxic agents or toxins to mAbs, offer an advance over naked antibody therapy by enhancing efficacy without increasing toxicity. Clinical utility has been demonstrated with the licensing of gemtuzumab ozogamicin (Mylotarg®) for the treatment of CD33-positive acute myeloid leukemia. Currently, two ADCs, brentuximab vedotin (Adcetris®) and adotrastuzumab emtansine (Kadcyla®), are approved by the U.S. Food and Drug Administration (FDA).

[0205] The present invention provides CAB antibodies (as well as other biologics) that preferentially bind to target tissues (e.g., tumors) associated with different diseases and tissues under defined physiological conditions. Conditional and reversible binding by CABs aims to reduce extratumoral toxicity and immunogenicity, avoid tissue-mediated drug deposition, and improve pharmacokinetics (PK). For example, in cancer, the unique cellular metabolism proposed by Warburg creates a characteristic microenvironment characterized by low pH and high lactic acid (Warburg 1924; Warburg 1956). Mecbotamab vedotin (BA3011) is a conditionally active biologic anti-AXL antibody-drug conjugate (CAB-AXL-ADC) developed as an anticancer drug for patients with advanced solid tumors. BA3011 utilizes a unique TME to preferentially bind to its target in proximity to Axl-expressing tumors. However, BA3011 exhibits reduced Axl binding in the absence of the appropriate environment. AXL is a cell surface transmembrane receptor protein tyrosine kinase highly expressed in several tumor types, including sarcomas. Increased AXL expression is associated with tumor resistance to chemotherapy, programmed death-1 (PD-1) inhibitors, molecular targeted therapy, and radiation therapy. The activated binding properties of CABs such as BA3011 are reversible, ensuring no permanent changes during migration from diseased tissue to normal tissue and the diseased tissue microenvironment. BA3011 is a humanized mAb without added non-antibody sequences to achieve its CAB properties.

[0206] BA3011 can also be administered in combination with checkpoint inhibitors, such as anti-programmed death-1 (PD-1) and anti-programmed death-ligand-1 (PD-L1) therapeutic antibodies. In general, many ADCs, especially those using MMAE as a cytotoxic payload, are being tested in combination with immuno-oncology (IO) therapies (Gerber 2016). Tumor cell immunogenic cell death (ICD), induced by certain cytotoxic compounds, potently stimulates the recruitment of effector T cells to tumors. Furthermore, because some cytotoxic agents directly stimulate the activation and maturation of dendritic cells, combining them with IO compounds improves antitumor immune responses. Among these, several cytotoxic agents are currently used as payloads for ADCs. Therefore, combination therapy of ADCs with IO compounds is expected to overcome the current limitations of immune checkpoint inhibitors by increasing the recruitment of CD8+ effector T cells to the tumor core. With regard to clinical trials, ADC-IO combinations may have broad implications for oncology drug development, as the synergistic effect of IO compounds and ADCs may facilitate the formation of tumor-specific immunological memory and ultimately result in durable responses in a greater proportion of cancer patients (Coats 2019). Regarding the combination of BA3011 and checkpoint inhibitors, transcriptome analysis of PD-1-resistant melanoma patients revealed a series of elevated genes involved in immunosuppression, angiogenesis, macrophage chemotaxis, extracellular matrix remodeling, and epithelial-mesenchymal transition (EMT). Among these upregulated genes was Axl, a target of BA3011 (Hugo 2016; Bu 2016). The upregulation of Axl in PD-1-resistant tumors strongly suggests a role in resistance and relapse in this population, providing ample justification for combining BA3011 with PD-1 inhibitors such as nivolumab. Exemplary Linkers

[0207] A "linker" (L) is a bifunctional or polyfunctional moiety that can be used to attach one or more moieties, e.g., a drug moiety (D), to an antibody (Ab) to form an immunoconjugate, e.g., an ADC of Formula I. In some embodiments, an ADC can be prepared using a linker with reactive functional groups for covalently binding to a drug and to an antibody. For example, in some embodiments, a cysteine ​​thiol of an antibody (Ab) can form a bond with a reactive functional group of a linker or a drug-linker intermediate to create an ADC.

[0208] In one embodiment, linker has a functional group that can react with the free cysteine ​​present on antibody to form a covalent bond.Non-limiting examples of such reactive functional groups include maleimide, haloacetamide, α-haloacetyl, activated ester (for example, succinimide ester, 4-nitrophenyl ester, pentafluorophenyl ester, tetrafluorophenyl ester), anhydride, acid chloride, sulfonyl chloride, isocyanate, and isothiocyanate.For example, see the conjugation method in page 766 of Klussman, et al., Bioconjugate Chemistry, vol.15, pp.765-773, 2004.

[0209] In some embodiments, the linker has a functional group that can react with an electrophilic group present on an antibody. Exemplary such electrophilic groups include, but are not limited to, aldehyde and ketone carbonyl groups. In some embodiments, a heteroatom of the reactive functional group of the linker can react with an electrophilic group on an antibody to form a covalent bond to an antibody unit. Non-limiting exemplary such reactive functional groups include, but are not limited to, hydrazide, oxime, amino, hydrazine, thiosemicarbazone, hydrazine carboxylate, and arylhydrazide.

[0210] The linker may comprise one or more linker components. Exemplary linker components include 6-maleimidocaproyl ("MC"), maleimidopropanoyl ("MP"), valine-citrulline ("val-cit" or "vc"), alanine-phenylalanine ("ala-phe"), p-aminobenzyloxycarbonyl ("PAB"), N-succinimidyl 4-(2-pyridylthio)pentanoate ("SPP"), and 4-(N-maleimidomethyl)cyclohexane-1-carboxylate ("MCC"). Various linker components are known in the art, some of which are described below.

[0211] The linker may be a "cleavable linker" that facilitates the release of the drug. Non-limiting examples of cleavable linkers include acid-labile linkers (e.g., containing hydrazones), protease-sensitive (e.g., peptidase-sensitive) linkers, photolabile linkers, or disulfide-containing linkers (Chari et al., Cancer Research, vol. 52, pp. 127-131, 1992; U.S. Pat. No. 5,208,020).

[0212] In some embodiments, the linker has the following formula II: -Aa-Ww-Yy-, where A is a "stretcher unit" and a is an integer from 0 to 1; W is an "amino acid unit" and w is an integer from 0 to 12; Y is a "spacer unit" and y is 0, 1, or 2. An ADC comprising a linker of formula II has formula I(A): Ab-(Aa-Ww-Yy-D)p, where Ab, D, and p are as defined above for formula I. Exemplary embodiments of such linkers are described in U.S. Patent No. 7,498,298.

[0213] In some embodiments, a linker component comprises a "stretcher unit" (A) that attaches the antibody to another linker component or to a drug moiety. Non-limiting exemplary stretcher units are shown below (where the wavy line indicates the site of covalent attachment to an antibody, drug, or additional linker component): [ka]

[0214] In some embodiments, the linker component comprises an "amino acid unit" (W). In some such embodiments, the amino acid unit allows for cleavage of the linker by a protease, thereby facilitating release of the drug from the immunoconjugate upon exposure to an intracellular protease, e.g., a lysosomal enzyme (Doronina et al., Nat. Biotechnol., vol. 21, pp. 778-784, 2003). Exemplary amino acid units include, but are not limited to, dipeptides, tripeptides, tetrapeptides, and pentapeptides. Exemplary dipeptides include, but are not limited to, valine-citrulline (vc or val-cit), alanine-phenylalanine (af or ala-phe), phenylalanine-lysine (fk or phe-lys); phenylalanine-homolysine (phe-homolys); and N-methyl-valine-citrulline (Me-val-cit). Exemplary tripeptides include, but are not limited to, glycine-valine-citrulline (gly-val-cit) and glycine-glycine-glycine (gly-gly-gly). The amino acid unit may contain naturally occurring amino acid residues and / or minor amino acids and / or non-naturally occurring amino acid analogs, such as citrulline. The amino acid unit can be designed and optimized for enzymatic cleavage by specific enzymes, such as tumor-associated proteases, cathepsins B, C, and D, or plasmin proteases.

[0215] Typically, peptide-type linkers can be prepared by forming a peptide bond between two or more amino acids and / or peptide fragments. Such peptide bonds can be prepared, for example, according to lipid phase synthesis (e.g., E. Schroder and K. Luebke (1965) "The Peptides", volume 1, pp. 76-136, Academic Press).

[0216] In some embodiments, the linker component comprises a "spacer" unit (Y) that links the antibody to the drug moiety directly or via a stretcher unit and / or an amino acid unit. The spacer unit can be "self-immolative" or "non-self-immolative." A "non-self-immolative" spacer unit is one in which some or all of the spacer unit remains attached to the drug moiety upon cleavage of the ADC. Examples of non-self-immolative spacer units include, but are not limited to, a glycine spacer unit and a glycine-glycine spacer unit. In some embodiments, enzymatic cleavage of an ADC containing a glycine-glycine spacer unit by tumor cell-associated proteases results in release of the glycine-glycine-drug moiety from the remainder of the ADC. In some such embodiments, the glycine-glycine-drug moiety is subjected to a hydrolysis step in the tumor cell, thus cleaving the glycine-glycine spacer unit from the drug moiety.

[0217] The "self-immolating" spacer unit allows for the release of the drug moiety. In certain embodiments, the spacer unit of the linker comprises a p-aminobenzyl unit. In some such embodiments, p-aminobenzyl alcohol is attached to the amino acid unit via an amide bond, and a carbamate, methylcarbamate, or carbonate is created between the benzyl alcohol and the drug (Hamann et al. Expert Opin. Ther. Patents, vol. 15, pp. 1087-1103, 2005). In some embodiments, the spacer unit comprises p-aminobenzyloxycarbonyl (PAB). In some embodiments, an ADC comprising a self-immolating linker has the structure: [ka] where Q is -C1-C8 alkyl, -O-(C1-C8 alkyl), -halogen, -nitro, or -cyano; m is an integer ranging from 0 to 4; X can be one or more additional spacer units or can be absent; and p ranges from 1 to about 20. In some embodiments, p ranges from 1 to 10, 1 to 7, 1 to 5, or 1 to 4. Non-limiting exemplary X spacer units include: [ka] wherein R1 and R2 are independently selected from H and C1-C6 alkyl. In some embodiments, R1 and R2 are each -CH3.

[0218] Other examples of self-immolating spacers include, but are not limited to, aromatic compounds that are electronically similar to the PAB group, such as 2-aminoimidazole-5-methanol derivatives (U.S. Pat. No. 7,375,078; Hay et al., Bioorg. Med. Chem. Lett., vol. 9, p. 2237-, 1999) and ortho- or para-aminobenzyl acetals. In some embodiments, spacers that undergo cyclization upon amide bond hydrolysis can be used, such as substituted and unsubstituted 4-aminobutyric acid amides (Rodrigues et al., Chemistry Biology, Vol. 2, pp. 223-, 1995), appropriately substituted bicyclo[2.2.1] and bicyclo[2.2.2] ring systems (Storm et al., J. Amer. Chem. Soc., Vol. 94, p. 5815-, 1972), and 2-aminophenylpropionic acid amides (Amsbury et al., J. Org. Chem., Vol. 55, p. 5867, 1990). Attachment of a drug to the α-carbon of a glycine residue is another example of a self-immolating spacer that can be useful in ADCs (Kingsbury et al., J. Med. Chem., Vol. 27, p. 1447, 1984).

[0219] In some embodiments, the linker L can be a dendritic linker for covalently linking two or more drug moieties to an antibody via a branched, multifunctional linker moiety (Sun et al., Bioorganic & Medicinal Chemistry Letters, vol. 12, pp. 2213-2215, 2002; Sun et al., Bioorganic & Medicinal Chemistry, vol. 11, pp. 1761-1768, 2003). Dendritic linkers can increase the drug-to-antibody molar ratio, i.e., loading, which is related to the efficacy of the ADC. Thus, if an antibody bears only one reactive cysteine ​​thiol group, multiple drug moieties can be attached via a dendritic linker.

[0220] Non-limiting exemplary linkers are shown below in the context of ADCs of Formula I: [ka] [ka] [ka] wherein R1 and R2 are independently selected from H and C1-C6 alkyl. In some embodiments, R1 and R2 are each -CH3. [ka] (wherein n is 0 to 12). In some embodiments, n is 2 to 10. In some embodiments, n is 4 to 8.

[0221] Further non-limiting exemplary ADCs include those having the structure: [ka] each R is independently H or C1-C6 alkyl; and n is 1 to 12.

[0222] In some embodiments, the linker is substituted with groups that modulate solubility and / or reactivity. Non-limiting examples include charged substituents, such as sulfonates (-SO3 - ) or ammonium may increase the water solubility of the linker reagent and facilitate the coupling reaction of the linker reagent with the antibody and / or drug moiety, or may facilitate the coupling reaction of Ab-L (antibody-linker intermediate) with D, or the coupling reaction of DL (drug-linker intermediate) with Ab, depending on the synthetic route used to prepare the ADC. In some embodiments, a portion of the linker is coupled to the antibody, a portion of the linker is coupled to the drug, and then Ab-(linker moiety)a is coupled to drug-(linker moiety)b to form the ADC of Formula I.

[0223] The compounds of the present invention expressly contemplate ADCs prepared using the following linker reagents, but are not limited to: bismaleimidotrioxyethylene glycol (BMPEO), N-(β-maleimidopropyloxy)-N-hydroxysuccinimide ester (BMPS), N-(ε-maleimidocaproyloxy)succinimide ester (EMCS), N-[γ-maleimidobutyryloxy]succinimide ester (GMBS), 1,6-hexane-bisvinylsulfone (HBVS), succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxy-(6-amidocaprate) (LC-SMCC), m-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS), 4-(4-N-maleimidophenyl)butyric acid hydrazide, succinimidyl 3-(Bromoacetamido)propionate (SBAP), succinimidyl iodoacetate (SIA), succinimidyl (4-iodoacetyl)aminobenzoate (SIAB), N-succinimidyl-3-(2-pyridyldithio)propionate (SPDP), N-succinimidyl-4-(2-pyridylthio)pentanoate (SPP), succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC), succinimidyl 4-(p-maleimidophenyl)butyrate (SMPB), succinimidyl 6-[(β-maleimidopropionamido)hexanoate] (SMPH), iminothiolane (IT), sulfo-EMCS, sulfo-GMBS, sulfo-KMUS, sulfo-MBS, sulfo-SIAB, sulfo-SMCC, and sulfo-SMPB, and succinimidyl-(4-vinylsulfone)benzoate (SVSB), and bismaleimide reagents including: dithiobismaleimidoethane (DTME), 1,4-bismaleimidobutane (BMB), 1,4 bismaleimido-2,3-dihydroxybutane (BMDB), bismaleimidohexane (BMH), bismaleimidoethane (BMOE), BM(PEG)2 (shown below), and BM(PEG)3 (shown below);Bifunctional derivatives of imidoesters (such as dimethyl adipimidate HCl), active esters (such as disuccinimidyl suberate), aldehydes (such as glutaraldehyde), bis-azido compounds (such as bis(p-azidobenzoyl)hexanediamine), bis-diazonium derivatives (such as bis-(p-diazoniumbenzoyl)-ethylenediamine), diisocyanates (such as toluene 2,6-diisocyanate), and bis-active fluorine compounds (such as 1,5-difluoro-2,4-dinitrobenzene). In some embodiments, bis-maleimide reagents allow for the attachment of thiol groups of cysteines in antibodies to thiol-containing drug moieties, linkers, or linker-drug intermediates. Other functional groups reactive with thiol groups include, but are not limited to, iodoacetamide, bromoacetamide, vinylpyridine, disulfides, pyridyl disulfides, isocyanates, and isothiocyanates.

[0224] Certain useful linker reagents can be obtained from a variety of commercial sources, e.g., Pierce Biotechnology, Inc. (Rockford, Ill.), Molecular Biosciences Inc. (Boulder, Colo.), or synthesized according to procedures described in the art; e.g., Toki et al., J. Org. Chem., Vol. 67, pp. 1866-1872, 2002; Dubowchik et al., Tetrahedron Letters, Vol. 38, pp. 5257-60, 1997; Walker, J. Org. Chem., Vol. 60, pp. 5352-5355, 1995; Frisch et al., Biosonjugate Chem., Vol. 7, pp. 180-186, 1995; U.S. Pat. No. 6,214,345; WO Nos. 02 / 088172; US2003130189; US2003096743; WO 03 / 026577; WO 03 / 043583; and WO 04 / 032828.

[0225] Carbon-14 labeled 1-isothiocyanatobenzyl-3-methyldiethylenetriaminepentaacetic acid (MX-DTPA) is an exemplary chelating agent for conjugating radionucleotides to antibodies. See, e.g., WO 94 / 11026. Exemplary Drug Moieties 1) Maytansine and maytansinoids

[0226] In some embodiments, the immunoconjugate comprises an antibody conjugated to one or more maytansinoid molecules. Maytansinoids are derivatives of maytansine, which are mitotic inhibitors that act by inhibiting tubulin polymerization. Maytansine was first isolated from the East African shrub Maytenus serrata (U.S. Pat. No. 3,896,111). Subsequently, it was discovered that certain microorganisms also produce maytansinoids, such as maytansinol and C-3 maytansinol esters (U.S. Pat. No. 4,151,042). Synthetic maytansinoids are disclosed, for example, in U.S. Patent Nos. 4,137,230; 4,248,870; 4,256,746; 4,260,608; 4,265,814; 4,294,757; 4,307,016; 4,308,268; 4,308,269; 4,309,428; 4,313,946; 4,315,929; 4,317,821; 4,322,348; 4,331,598; 4,361,650; 4,364,866; 4,424,219; 4,450,254; 4,362,663; and 4,371,533.

[0227] Maytansinoid drug moieties are attractive drug moieties for antibody-drug conjugates because they are (i) relatively accessible to prepare by fermentation or chemical modification, or derivatization of fermentation products, (ii) amenable to derivatization with functional groups suitable for conjugation to antibodies via non-disulfide linkers, (iii) stable in plasma, and (iv) effective against a variety of tumor cell lines.

[0228] Certain maytansinoids suitable for use as maytansinoid drug moieties are known in the art and can be isolated from natural sources according to known methods or produced using genetic engineering techniques (see, e.g., Yu et al., PNAS, vol. 99, pp. 7968-7973, 2002). Maytansinoids can also be prepared synthetically according to known methods.

[0229] Exemplary maytansinoid drug moieties include, but are not limited to, those with the following modified aromatic rings: C-19-dechloro (U.S. Pat. No. 4,256,746) (prepared, e.g., by aluminum lithium hydride reduction of ansamintocin P2); C-20-hydroxy (or C-20-demethyl) + / -C-19-dechloro (U.S. Pat. Nos. 4,361,650 and 4,307,016) (prepared, e.g., by demethylation with Streptomyces or Actinomycetes, or by dechlorination with LAH); and C-20-demethoxy, C-20-acyloxy (-OCOR), + / -dechloro (U.S. Pat. No. 4,294,757) (prepared, e.g., by acylation with acyl chloride), and those with modifications at other positions on the aromatic ring.

[0230] Exemplary maytansinoid drug moieties also include those with modifications such as: C-9-SH (U.S. Pat. No. 4,424,219) (e.g., prepared by reaction of maytansinol with H2S or P2S5); C-14-alkoxymethyl (demethoxy / CH2OR) (U.S. Pat. No. 4,331,598); C-14-hydroxymethyl or acyloxymethyl (CH2OH or CHOAc) (U.S. Pat. No. 4,450,254) (e.g., prepared from Nocardia); C-15-hydroxy / acyloxy (U.S. Pat. No. 4,364,866) (e.g., prepared by conversion of maytansinol by Streptomyces); C-15-methoxy (U.S. Pat. Nos. 4,313,946 and 4,315,929) (e.g., isolated from Trewia nudlflora); C-18-N-demethyl (U.S. Pat. Nos. 4,362,663 and 4,322,348) (prepared, for example, by demethylation of maytansinol by Streptomyces); and 4,5-deoxy (U.S. Pat. No. 4,371,533) (prepared, for example, by titanium trichloride / LAH reduction of maytansinol).

[0231] Many positions on a maytansinoid compound are useful as attachment positions. For example, an ester bond can be formed by reaction with a hydroxyl group using conventional coupling techniques. In some embodiments, the reaction can occur at the C-3 position, which bears a hydroxyl group, the C-14 position, which is modified with hydroxymethyl, the C-15 position, which is modified with a hydroxyl group, and the C-20 position, which bears a hydroxyl group. In some embodiments, the bond is formed at the C-3 position of maytansinol or a maytansinol analog.

[0232] Maytansinoid drug moieties include those having the following structure: [ka] (wherein the wavy line indicates the covalent attachment of the sulfur atom of the maytansinoid drug moiety to the linker of the ADC). Each R can independently be H or C1-C6 alkyl. The alkylene chain connecting the amide group to the sulfur atom can be methanyl, ethanyl, or propyl, i.e., m is 1, 2, or 3 (U.S. Pat. No. 633,410; U.S. Pat. No. 5,208,020; Chari et al., Cancer Res., vol. 52, pp. 127-131, 1992; Liu et al., Proc. Nall. Acad. Sci. USA, vol. 93, pp. 8618-8623, 1996).

[0233] In the ADCs of the invention, all stereoisomers of the maytansinoid drug moiety are contemplated, i.e., any combination of R and S configurations of the chiral carbon (U.S. Pat. No. 7,276,497; U.S. Pat. No. 6,913,748; U.S. Pat. No. 6,441,163; U.S. Pat. No. 633,410 (RE39151); U.S. Pat. No. 5,208,020; Widdison et al (2006) J. Med. Chem. 49:4392-4408). In some embodiments, the maytansinoid drug moiety has the following stereochemistry: [ka]

[0234] Exemplary embodiments of maytansinoid drug moieties include, but are not limited to, those having the structure: [ka] [ka] [ka]

[0235] DM1; DM3 and DM4, each having the formula: (wherein the wavy line indicates the covalent bond of the sulfur atom of the drug to the linker (L) of the antibody-drug conjugate). An exemplary antibody-drug conjugate in which DM1 is attached to a thiol group of an antibody via a BMPEO linker has the structure and abbreviation: [ka] where Ab is an antibody; n is 0, 1, or 2; and p is 1 to about 20. In some embodiments, p is 1 to 10, p is 1 to 7, p is 1 to 5, or p is 1 to 4.

[0236] Immunoconjugates containing maytansinoids, methods for their preparation and therapeutic uses are disclosed, for example, in U.S. Patent Nos. 5,208,020 and 5,416,064; U.S. Patent Application Publication No. 2005 / 0276812A1; and European Patent No. 0425235B1. See also Liu et al., Proc. Natl. Acad. Sci. USA, vol. 93, pp. 8618-8623, 1996; and Chari et al., Cancer Research, vol. 52, pp. 127-131, 1992.

[0237] In some embodiments, antibody-maytansinoid conjugates can be prepared by chemically linking an antibody to a maytansinoid molecule without substantially diminishing the biological activity of either the antibody or the maytansinoid molecule. See, e.g., U.S. Patent No. 5,208,020. In some embodiments, ADCs with an average of 3 to 4 maytansinoid molecules conjugated per antibody molecule have shown efficacy in improving target cell cytotoxicity without adversely affecting antibody function or solubility. In some instances, even a single molecule of toxin / antibody is expected to improve cytotoxicity compared to the use of naked antibodies.

[0238] Exemplary linking groups for producing antibody-maytansinoid conjugates include, for example, those described herein and those disclosed in U.S. Pat. No. 5,208,020; European Patent No. 0425235B1; Chari et al., Cancer Research, vol. 52, pp. 127-131, 1992; U.S. Patent Application Publication No. 2005 / 0276812A1; and U.S. Patent Application Publication No. 2005 / 016993A1. (2) Auristatins and dolastatins

[0239] Drug moieties include dolastatins, auristatins, and their analogs and derivatives (U.S. Pat. Nos. 5,635,483; 5,780,588; 5,767,237; 6,124,431). Auristatins are derivatives of the marine mollusk compound dolastatin-10. Without being bound by any particular theory, dolastatins and auristatins have been shown to inhibit microtubule dynamics, GTP hydrolysis, and nuclear and cell division (Woyke et al., Antimicrob. Agents and Chemother., vol. 45, pp. 3580-3584, 2001), as well as to have anticancer activity (U.S. Pat. No. 5,663,149) and antifungal activity (Pettit et al., Antimicrob. Agents Chemother., vol. 42, pp. 2961-2965, 1998). Dolastatin / auristatin drug moieties can be attached to antibodies through the N-terminus or C-terminus of the peptidic drug moiety (WO 02 / 088172; Doronina et al., Nature Biotechnology, vol. 21, pp. 778-784, 2003; Francisco et al., Blood, vol. 102, pp. 1458-1465, 2003).

[0240] Exemplary auristatin embodiments include the N-terminally linked monomethyl auristatin drug moieties DE and DF disclosed in U.S. Pat. Nos. 7,498,298 and 7,659,241: [ka] (In the formula, D E and D F The wavy lines indicate the site of covalent attachment to the antibody or antibody-linker component, and independently at each position: R 2 is selected from H and C1-C8 alkyl; R 3 is selected from H, C1-C8 alkyl, C3-C8 carbocycle, aryl, C1-C8 alkyl-aryl, C1-C8 alkyl-(C3-C8 carbocycle), C3-C8 heterocycle and C1-C8 alkyl-(C3-C8 heterocycle); R 4 is selected from H, C1-C8 alkyl, C3-C8 carbocycle, aryl, C1-C8 alkyl-aryl, C1-C8 alkyl-(C3-C8 carbocycle), C3-C8 heterocycle and C1-C8 alkyl-(C3-C8 heterocycle); R 5 is selected from H and methyl; or R 4 and R 5 together form a carbocyclic ring of the formula -(CR a R b ) n -(In the formula, R a and R b are independently selected from H, C1-C8 alkyl, and C3-C8 carbocyclic compounds, and n is selected from 2, 3, 4, 5, and 6; R 6 is selected from H and C1-C8 alkyl; R 7 is selected from H, C1-C8 alkyl, C3-C8 carbocycle, aryl, C1-C8 alkyl-aryl, C1-C8 alkyl-(C3-C8 carbocycle), C3-C8 heterocycle and C1-C8 alkyl-(C3-C8 heterocycle); Each R 8 are independently selected from H, OH, C1-C8 alkyl, C3-C8 carbocycle, and O—(C1-C8 alkyl); R 9 is selected from H and C1-C8 alkyl; R 10 is selected from aryl or a C3-C8 heterocycle; Z is O, S, NH, or NR 12 and R 12 is C1-C8 alkyl; R 11 is H, C1-C20 alkyl, aryl, C3-C8 heterocycle, -(R 13 O) m -R 14 , or (R 13 O) m -CH(R 15 )2 is selected; m is an integer ranging from 1 to 1000; R 13 is a C2-C8 alkyl; R 14 is H or C1-C8 alkyl; Each occurrence of e is independently H, COOH, -(CH2) n -N(R 16 )2, -(CH2) n -SO3H, or (CH2) n -SO3-C1-C8 alkyl; Each occurrence of e is independently H, C1-C8 alkyl, or (CH2) n -COOH; R 18 is -C(R 8 )2-C(R 8 )2-aryl, -C(R 8 )2-C(R 8 )2 (C3-C8 heterocycle), and C(R 8 )2-C(R 8 )2 (C3-C8 carbocyclic ring); where n is an integer ranging from 0 to 6.

[0241] In one embodiment, R3 , R 4 and R 7 are independently isopropyl or sec-butyl, and R 5 is —H or methyl. In an exemplary embodiment, R 3 and R 4 are isopropyl, and R 5 is -H, and R 7 is sec-butyl.

[0242] In yet other embodiments, R 2 and R 6 are methyl, and R 9 is -H.

[0243] In yet other embodiments, R 8 Each occurrence of is -OCH3.

[0244] In an exemplary embodiment, R 3 and R 4 are isopropyl, and R 2 and R 6 are methyl, and R 5 is -H, and R 7 is sec-butyl, and R 8 Each occurrence of is -OCH3 and R 9 is -H.

[0245] In one embodiment, Z is —O— or —NH—.

[0246] In one embodiment, R 10 is aryl.

[0247] In an exemplary embodiment, R 10 is -phenyl.

[0248] In an exemplary embodiment, when Z is —O—, R 11 is -H, methyl or t-butyl.

[0249] In one embodiment, when Z is —NH, R 11 is -CH(R 15 )2 and R 15 is -(CH2) n -N(R 16 )2 and R 16 is -C1-C8 alkyl or (CH2) n -COOH.

[0250] In another embodiment, when Z is -NH, R 11 is -CH(R 15 )2 and R 15 is -(CH2) n -SO3H.

[0251] Formula D E An exemplary auristatin embodiment of is MMAE, where the wavy line indicates the covalent attachment to the linker (L) of the antibody-drug conjugate: [ka]

[0252] Formula D E An exemplary auristatin embodiment of is MMAE, where the wavy line indicates the covalent attachment to the linker (L) of the antibody-drug conjugate: [ka]

[0253] Other exemplary embodiments include monomethylvaline compounds with a phenylalanine carboxy modification at the C-terminus of the pentapeptide auristatin drug moiety (WO 2007 / 008848) and monomethylvaline compounds with a phenylalanine side chain modification at the C-terminus of the pentapeptide auristatin drug moiety (WO 2007 / 008603).

[0254] Non-limiting exemplary embodiments of ADCs of Formula I comprising MMAF and various linker components also include Ab-MC-PAB-MMAF and Ab-PAB-MMAF. Immunoconjugates comprising MMAF attached to an antibody by a non-proteolytically cleavable linker have been shown to possess activity equivalent to that of immunoconjugates comprising MMAF attached to an antibody by a proteolytically cleavable linker (see Doronina et al., Bioconjugate Chem., vol. 17, pp. 114-124, 2006). In some such embodiments, drug release is believed to be influenced by antibody degradation in cells.

[0255] Typically, peptide-based drug moieties can be prepared by forming a peptide bond between two or more amino acids and / or peptide fragments. Such peptide bonds can be prepared, for example, according to solution-phase synthesis methods well known in the field of peptide chemistry (see, for example, E. Schroeder and K. Luebke, "The Peptides," volume 1, pp. 76-136, 1965, Academic Press). Auristatin / dolastatin drug moieties, in some embodiments, can be prepared according to the following methods: U.S. Pat. No. 7,498,298, U.S. Pat. No. 5,635,483, U.S. Pat. No. 5,780,588; Pettit et al., J. Am. Chem. Soc., vol. 111, pp. 5463-5465, 1998; Pettit et al., Anti-Cancer Drug Design, vol. 13, pp. 243-277, 1998; Pettit et al., Synthesis, vol. 6, pp. 719-725, 1996; Pettit et al., J. Chem. Soc. Perkin Trans., vol. 15, pp. 859-863, 1996; and Doronina, Nat. Biotechnol., vol. 21, pp. 778-784, 2003.

[0256] In some embodiments, a compound of formula D, such as MMAE E , and formula D such as MMAF E and drug linker intermediates such as MC-MMAF, MC-MMAE, MC-vc-PAB-MMAF, and MC-vc-PAB-MMAE and derivatives thereof are described in U.S. Pat. No. 7,498,298; Doronina et al., Bioconjugate Chem., vol. 17, pp. 114-124, 2006; and Doronina et al., Nat. Biotech., vol. 21, pp. 778-784, 2003, and are then conjugated to an antibody of interest. (3) Callicare sewing machine

[0257] In some embodiments, the immunoconjugate comprises an antibody conjugated to one or more calicheamicin molecules. The calicheamicin family of antibiotics and their analogs can produce double-stranded DNA breaks at sub-picomolar concentrations (Hinman et al., Cancer Research, vol. 53, pp. 3336-3342, 1993; Lode et al., Cancer Research, vol. 58, pp. 2925-2928, 1998). Although calicheamicin has an intracellular site of action, in some instances, it does not readily cross the cell membrane. Therefore, cellular uptake of these agents via antibody-mediated internalization can, in some embodiments, greatly enhance their cytotoxic effects. Non-limiting exemplary methods for preparing antibody-drug conjugates having a calicheamicin drug moiety are described, for example, in U.S. Pat. Nos. 5,712,374; 5,714,586; 5,739,116; and 5,767,285. (4) Pyrrolobenzodiazepines

[0258] In some embodiments, the ADC comprises a pyrrolobenzodiazepine (PBD). In some embodiments, the PBD dimer recognizes and binds to a specific DNA sequence. The natural product anthramycin, PBD, was first reported in 1965 (Leimgruber et al., J. Am. Chem. Soc., vol. 87, pp. 5793-5795, 1965; Leimgruber et al., J. Am. Chem. Soc., vol. 87, pp. 5791-5793, 1965). Since then, numerous naturally occurring PBDs and analogues have been reported (Thurston et al., Chem. Rev. vol. 1994, pp. 433-465 1994), including dimers of tricyclic PBD scaffolds (U.S. Pat. No. 6,884,799; U.S. Pat. No. 7,049,311; U.S. Pat. No. 7,067,511; U.S. Pat. No. 7,265,105; U.S. Pat. No. 7,511,032; U.S. Pat. No. 7,528,126; U.S. Pat. No. 7,557,099). Without being bound by any particular theory, it is believed that the dimeric structure confers the proper three-dimensional shape for isohelicity with the minor groove of B-form DNA, resulting in a smooth fit at the binding site (Kohn, In Antibiotics III. Springer-Verlag, New York, pp. 3-11 (1975); Hurley and Needham-VanDevanter, Acc. Chem. Res., vol. 19, pp. 230-237, 1986). Dimeric PBD compounds bearing C2 aryl substituents have been shown to be useful as cytotoxic agents (Hartley et al., Cancer Res., vol. 70, pp. 6849-6858, 2010; Antonow, J. Med. Chem., vol. 53, pp. 2927-2941, 2010; Howard et al., Bioorganic and Med. Chem. Letters, vol. 19, pp. 6463-6466, 2009).

[0259] PBD dimers have been conjugated to antibodies, and the resulting ADCs have been shown to have anticancer properties. Non-limiting exemplary binding sites on PBD dimers include the five-membered pyrrolo ring, the tether between PBD units, and the N10-C11 imine group (WO 2009 / 016516; U.S. Patent Application Publication No. 2009 / 304710; U.S. Patent Application Publication No. 2010 / 047257; U.S. Patent Application Publication No. 2009 / 036431; U.S. Patent Application Publication No. 2011 / 0256157; WO 2011 / 130598).

[0260] A non-limiting exemplary PBD dimer component of an ADC has Formula A: [ka] and salts and solvates thereof, wherein The wavy line indicates the site of covalent attachment to the linker; The dotted lines indicate the optional presence of a double bond between C1 and C2 or between C2 and C3; R 2 are H, OH, =O, =CH2, CN, R, OR, =CH-R D , =C(R D ) 2 , O—SO—R, CO—R, and COR, and optionally further selected from halo or dihalo; R D are independently selected from R, COR, COR, CHO, COH, and halo; R 6 and R 9 are independently selected from H, R, OH, OR, SH, SR, NH, NHR, NRR', NO, MeSn, and halo; R 7 are independently selected from H, R, OH, OR, SH, SR, NH, NHR, NRR', NO, MeSn, and halo; Q is independently selected from O, S, and NH; R 11is either H or R, or when Q is O, SO3M, where M is a metal cation; R and R' are optionally substituted C1-8 alkyl, C1- 12 Alkyl, C3-8 heterocyclyl, C3- 20 Heterocycles, and C5~ 20 aryl groups, optionally in conjunction with the group NRR′, R and R′ together with the nitrogen atom to which they are attached form an optionally substituted 4-, 5-, 6-, or 7-membered heterocyclic ring; R 12 , R 16 , R 19 , and R 17 are R 2 , R 6 , R 9 , and R 7 as defined for R" is C 3~12 alkylene groups, the chain of which may be interrupted by one or more heteroatoms, such as O, S, N(H), NMe, and / or aromatic rings, such as benzene or pyridine, which rings are optionally substituted; X and X' are independently selected from O, S, and N(H).

[0261] In some embodiments, R and R' are optionally substituted C1- 12 Alkyl, C3~ 20 Heterocycles, and C5~ 20 aryl groups, and optionally in conjunction with the group NRR′, R and R′ together with the nitrogen atom to which they are attached form an optionally substituted 4-, 5-, 6-, or 7-membered heterocyclic ring. In some embodiments, R 9 and R 19 is H, and in some embodiments, R 6 and R 16 is H.

[0262] In some embodiments, R 7and R 17 are both OR 7A and R 7A is optionally substituted C 1~4 In some embodiments, R 7A is Me. In some embodiments, R 7A is ChPh, where Ph is a phenyl group. In some embodiments, X is O. In some embodiments, R 11 is H. In some embodiments, there is a double bond between C2 and C3 in each monomer unit.

[0263] In some embodiments, R 2 and R 12 is independently selected from H and R. In some embodiments, R 2 and R 12 is independently R. In some embodiments, R 2 and R 12 are independently optionally substituted C 5~20 Aryl or C 5~7 Aryl or C 8~10 In some embodiments, R 2 and R 12 is independently an optionally substituted phenyl, thienyl, naphthyl, pyridyl, quinolinyl, or isoquinolinyl. 2 and R 12 are =O, =CH2, =CH-R D , and =C(R D )2. In some embodiments, R 2 and R 12 are each ═CH. In some embodiments, R 2 and R 12 are each H, and in some embodiments, R 2 and R 12 are each ═O. In some embodiments, R 2 and R 12 are each ═CF. In some embodiments, R2 and / or R 12 are independently = C(R D )2. In some embodiments, R 2 and / or R 12 are independently =CH-R D is.

[0264] In some embodiments, R 2 and / or R 12 =CH-R D When , each group can independently have any of the configurations shown below: [ka] In some embodiments, =CH-R D is configuration (I). In some embodiments, R" is a C3 alkylene group or a C5 alkylene group.

[0265] The PBD dimer-val-cit-PAB-Ab and PBD dimer-Phe-Lys-PAB-Ab linkers are protease cleavable, while the PBD dimer-maleimide-acetal linker is acid labile.

[0266] PBD dimers and ADCs containing PBD dimers can be prepared according to methods known in the art (see, for example, International Publication No. WO 2009 / 016516; U.S. Patent Application Publication No. 2009 / 304710; U.S. Patent Application Publication No. 2010 / 047257; U.S. Patent Application Publication No. 2009 / 036431; U.S. Patent Application Publication No. 2011 / 0256157; and International Publication No. WO 2011 / 130598). (5) Anthracyclines

[0267] In some embodiments, the ADC may comprise an anthracycline. An anthracycline is an antibiotic compound that exhibits cytotoxic activity. Without wishing to be bound by any particular theory, research has indicated that anthracyclines act to kill cells through various mechanisms, including: 1) the drug molecule intercalates into the cell's DNA, thereby inhibiting DNA-dependent nucleic acid synthesis; 2) the drug generates free radicals that react with cellular macromolecules and damage the cell; and / or 3) the drug molecule interacts with the cell membrane (see, e.g., C. Peterson et al., "Transport and Storage of Anthracycline in Experimental Systems and Human Leukemia" in Anthracycline Antibiotics in Cancer Therapy; N.R. Bachur, "Free Radical Damage" id. at pp. 97-102). Due to their cytotoxic potential, anthracyclines are used in the treatment of numerous cancers, including leukemia, breast cancer, lung cancer, ovarian adenocarcinoma, and sarcoma (see, e.g., P. H-Wiernik, in Anthracycline: Current Status And New Developments p 11).

[0268] Non-limiting exemplary anthracyclines include doxorubicin, epirubicin, idarubicin, daunomycin, nemorubicin, and derivatives thereof. Immunoconjugates and prodrugs of daunorubicin and doxorubicin have been prepared and studied (Kratz et al., Current Med. Chem., vol. 13, pp. 477-523, 2006; Jeffrey et al., Bioorganic & Med. Chem. Letters, vol. 16, pp. 358-362, 1996; Torgov et al., Bioconj.Chem., vol. 16, pp. 717-721, 2005; Nagy et al., Proc. Natl. Acad.Sci. USA, vol. 97, pp. 829-834, 2000; Dubowchik et al., Bioorg. & Med. Chem. Letters, vol. 12, pp. 1529-1532, 2002; King et al., Bioorganic & Med. Chem. Letters, vol. 16, pp. 717-721, 2005). et al., J. Med. Chem., vol. 45, pp. 4336-4343, 2002; EP 0328147; US Pat. No. 6,630,579). The antibody-drug conjugate BR96-doxorubicin, which specifically reacts with the tumor-associated antigen Lewis-Y, has been evaluated in phase I and phase II trials (Saleh et al., J. Clin. Oncology, vol. 18, pp. 2282-2292, 2000; Ajani et al., Cancer Jour., vol. 6, pp. 78-81, 2000; Tolcher et al., J. Clin. Oncology, vol. 17, pp. 478-484, 1999).

[0269] PNU-159682 is a potent metabolite (or derivative) of nemorubicin (Quintieri et al., Clinical Cancer Research, vol. 11, pp. 1608-1617, 2005). Nemorubicin, a semisynthetic analog of doxorubicin with a 2-methoxymorpholino group at the glycosidic amino group, is undergoing clinical evaluation (Grandi et al. Cancer Treat.Rev. vol.17, pp.133-138, 1990; Ripamonti et al. Brit.J.Cancer, vol.65, pp.703-707, 1992), including a phase II / III trial for hepatocellular carcinoma (Sun et al., Proceedings of the American Society for Clinical Oncology, vol.22, Abs1448, 2003; Quintieri, Proceedings of the American Association of Cancer Research, vol.44:1st Ed, Abs4649, 2003; Pacciarini et al., Jour.Clin.Oncology, vol.24, p.14116, 2006).

[0270] Anthracyclines, such as PNU-159682, can be conjugated to antibodies via several binding sites and a variety of linkers (U.S. Patent Application Publication No. 2011 / 0076287; WO 2009 / 099741; U.S. Patent Application Publication No. 2010 / 0034837; WO 2010 / 009124), including those described herein.

[0271] The linker of PNU-159682-maleimide acetal-Ab is acid-labile, while PNU-159682-val-cit-PAB-Ab, PNU-159682-val-cit-PAB-spacer-Ab, and PNU-159682-val-cit-PAB-spacer (R 1 R 2The linker in the )-Ab is protease cleavable.

[0272] (6) Other drug moieties

[0273] Drug moieties also include geldanamycin (Mandler et al., J. Nat. Cancer Inst., vol. 92, pp. 1573-1581, 2000; Mandler et al., Bioorganic & Med. Chem. Letters, vol. 10, pp. 1025-1028, 2000; Mandler et al., Bioconjugate Chem., vol. 13, pp. 786-791, 2002); and enzymatically active toxins or fragments thereof, including, but not limited to, diphtheria A chain, nonbinding active fragments of diphtheria toxin, exotoxin A chain (from Pseudomonas aeruginosa), ricin A chain, abrin A chain, modeccin A chain, alpha-sarcin, Aleurites curcas (Aleurites curcas), ... fordii protein, dianthin protein, Phytolacca americana proteins (PAPI, PAPII, and PAP-S), Momordica charantia inhibitor, curcin, crotin, Sapaonaria officinalis inhibitor, gelonin, mitogellin, restrictocin, phenomycin, enomycin, and trichothecenes. See, e.g., WO 93 / 21232.

[0274] Drug moieties also include compounds with nucleolytic activity (eg, ribonucleases or DNA endonucleases).

[0275] In certain embodiments, the immunoconjugate may include a highly radioactive atom. A variety of radioisotopes are available for the production of radioconjugated antibodies. Examples include At 211 , I 131 , I 125 , Y 90 ,Re186 ,Re 188 , Sm 153 , Bi 212 , P 32 , Pb 212 In some embodiments, when the immunoconjugate is used for detection, it can be used with a radioactive atom for scintigraphy studies, e.g., Tc 99 Or I 123 or spin labels for nuclear magnetic resonance (NMR) imaging (also known as magnetic resonance imaging (MRI)), such as zirconium-89, iodine-123, iodine-131, indium-111, fluorine-19, carbon-13, nitrogen-15, oxygen-17, gadolinium, manganese, or iron. Zirconium-89 can be complexed to various metal chelators and, for example, conjugated to antibodies for PET imaging (WO2011 / 056983).

[0276] Radiolabels or other labels may be incorporated into the immunoconjugate by known methods. For example, peptides may be biosynthesized or chemically synthesized using suitable amino acid precursors, e.g., containing one or more fluorine-19 atoms in place of one or more hydrogen atoms. In some embodiments, Tc 99 , I 123 ,Re 186 ,Re 188 , and In 111 Labels such as iodine-123 can be attached via cysteine ​​residues in the antibody. In some embodiments, yttrium-90 can be attached via lysine residues of the antibody. In some embodiments, iodine-123 can be incorporated using the IODOGEN method (Fraker et al., Biochem. Biophys. Res. Commun., vol. 80, pp. 49-57, 1978). "Monoclonal Antibodies in Immunoscintigraphy" (Chatal, CRC Press 1989) describes certain other methods.

[0277] In certain embodiments, an immunoconjugate may comprise an antibody conjugated to a prodrug-activating enzyme. In some such embodiments, the prodrug-activating enzyme converts a prodrug (e.g., a peptidyl chemotherapeutic agent, see WO 81 / 01145) into an active drug, such as an anti-cancer drug. Such immunoconjugates are, in some embodiments, useful in antibody-dependent enzyme-mediated prodrug therapy ("Adept"). Enzymes that can be conjugated to an antibody include, but are not limited to, alkaline phosphatase, useful for converting phosphate-containing prodrugs to free drugs; arylsulfatases, useful for converting sulfate-containing prodrugs to free drugs; cytosine deaminase, useful for converting non-toxic 5-fluorocytosine to the anti-cancer drug 5-fluorouracil; proteases useful for converting peptide-containing prodrugs to free drugs, such as Serratia protease, pyrolysis, subtilisin, carboxypeptidase, and cathepsins (such as cathepsins B and L); D-amino acid Examples of suitable enzymes include D-alanylcarboxypeptidase, useful for converting prodrugs containing substituent groups; carbohydrate-cleaving enzymes, such as β-galactosidase and neuraminidase, useful for converting glycosylated prodrugs into free drugs; β-lactamase, useful for converting β-lactam-derivatized drugs into free drugs; and penicillin amidases, such as penicillin V amidase and penicillin G amidase, useful for converting amine nitrogen-derivatized drugs bearing phenoxyacetyl or phenylacetyl groups into free drugs. In some embodiments, enzymes can be covalently bound to antibodies by recombinant DNA techniques well known in the art. See, for example, Neuberger et al., Nature, vol. 312, pp. 604-608, 1984. Drug burden

[0278] Drug loading is represented by the average number of drug moieties per antibody in a molecule of Formula I. Drug loading can range from 1 to 20 drug moieties (D) per antibody. ADCs of Formula I contain a population of antibodies conjugated with drug moieties ranging from 1 to 20. The average number of drug moieties per antibody used in ADC preparations from conjugation reactions can be characterized by conventional means, such as mass spectrometry, ELISA assays, and HPLC. Quantitative distribution of ADCs in units of p can also be measured. In some cases, separation, purification, and characterization of homogeneous ADCs with a certain value of p from ADCs with other drug loads can be achieved by means such as reverse-phase HPLC or electrophoresis.

[0279] For some antibody-drug conjugates, p may be limited by the number of attachment sites on the antibody. For example, if the bond is a cysteine ​​thiol, as in certain exemplary embodiments above, the antibody may have only one or a few cysteine ​​thiol groups, or only one or a few sufficiently reactive thiol groups to which a linker may be attached. In certain embodiments, higher drug loading, e.g., p > 5, may cause aggregation, insolubility, toxicity, or loss of cell permeability of certain antibody-drug conjugates. In certain embodiments, the average drug loading of an ADC ranges from 1 to about 8, from about 2 to about 6, or from about 3 to about 5. Indeed, it has been shown that for some ADCs, the optimal ratio of drug moieties per antibody may be less than 8, from about 2 to about 5 (U.S. Patent No. 7,498,298).

[0280] In some embodiments, fewer than the theoretical maximum number of drug moieties are conjugated to the antibody during the conjugation reaction.Antibodies may contain lysine residues that do not react with drug-linker intermediates or linker reagents, for example, as discussed below.Generally, antibodies do not contain many free and reactive cysteine ​​thiol groups that can be linked to drug moieties; in fact, most cysteine ​​thiol residues in antibodies exist as disulfide bridges.In certain embodiments, antibodies can be reduced with a reducing agent such as dithiothreitol (DTT) or tricarbonylethylphosphine (TCEP) to generate reactive cysteine ​​thiol groups under partial or total reduction conditions.In certain embodiments, antibodies are subjected to denaturing conditions to reveal reactive nucleophilic groups such as lysine or cysteine.

[0281] The loading (drug / antibody ratio) of ADCs can be controlled in different ways, for example, by (i) limiting the molar excess of drug-linker intermediate or linker reagent relative to antibody, (ii) limiting the conjugation reaction time or temperature, and (iii) partial or limited reduction conditions of cysteine ​​thiol modifications.

[0282] When two or more nucleophilic groups react with a drug-linker intermediate or linker reagent, it is understood that the resulting product is a mixture of ADCs with a distribution of one or more drug moieties attached to the antibody. The average number of drugs per antibody can be calculated from the mixture by a double ELISA antibody assay, which is specific for both the antibody and the drug. Individual ADCs can be identified in the mixture by mass spectrometry and separated by HPLC, for example, hydrophobic interaction chromatography (see, for example, McDonagh et al., Prot.Engr.Design & Selection, vol.19, pp.299-307, 2006; Hamblett et al., Clin.Cancer Res., vol.10, pp.7063-7070, 2004). In some embodiments, homogeneous ADCs with a single loading value can be isolated from the conjugation mixture by electrophoresis or chromatography. A method for preparing immunoconjugates

[0283] Immunoconjugates that are ADCs of Formula I can be prepared by several routes employing organic chemistry reactions, conditions, and reagents known to those skilled in the art, including: (1) reacting a nucleophilic group on an antibody with a bivalent linker reagent to form Ab-L via a covalent bond, followed by reaction with a drug moiety, D; and (2) reacting a nucleophilic group on a drug moiety with a bivalent linker reagent to form DL via a covalent bond, followed by reaction with a nucleophilic group on an antibody. An exemplary method for preparing ADCs of Formula I via the latter route is described in U.S. Pat. No. 7,498,298.

[0284] Nucleophilic groups on antibodies include, but are not limited to, (i) N-terminal amine groups, (ii) side-chain amine groups, such as lysine, (iii) side-chain thiol groups, such as cysteine, and (iv) sugar hydroxyl or amino groups on glycosylated antibodies. Amine, thiol, and hydroxyl groups are nucleophilic and can react with electrophilic groups on linker moieties and linker reagents to form covalent bonds, such as (i) active esters, such as NHS esters, HOBt esters, haloformates, and acid halides; (ii) alkyl and benzyl halides, such as haloacetamides; and (iii) aldehyde, ketone, carboxyl, and maleimide groups. Some antibodies have reducible interchain disulfides, i.e., cysteine ​​bridges. Antibodies can be made reactive for conjugation with linker reagents by treatment with a reducing agent, such as DTT (dithiothreitol) or tricarbonylethylphosphine (TCEP), to completely or partially reduce the antibody. Thus, each cysteine ​​bridge theoretically forms two reactive thiol nucleophiles. Additional nucleophilic groups can be introduced into antibodies through modification of lysine residues, for example, by reacting the lysine residue with 2-iminothiolane (Traut's reagent) to convert the amine to a thiol. Reactive thiol groups can also be introduced into antibodies by introducing one, two, three, four, or more cysteine ​​residues (e.g., by preparing a variant antibody containing one or more non-native cysteine ​​amino acid residues).

[0285] The antibody-drug conjugates of the present invention can also be produced by the reaction between an electrophilic group on an antibody, such as an aldehyde or ketone carbonyl group, and a nucleophilic group on a linker reagent or drug. Useful nucleophilic groups on a linker reagent include, but are not limited to, hydrazide, oxime, amino, hydrazine, thiosemicarbazone, hydrazine carboxylate, and arylhydrazide. In one embodiment, an antibody is modified to introduce an electrophilic moiety that can react with a nucleophilic substituent on a linker reagent or drug. In another embodiment, the sugars of a glycosylated antibody can be oxidized, for example, with a periodate oxidation reagent, to form aldehyde or ketone groups that can react with amine groups on a linker reagent or drug moiety. The resulting imine Schiff base groups can form stable bonds or can be reduced, for example, with a borohydride reagent, to form stable amine bonds. In one embodiment, the reaction of the carbohydrate moiety of a glycosylated antibody with either galactose oxidase or sodium metaperiodate can generate carbonyl (aldehyde and ketone) groups in the antibody that can react with appropriate groups on a drug (Hermanson, Bioconjugate Techniques). In another embodiment, an antibody containing an N-terminal serine or threonine residue can be reacted with sodium metaperiodate to generate an aldehyde in place of the first amino acid (Geoghegan & Stroh, Bioconjugate Chem., vol. 3, pp. 138-146, 1992; U.S. Patent No. 5,362,852). Such aldehydes can react with drug moieties or linker nucleophiles.

[0286] Exemplary nucleophilic groups on the drug moiety include, but are not limited to, amine, thiol, hydroxyl, hydrazide, oxime, hydrazine, thiosemicarbazone, hydrazine carboxylate, and arylhydrazide groups that can react with electrophilic groups on the linker moiety or linker reagent to form a covalent bond, including: (i) activated esters such as NHS esters, HOBt esters, haloformates, and acid halides; (ii) alkyl and benzyl halides such as haloacetamides; and (iii) aldehyde, ketone, carboxyl, and maleimide groups.

[0287] Non-limiting exemplary cross-linking reagents that can be used to prepare ADCs are described in the section entitled "Exemplary Linkers" herein. Methods for linking two moieties, such as a proteinaceous moiety and a chemical moiety, using such cross-linking reagents are known in the art. In some embodiments, a fusion protein comprising an antibody and a cytotoxic agent can be produced, for example, by recombinant technology or peptide synthesis. The recombinant DNA molecule can contain regions encoding the antibody and cytotoxic moieties of the conjugate that are adjacent to each other or separated by a region encoding a linker peptide that does not destroy the desired properties of the conjugate.

[0288] In yet another embodiment, the antibody can be conjugated to a "receptor" (e.g., streptavidin) for use in tumor pretargeting, in which the antibody-receptor conjugate is administered to a patient, followed by removal of unbound conjugate from the circulation using a clearing agent, and then administration of a "ligand" (e.g., avidin) conjugated to a cytotoxic agent (e.g., a drug or radionucleotide). Methods and Compositions for Diagnostics and Detection

[0289] In certain embodiments, any of the anti-Axl antibodies or antibody fragments provided herein can be used to detect the presence of Axl in a biological sample. As used herein, the term "detecting" encompasses quantitative or qualitative detection. In certain embodiments, the biological sample contains cells or tissues, such as breast, pancreatic, esophageal, lung, and / or brain cells or tissues.

[0290] A further aspect of the invention relates to an anti-Axl antibody of the invention for diagnosing and / or monitoring cancer or another disease in which Axl levels are increased or decreased from normal physiological levels in at least one location in the body.

[0291] In a preferred embodiment, the antibody or antibody fragment of the present invention can be labeled with a detectable molecule or substance, such as a fluorescent molecule, a radioactive molecule, or any other label known in the art. For example, the antibody of the present invention can be labeled with a radioactive molecule. Suitable radioactive molecules include, but are not limited to: 123 I, 124 I, 111 In, 186 Re, and 188 Radioactive atoms used in scintigraphy studies, such as Re, may also be labeled with spin labels for nuclear magnetic resonance (NMR) imaging, such as iodine-123, iodine-131, indium-I11, fluorine-19, carbon-13, nitrogen-15, oxygen-17, gadolinium, manganese, or iron. After administration of the antibody, the distribution of the radiolabeled antibody within the patient is detected. Any suitable known method can be used. Some non-limiting examples include computed tomography (CT), positron emission tomography (PET), magnetic resonance imaging (MRI), fluorescence, chemiluminescence, and ultrasound imaging.

[0292] The antibodies or antibody fragments of the present invention may be useful for diagnosing and staging cancers and diseases associated with Axl overexpression, including squamous cell carcinoma, small cell lung cancer, non-small cell lung cancer, gastric cancer, pancreatic cancer, glial cell tumors such as glioblastoma and neurofibromatosis, cervical cancer, ovarian cancer, liver cancer, bladder cancer, hepatoma (hepatocellular carcinoma), breast cancer, colon cancer, melanoma, colorectal cancer, endometrial cancer, salivary gland cancer, kidney cancer, renal cancer, prostate cancer, vulvar cancer, thyroid cancer, liver cancer, sarcoma, blood cancer (leukemia), astrocytoma, and various head and neck cancers, or hyperproliferative diseases associated with Axl expression or overexpression.

[0293] The antibodies or antibody fragments of the present invention may be useful for diagnosing diseases other than cancer in which Axl expression is increased or decreased. (Both soluble and cellular forms of Axl can be used for such diagnosis. Typically, such diagnostic methods involve the use of a biological sample obtained from a patient. As used herein, the term "biological sample" encompasses various sample types obtained from a subject that can be used in diagnostic or monitoring assays. Biological samples include, but are not limited to, blood and other liquid samples of biological origin, solid tissue samples such as biopsy specimens or tissue cultures or cells derived therefrom, and their progeny. For example, biological samples include cells obtained from tissue samples recovered from individuals suspected of having a cancer associated with Axl overexpression, and in preferred embodiments, glioma, gastric cancer, lung cancer, pancreatic cancer, breast cancer, prostate cancer, kidney cancer, liver cancer, and endometrial cancer. Biological samples include clinical samples, cells in culture, cell supernatants, cell lysates, serum, plasma, biological fluids, and tissue samples. In a particular embodiment, the invention is a method for diagnosing cancer associated with Axl overexpression in a subject by detecting Axl on cells from the subject using an antibody of the invention. In particular, the method comprises: contacting a biological sample of a subject with an antibody or antibody fragment according to the invention under conditions suitable for the antibody or antibody fragment to form a complex with cells of the biological sample that express Axl; and

[0294] detecting and / or quantifying said complex, wherein detection of said complex is indicative of cancer associated with Axl overexpression.

[0295] To monitor the progression of cancer, the method can be repeated at different time points to determine whether antibody binding to the sample increases or decreases, and then it can be determined whether the cancer is progressing, regressing, or stable.

[0296] In a specific embodiment, the present invention is a method for diagnosing diseases associated with expression or overexpression of Axl or a decrease or increase in the soluble form of Axl, such as human immune disorders, thrombotic diseases (thrombosis and atherothrombosis), and cardiovascular diseases.

[0297] In one embodiment, an anti-Axl antibody or antibody fragment is provided for use in a diagnostic or detection method. In a further aspect, a method for detecting the presence of Axl in a biological sample is provided. In a further aspect, a method for quantifying the amount of Axl in a biological sample is provided. In certain embodiments, the method comprises contacting a biological sample with an anti-Axl antibody or antibody fragment described herein under conditions that allow binding of the anti-Axl antibody or antibody fragment to Axl, and detecting whether a complex is formed between the anti-Axl antibody or antibody fragment and Axl. Such methods may be performed in vitro or in vivo. In one embodiment, the anti-Axl antibody or antibody fragment is used to select subjects eligible for a therapy. In some embodiments, the therapy comprises administering an anti-Axl antibody or antibody fragment to a subject.

[0298] In some embodiments, a labeled anti-Axl antibody or antibody fragment is provided. Labels include, but are not limited to, directly detectable labels or moieties (e.g., fluorescent labels, chromogenic labels, electron-dense labels, chemiluminescent labels, and radioactive labels), as well as indirectly detectable moieties (e.g., by enzymatic reaction or molecular interaction), such as enzymes or ligands. Exemplary labels include, but are not limited to, radioisotopes ( 32 P, 14 C. 125 I, 3 H, and 131 I), or fluorophores (rare earth chelates, or fluorescein and its derivatives, rhodamine and its derivatives, dansyl, umbelliferone, etc.), luciferases (e.g., firefly luciferase and bacterial luciferase (U.S. Pat. No. 4,737,456)), luciferin, 2,3-dihydrophthalazinediones, horseradish peroxidase (HRP), alkaline phosphatase, β-galactosidase, glucoamylase, lysozyme, sugar oxidases (e.g., glucose oxidase, galactose oxidase, and glucose-6-phosphate dehydrogenase), heterocyclic oxidases (uricase, xanthine oxidase, etc.), coupled enzymes that oxidize dye precursors using hydrogen peroxide (e.g., HRP, lactoperoxidase, or microperoxidase), biotin / avidin, bacteriphage labels, stable free radicals, etc. Pharmaceutical preparations

[0299] Anti-Axl antibodies or antibody fragments have cell-killing activity. This cell-killing activity extends to multiple different cell line types. Furthermore, when conjugated to a cytotoxic agent, these antigens or antibody fragments can reduce tumor size and exhibit reduced toxicity. See Examples 3 and 6-9 of the present application. Therefore, anti-Axl antibodies, their fragments, or immunoconjugates can be useful for treating proliferative diseases associated with Axl expression. The antibodies, fragments, or immunoconjugates can be used alone or in combination with any suitable drug or other conventional treatment.

[0300] Anti-Axl antibodies or antibody fragments can be used to treat hyperproliferative disorders associated with Axl and / or Gas6 expression, overexpression, or activation. There are no specific limitations on the type or tissue of cancer that can be treated, other than the requirement for Axl expression. Examples include squamous cell carcinoma, small cell lung cancer, non-small cell lung cancer, gastric cancer, pancreatic cancer, glial cell tumors such as glioblastoma and neurofibromatosis, cervical cancer, ovarian cancer, liver cancer, bladder cancer, hepatoma (hepatocellular carcinoma), breast cancer, colon cancer, melanoma, colorectal cancer, endometrial cancer, salivary gland cancer, kidney cancer, renal cancer, prostate cancer, vulvar cancer, thyroid cancer, liver cancer, sarcoma, blood cancer (leukemia), astrocytoma, and various head and neck cancers. More preferred cancers are glioblastoma, gastric cancer, lung cancer, pancreatic cancer, breast cancer, prostate cancer, kidney cancer, liver cancer, and endometrial cancer.

[0301] Anti-Axl antibodies or antibody fragments are potent activators of the innate immune response and can therefore be used to treat human immune disorders, such as sepsis. The anti-Axl antibodies or antibody fragments of the present invention can also be used as adjuvants for immunization, such as vaccines, and as anti-infective agents against, for example, bacteria, viruses, and parasites.

[0302] Anti-Axl antibodies or antibody fragments can be used to protect against, prevent, or treat thrombotic diseases, such as venous and arterial thrombosis and atherothrombosis. Anti-Axl antibodies or antibody fragments can also be used to protect against, prevent, or treat cardiovascular diseases, as well as to prevent or inhibit the invasion of viruses, such as Lassa and Ebola viruses, and to treat viral infections.

[0303] In each of the embodiments of the methods of treatment described herein, the anti-Axl monoclonal antibody, antibody fragment, or anti-Axl monoclonal immunoconjugate can be delivered in a manner consistent with conventional methods associated with the management of the disease or disorder for which treatment is sought. In accordance with the disclosure herein, an effective amount of the antibody, antibody fragment, or immunoconjugate is administered to a subject in need of such treatment for a time and under conditions sufficient to prevent or treat the disease or disorder. Accordingly, one aspect of the present invention relates to a method of treating a disease associated with Axl expression, comprising administering a therapeutically effective amount of an antibody, antibody fragment, or immunoconjugate of the present invention to a subject in need of treatment for the disease associated with Axl expression.

[0304] For administration, anti-Axl monoclonal antibodies, antibody fragments, or immunoconjugates can be formulated as pharmaceutical compositions. Pharmaceutical compositions containing anti-Axl monoclonal antibodies, antibody fragments, or antibody-drug conjugates can be formulated according to known methods for preparing pharmaceutical compositions. In such methods, therapeutic molecules are typically combined with a mixture, solution, or composition containing a pharmaceutically acceptable carrier.

[0305] A pharmaceutically acceptable carrier is a substance that can be tolerated by a recipient patient. Sterile phosphate-buffered saline is one example of a pharmaceutically acceptable carrier. Other suitable pharmaceutically acceptable carriers are well known to those skilled in the art. (See, for example, Gennaro (ed.), Remington's Pharmaceutical Sciences (Mack Publishing Company, 19th ed. 1995)). The formulation may further include one or more excipients, preservatives, solubilizers, buffers, albumin to prevent protein loss on the vial surface, etc.

[0306] The form, administration route, dosage, and regimen of the pharmaceutical composition will naturally depend on the condition to be treated, the severity of the disease, the age, weight, and sex of the patient, etc. These considerations can be taken into account by those skilled in the art to formulate a suitable pharmaceutical composition. The pharmaceutical composition of the present invention can be formulated for topical administration, oral administration, parenteral administration, intranasal administration, intravenous administration, intramuscular administration, subcutaneous administration, or intraocular administration, etc.

[0307] Preferably, the pharmaceutical composition contains a pharmaceutically acceptable vehicle for injectable preparations. These may be present in a particular isotonic sterile saline solution (monosodium or disodium phosphate, sodium, potassium, calcium or magnesium chloride, etc. or a mixture of such salts), or in a dried, especially lyophilized, composition that allows the constitution of an injectable solution upon addition of, for example, sterile water or saline.

[0308] In some embodiments, tonicity agents, sometimes known as "stabilizers," are present to adjust or maintain the tonicity of the liquid in the composition. When used with large, charged biomolecules such as proteins and antibodies, they are often referred to as "stabilizers" because they can interact with the charged groups on amino acid side chains, reducing the likelihood of intermolecular and intramolecular interactions. Tonicity agents can be present in any amount from 0.1 to 25% by weight of the pharmaceutical composition, preferably 1 to 5% by weight. Preferred tonicity agents include polyhydric sugar alcohols, preferably trihydric or higher sugar alcohols such as glycerin, erythritol, arabitol, xylitol, sorbitol, and mannitol.

[0309] Additional excipients include agents that can function as one or more of the following: (1) bulking agents, (2) solubility enhancers, (3) stabilizers, and (4) agents that prevent denaturation or adhesion to container walls. Such excipients include polyhydric sugar alcohols (listed above), amino acids (e.g., alanine, glycine, glutamine, asparagine, histidine, arginine, lysine, ornithine, leucine, 2-phenylalanine, glutamic acid, threonine), organic sugars or sugar alcohols (e.g., sucrose, lactose, lactitol, trehalose, stachyose, mannose, sorbose, xylose, ribose, ribitol, myo-inisitose, myonisitol, galactose, galactitol, glycerol, cyclitols (e.g., inositol), polyethylene glycol), These may include sulfur-containing reducing agents (e.g., urea, glutathione, thioctic acid, sodium thioglycolate, thioglycerol, α-mothioglycerol, and sodium thiosulfate), low molecular weight proteins (e.g., human serum albumin, bovine serum albumin, gelatin, or other immunoglobulins), hydrophilic polymers (e.g., polyvinylpyrrolidone), monosaccharides (e.g., xylose, mannose, fructose, glucose), disaccharides (e.g., lactose, maltose, sucrose), trisaccharides (e.g., raffinose), and polysaccharides (e.g., dextrin or dextran).

[0310] Non-ionic surfactants or detergents (also known as "wetting agents") can be used to aid in solubilizing the therapeutic agent and to protect the therapeutic protein from agitation-induced aggregation, which also allows the formulation to be exposed to shear surface stresses without causing denaturation of the active therapeutic protein or antibody. The non-ionic surfactant may be present in a concentration range of about 0.05 mg / ml to about 1.0 mg / ml, preferably about 0.07 mg / ml to about 0.2 mg / ml.

[0311] Suitable nonionic surfactants include polysorbates (e.g., 20, 40, 60, 65, 80), poloxamers (e.g., 184, 188), PLURONIC® polyols, TRITON®, polyoxyethylene sorbitan monoethers (e.g., TWEEN®-20, TWEEN®-80), lauromacrogol 400, polyoxyl 40 stearate, polyoxyethylene hydrogenated castor oil 10, 50, and 60, glycerol monostearate, sucrose fatty acid esters, methylcellulose, and carboxymethylcellulose. Usable anionic detergents include sodium lauryl sulfate, dioctyl sodium sulfosuccinate, and dioctyl sodium sulfonate. Cationic detergents include benzalkonium chloride or benzethonium chloride.

[0312] The dose used for administration can be adapted depending on various parameters, in particular depending on the mode of administration used, the pathology involved, or alternatively the desired duration of treatment. To prepare a pharmaceutical composition, an effective amount of the antibody or antibody fragment can be dissolved or dispersed in a pharmaceutically acceptable carrier or aqueous medium.

[0313] Suitable dosage forms for injection include sterile aqueous solutions or dispersions, formulations including sesame oil, peanut oil, or aqueous propylene glycol, and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In all cases, the dosage form must be sterile and fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be protected from the contaminating action of microorganisms such as bacteria and fungi.

[0314] The solution of active compound as free base or pharmacologically acceptable salt can be prepared in water with suitable surfactant mixture.Dispersion can also be prepared in glycerol, liquid polyethylene glycol and their mixture, and in oil.Under normal storage and use conditions, these preparations contain preservatives to prevent the growth of microorganisms.

[0315] The antibody or antibody fragment can be formulated into a composition in neutral or salt form. Pharmaceutically acceptable salts include acid addition salts (formed with the free amino groups of the protein) and are formed with inorganic acids (e.g., hydrochloric or phosphoric acid), or organic acids such as acetic acid, oxalic acid, tartaric acid, mandelic acid, and the like. Salts formed with the free carboxyl groups can also be derived from inorganic bases (e.g., sodium, potassium, ammonium, calcium, or ferric hydroxide), and organic bases such as isopropylamine, trimethylamine, histidine, procaine, and the like.

[0316] The carrier can also be a solvent or dispersion medium containing water, ethanol, polyol (e.g., glycerol, propylene glycol, and liquid polyethylene glycol, etc.), suitable mixtures thereof, and vegetable oils. Proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by maintaining the required particle size, and by the use of surfactants. Prevention of microbial action can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In many cases, it is preferable to include isotonic agents, for example, sugars or sodium chloride. Prolonged absorption of injectable compositions can be achieved by using agents that delay absorption in the composition, for example, aluminum monostearate and gelatin.

[0317] Sterile injectable solution can be prepared by incorporating the required amount of active compound into suitable solvent, which contains one or more other components than those listed above as needed, and then filtration sterilization.Generally, dispersion is prepared by incorporating various sterilized active components into sterile vehicle, and contains basic dispersion medium and other components that are required from those listed above.For the sterile powder that is used to prepare sterile injectable solution, the preferred preparation method is vacuum drying and freeze-drying technology, and obtain the powder of active component and any additional desired component from the solution that has been previously sterilized by filtration.

[0318] Preparation of larger or more concentrated solutions for direct injection is also contemplated, and it is envisioned that the use of dimethyl sulfoxide (DMSO) as a solvent will result in very rapid penetration, delivering high concentrations of active agent to small tumor areas.

[0319] Upon formulation, solutions will be administered in a manner compatible with the dosage formulation, and in such amount as is therapeutically effective. The formulations are easily administered in a variety of dosage forms, such as the type of injectable solutions described above, although drug release capsules and the like can also be used.

[0320] For parenteral administration in aqueous solution, the solution should be suitably buffered, if necessary, and the liquid diluent should first be rendered isotonic with sufficient saline or glucose. These particular aqueous solutions are particularly suitable for intravenous, intramuscular, subcutaneous, and intraperitoneal administration. In this regard, sterile aqueous media that can be used will be known to those skilled in the art in light of the present disclosure. For example, one dose can be dissolved in 1 ml of isotonic NaCl solution and added to 1000 ml of subcutaneous infusion therapy fluid or injected at the proposed infusion site (see, e.g., "Remington's Pharmaceutical Sciences," 15th Edition, pages 1035-1038 and 1570-1580). Some variation in dosage will necessarily occur depending on the condition of the subject being treated. The person responsible for administration will, in any event, determine the appropriate dose for the individual subject.

[0321] The antibody or antibody fragment can be formulated to deliver 0.0001 to 10.0 milligrams, or about 0.001 to 5 milligrams, or about 0.001 to 1 milligram, or about 0.001 to 0.1 milligrams, or about 0.1 to 1.0 or even about 10 milligrams per dose in a therapeutic mixture. Multiple doses can also be administered at selected time intervals.

[0322] In addition to compounds formulated for parenteral administration, such as intravenous or intramuscular injection, other pharmaceutically acceptable dosage forms include, for example, tablets or other solids for oral administration, sustained release capsules, as well as any other dosage form currently in use.

[0323] In certain embodiments, the use of liposomes and / or nanoparticles for the introduction of antibodies or antibody fragments into host cells is contemplated. The formation and use of liposomes and / or nanoparticles is known to those of skill in the art.

[0324] Nanocapsules can generally entrap compounds in a stable and reproducible manner.To avoid the side effects of intracellular polymer overload, these ultrafine particles (sizes of around 0.1 μm) are generally designed using polymers that can be degraded in vivo.The biodegradable polyalkyl-cyanoacrylate nanoparticles that meet these requirements are intended for use in the present invention, and these particles can be easily produced.

[0325] Liposomes are formed from phospholipids dispersed in an aqueous medium that spontaneously form multilamellar concentric bilayer vesicles (also called multilamellar vesicles, or MLVs). MLVs generally have diameters between 25 nm and 4 μm. Sonication of MLVs results in the formation of small unilamellar vesicles (SUVs) with diameters ranging from 200 to 500 Å, which contain aqueous solution within their cores. The physical characteristics of liposomes depend on pH, ionic strength, and the presence of divalent cations.

[0326] Pharmaceutical formulations containing the anti-Axl antibodies or antibody fragments described herein are prepared in the form of lyophilized formulations or aqueous solutions by mixing such antibodies or antibody fragments having the desired degree of purity with one or more optional pharmaceutically acceptable carriers (Remington's Pharmaceutical Sciences 16th edition, Osol, A. Ed. (1980)). Pharmaceutically acceptable carriers are generally non-toxic to recipients at the dosages and concentrations used and include, but are not limited to, buffers (such as phosphate, citric acid, and other organic acids), antioxidants (including ascorbic acid and methionine), preservatives (such as octadecyldimethylbenzylammonium chloride), hexamethonium chloride, benzalkonium chloride, benzethonium chloride, phenol, butyl, or benzyl alcohol, alkylparabens (such as methylparaben or propylparaben), catechol, resorcinol, cyclohexanol, 3-pentanol, and m-cresol), low molecular weight polypeptides (about 1 0 residues), proteins (such as serum albumin, gelatin, or immunoglobulins), hydrophilic polymers (such as polyvinylpyrrolidone), amino acids (such as glycine, glutamine, asparagine, histidine, arginine, or lysine), monosaccharides, disaccharides, and other carbohydrates (including glucose, mannose, or dextrins), chelating agents (such as EDTA), sugars (such as sucrose, mannitol, trehalose, or sorbitol), salt-forming counterions (such as sodium), metal complexes (e.g., Zn-protein complexes), and / or non-ionic surfactants (such as polyethylene glycol (PEG)).

[0327] Exemplary pharmaceutically acceptable carriers herein further include interstitial drug dispersants, such as soluble neutral-active hyaluronidase glycoproteins (sHASEGPs), e.g., human soluble PH-20 hyaluronidase glycoproteins, e.g., rHuPH20 (HYLENEX®, Baxter International, Inc.). Certain exemplary sHASEGPs, including rHuPH20, and methods of use are described in U.S. Patent Publication Nos. 2005 / 0260186 and 2006 / 0104968. In one embodiment, a sHASEGP is combined with one or more additional glycosaminoglycanases, such as chondroitinases.

[0328] Exemplary lyophilized antibody formulations are described in U.S. Patent No. 6,267,958. Aqueous antibody formulations include those described in U.S. Patent No. 6,171,586 and WO 2006 / 044908, the latter formulations including a histidine-acetate buffer.

[0329] The formulations herein may also contain two or more active ingredients, as needed for the particular indication being treated. Preferably, ingredients with complementary activities that do not adversely affect each other may be combined in a single formulation. For example, it may be desirable to provide an EGFR antagonist (e.g., erlotinib), an anti-androgen (e.g., a VEGF antagonist, which may be an anti-VEGF antibody), or a chemotherapeutic agent (e.g., a taxoid or platinum agent) in addition to the anti-Axl antibody, antibody fragment, or immunoconjugate of the present invention. Such active ingredients are suitably present in combination in amounts effective for the intended purpose.

[0330] Active ingredients can be encapsulated in microcapsules, for example, by coacervation technique or prepared by interfacial polymerization.For example, hydroxymethylcellulose or gelatin microcapsules, and poly(methyl methacrylate) microcapsules can be used in colloid drug delivery systems (for example, liposomes, albumin microspheres, microemulsions, nanoparticles, and nanocapsules) or in macroemulsions, respectively.This technique is disclosed in Remington's Pharmaceutical Sciences 16th edition, Osol, A. Ed. (1980).

[0331] Sustained-release preparations can be prepared. Suitable examples of sustained-release preparations include semipermeable matrices of solid hydrophobic polymers containing the antibody or antibody fragment, which matrices can be in the form of shaped articles, e.g., films, or microcapsules.

[0332] Formulations to be used for in vivo administration are generally sterile. Sterilization may be readily accomplished, for example, by filtration through sterile filtration membranes. Therapeutic methods and compositions

[0333] Any of the anti-Axl antibodies or antibody fragments or immunoconjugates provided herein can be used in therapeutic methods. In one aspect, an anti-Axl antibody or antibody fragment or immunoconjugate for use as a pharmaceutical is provided. In a further aspect, an anti-Axl antibody or antibody fragment or immunoconjugate for use in the treatment of cancer (e.g., breast cancer, non-small cell lung cancer, pancreatic cancer, brain tumor, pancreatic, brain, kidney, ovarian, stomach, leukemia, endometrial, colon, prostate, thyroid, liver cancer, osteosarcoma, and / or melanoma) is provided. In certain embodiments, an anti-Axl antibody or antibody fragment or immunoconjugate for use in a therapeutic method is provided. In certain embodiments, the present invention provides an anti-Axl antibody or antibody fragment or immunoconjugate for use in a method of treating an individual with cancer, comprising administering to the individual an effective amount of an anti-Axl antibody or antibody fragment or immunoconjugate. In certain embodiments, the present invention provides an anti-Axl antibody or antibody fragment or immunoconjugate for use in a method for treating an individual having an immune disorder (e.g., an autoimmune disorder), a cardiovascular disorder (e.g., atherosclerosis, hypertension, thrombosis), an infectious disease (e.g., Ebola virus, Marburg virus), or diabetes, comprising administering to the individual an effective amount of the anti-Axl antibody or antibody fragment. In one such embodiment, the method further comprises administering to the individual an effective amount of at least one additional therapeutic agent, such as one described below. In a further embodiment, the present invention provides an anti-Axl antibody or antibody fragment or immunoconjugate for use in inhibiting angiogenesis, inhibiting cell proliferation, inhibiting immune function, inhibiting inflammatory cytokine secretion (e.g., from tumor-associated macrophages), inhibiting tumor vasculature (e.g., intratumoral vasculature or tumor-associated vasculature), and / or inhibiting tumor stromal function.

[0334] In certain embodiments, the present invention provides an anti-Axl antibody or antibody fragment, or immunoconjugate for use in a method for inhibiting angiogenesis, cell proliferation, immune function, inflammatory cytokine secretion (e.g., from tumor-associated macrophages), tumor vasculature (e.g., intratumor vasculature or tumor-associated vasculature), and / or tumor stromal function in an individual, the method comprising administering to the individual an effective amount of the anti-Axl antibody or antibody fragment or immunoconjugate to inhibit angiogenesis, cell proliferation, immune function, inflammatory cytokine secretion (e.g., from tumor-associated macrophages), tumor vasculature development (e.g., intratumor vasculature or tumor-associated vasculature), and / or tumor stromal function. The "individual" in any of the above embodiments is preferably a human.

[0335] In a further aspect, the present invention provides use of an anti-Axl antibody or antibody fragment or immunoconjugate in the manufacture or preparation of a medicament. In one embodiment, the medicament is for the treatment of cancer (in some embodiments, breast cancer, non-small cell lung cancer, pancreatic cancer, brain tumor, pancreatic, brain, kidney, ovarian, stomach, leukemia, endometrial, colon, prostate, thyroid, liver cancer, osteosarcoma, and / or melanoma). In a further embodiment, the medicament is used in a method of treating cancer, comprising administering an effective amount of the medicament to an individual having cancer. In a further embodiment, the medicament is used in a method of treating an immune disorder (e.g., an autoimmune disorder), a cardiovascular disorder (e.g., atherosclerosis, hypertension, thrombosis), an infectious disease (e.g., Ebola virus, Marburg virus), or diabetes, comprising administering an effective amount of an anti-Axl antibody or antibody fragment to the individual. In one such embodiment, the method further comprises administering to the individual an effective amount of at least one additional therapeutic agent, such as: In further embodiments, the agent is an agent for inhibiting angiogenesis, cell proliferation, immune function, secretion of inflammatory cytokines (e.g., from tumor-associated macrophages), tumor vasculature (e.g., intratumor vasculature or tumor-associated vasculature), and / or tumor stromal function. In further embodiments, the medicament is used in a method for inhibiting angiogenesis, cell proliferation, immune function, inflammatory cytokine secretion (e.g., from tumor-associated macrophages), tumor vasculature (e.g., intratumor vasculature or tumor-associated vasculature), and / or tumor stromal function in an individual, the method comprising administering an effective amount of the medicament to the individual to inhibit angiogenesis, inhibit cell proliferation, promote immune function, induce inflammatory cytokine secretion (e.g., from tumor-associated macrophages), inhibit tumor vasculature development (e.g., intratumor vasculature or tumor-associated vasculature), and / or inhibit tumor stromal function. An "individual" according to any of the above embodiments may be a human.

[0336] In a further aspect, the present invention provides a method for treating cancer. In one embodiment, the method comprises administering to an individual having such cancer an effective amount of an anti-Axl antibody or antibody fragment, or immunoconjugate. In one such embodiment, the method further comprises administering to the individual an effective amount of at least one additional therapeutic agent described below. An "individual" according to any of the above embodiments may be a human.

[0337] Axl is a 140 kDa cell surface transmembrane receptor protein tyrosine kinase that belongs to a subfamily of closely related receptors, including TYRO3, Axl, and MER (TAM; Lai 1991; O'Bryan 1991). TAM activation and signaling are involved in various cellular responses, including cell survival, proliferation, migration, and adhesion (Hafizi 2006). Axl was originally identified as an oncogene in patients with chronic myeloid leukemia, and its overexpression results in transforming activity (Janssen 1991; O'Bryan 1991). Overexpression of Axl has been reported in a variety of human cancers (Craven 1995; Ito 1999; Berclaz 2001; Sun 2004; Shieh 2005) and has been associated with invasion and metastasis in lung cancer (Shieh 2005), prostate cancer (Sainaghi 2005), breast cancer (Meric 2002), gastric cancer (Wu 2002), renal cell carcinoma (Chung 2003), and glioblastoma (Hutterer 2008).

[0338] Recent studies have shown that overexpression of Axl via a "tyrosine kinase switch" confers resistance to imatinib in gastrointestinal stromal tumors (Mahadevan 2007). Axl expression is induced by chemotherapeutic agents, and Axl overexpression leads to drug resistance in acute myeloid leukemia (Hong 2008). Axl has also been shown to regulate endothelial cell migration and tube formation (Holland 2005). These findings suggest that Axl may be involved in the multifaceted regulation of tumorigenesis.

[0339] Solid tumor types expressing Axl are of interest for several reasons. Each of these diseases presents a significant unmet need for novel therapeutic options. Preclinical studies suggest that targeting Axl may offer antitumor activity in various tumor types, including NSCLC and melanoma. The proposed mechanisms and underlying biology of Axl-ADCs suggest promising antitumor activity against these malignancies. Axl is highly expressed and activated in numerous human sarcomas, including aggressive subtypes of leiomyosarcoma, Ewing's sarcoma, and liposarcoma (May 2015; Fleuren 2014; Dantas-Barbosa 2017). Leiomyosarcoma (LMS) accounts for 15% of adult sarcomas and is a challenging disease to treat in the metastatic stage. TAM receptors and their ligands, including TYRO3 and Axl, are overexpressed or activated in multiple malignancies, including LMS. Expression of TYRO3 and GAS6 is elevated in LMS patients, particularly those with metastases. Crizotinib and foretinib show potent antitumor activity in LMS through inactivation of TYRO3 and Axl, indicating the need for clinical trials with TYRO3 and Axl inhibitors in advanced LMS. These data suggest that Axl may be a novel therapeutic target for Axl-expressing sarcomas.

[0340] Immunotherapy, particularly PD-1 blockade, has emerged as a groundbreaking oncological treatment over the past decade. In the recent SARC028 trial (Petitprez 2020), most patients with undifferentiated pleomorphic sarcoma who responded to an investigational PD-1 inhibitor had PD-L1-positive tumors, suggesting the potential for combination therapy with PD-1 inhibitors. Immune biomarker expression varies by sarcoma subtype and may correlate with response to immunotherapy (Petitprez 2020). Sarcomas with lymphocytic infiltration and tertiary lymphoid structures have been shown to respond to the checkpoint inhibitor nivolumab (Petitprez 2020). Taken together, these findings suggest that combination therapy with PD-1 inhibitors may improve outcomes in patients with inflammatory soft tissue sarcomas. Treatment with BA3011 is not expected to cause developmental, skeletal, or gonadal disorders in pediatric sarcoma patients. Mice homozygous for the Axl knockout allele exhibit an apparently normal phenotype (Lu 1999).

[0341] In some embodiments, the method comprises administering an anti-Axl antibody or antibody fragment of the invention, or an immunoconjugate comprising the anti-Axl antibody or antibody fragment.

[0342] In one embodiment, a method for treating an Axl-expressing tumor comprises administering an immunoconjugate comprising an antibody or antibody fragment of the invention conjugated to an agent selected from a chemotherapeutic agent, a radioactive atom, a cytostatic agent, and a cytotoxic agent. The immunoconjugate is an antibody-drug conjugate (ADC) in which a conditionally active biological (CAB) anti-Axl antibody is linked to one or more drug moieties via a cleavable linker (CAB-Axl-ADC). For example, the CAB-Axl-ADC is mAbBA3011-cleavable linker-MMAE(n), where the drug moiety is monomethylauristatin E (MMAE), and (n) is an integer between 1 and 4, inclusive.

[0343] In some embodiments, the present invention provides a treatment regimen in which a CAB-Axl-ADC, such as mAbBA3011-cleavable linker-MMAE(n), wherein the drug moiety is monomethyl auristatin E (MMAE) and (n) is an integer between 1 and 4, inclusive, is administered at a dose of about 0.3 mg / kg to about 2.0 mg / kg, either once or twice every 21 days, on days 1 and 8 every 21 days, or on days 1 and 8 every 14 days. Such treatment regimens are surprisingly effective, as the antibody-drug conjugates of the invention administered at such doses and intervals provide surprisingly high response rates and acceptable toxicity or tolerability profiles. Accordingly, the present methods provide dosing regimens for administering a CAB-Axl-ADC antibody-drug conjugate to a subject. In some embodiments, the dosing regimen increases the likelihood that a subject will respond to therapy compared to other dosing regimens. In some embodiments, the dosing regimen does not increase the subject's chance of suffering from an adverse event (including dose-limiting toxicity) compared to other dosing regimens. The present invention also provides for maintenance therapy following the dosing regimen.

[0344] In certain embodiments, mAbBA3011-cleavable linker-MMAE (n) is administered at a dose of about 0.3 mg / kg to about 1.8 mg / kg once or twice every 21 days, on days 1 and 8 every 21 days, or on days 1 and 8 every 14 days. (n) is administered at a dose of about 0.8 mg / kg to about 1.8 mg / kg once or twice every 21 days, on days 1 and 8 every 21 days, or on days 1 and 8 every 14 days.

[0345] mAbBA3011 of the present invention - cleavable linker - MMAE (n)CAB-Axl-ADCs such as these preferentially bind under defined physiological conditions associated with different diseases and tissues. For example, in cancer, the unique cellular metabolism proposed by Warburg creates a characteristic microenvironment with low pH and high lactic acid (Warburg 1924; Warburg 1956). The mAb BA3011-cleavable linker-MMAE of the present invention. (n) mAbBA3011-cleavable linker-MMAE utilizes a specific TME and selectively binds to its target when in proximity to Axl-expressing tumors. (n) The activated binding properties of mAbBA3011-cleavable linker-MMAE are reversible and do not undergo permanent changes upon transfer from diseased normal tissue to diseased tissue microenvironments. (n) contains a humanized mAb (BA3011) without the addition of non-antibody sequences to achieve these properties.

[0346] In certain embodiments, a method of treating an Axl-expressing tumor comprises administering to a human subject in need of such treatment mAbBA301-cleavable linker-MMAE(n), where mAbBA301 is an antibody or antibody fragment having a heavy chain variable region comprising an hcCDR1 of SEQ ID NO: 14, an hcCDR2 of SEQ ID NO: 15, and an hcCDR3 of SEQ ID NO: 16, and a light chain variable region comprising an lcCDR1 of SEQ ID NO: 17, an lcCDR2 of SEQ ID NO: 18, and an lcCDR3 of SEQ ID NO: 19; and MMAE is monomethylauristatin E (MMAE), and (n) is an integer between 1 and 4, inclusive.

[0347] In yet another aspect, the present invention provides a pharmaceutical composition comprising a polypeptide, antibody or antibody fragment, or immunoconjugate of the invention together with a pharmaceutically acceptable carrier.

[0348] In another embodiment, the polypeptide, antibody or antibody fragment, or immunoconjugate useful in the methods of the invention is included in a kit with instructions for use in diagnosing or treating an Axl-expressing tumor.

[0349] In yet another embodiment, the method of treating Axl-expressing tumors comprises administering to a human subject in need of such treatment mAbBA301-cleavable linker-MMAE. (n) and a pharmaceutically acceptable carrier, wherein the pharmaceutical composition is administered by intravenous infusion on days 1 and 8 every 21 days at a dose of 1.8 mg / kg of human subject body weight. mAbBA301 is an antibody or antibody fragment having a heavy chain variable region comprising an hcCDR1 of SEQ ID NO: 14, an hcCDR2 of SEQ ID NO: 15, and an hcCDR3 of SEQ ID NO: 16, and a light chain variable region comprising an lcCDR1 of SEQ ID NO: 17, an lcCDR2 of SEQ ID NO: 18, and an lcCDR3 of SEQ ID NO: 19; and (n) is an integer between 1 and 4 (inclusive), preferably, (n) is equal to 4.

[0350] In a specific embodiment, the heavy chain variable region comprises SEQ ID NO:20 and the light chain variable region of mAbBA301 comprises SEQ ID NO:21.

[0351] In another embodiment, the cleavable linker is mc-vc-PAB.

[0352] In certain embodiments, the Axl-expressing tumor is a sarcoma, adenocarcinoma, or non-small cell lung cancer. Preferably, the Axl-expressing tumor is a sarcoma.

[0353] In certain embodiments, the method further comprises administering a programmed death receptor-1 (PD-1) blocking antibody.

[0354] In yet another embodiment, the Axl-expressing tumor has a Tumor Membrane P Score of at least 50, at least 55, at least 60, at least 65, at least 70, at least 75, at least 80, at least 85, at least 90, or at least 95. Preferably, the Axl-expressing tumor has a Tumor Membrane P Score of at least 70, at least 75, at least 80, at least 85, at least 90, or at least 95.

[0355] In certain embodiments, the method further comprises administering a granulocyte colony-stimulating factor or an analog thereof.

[0356] In yet another embodiment, the pharmaceutically acceptable carrier has a pH of 6.0 and comprises 20 mM histidine-HCl, 70 mg / mL sucrose, and 0.5 mg / mL polysorbate 80.

[0357] In a further aspect, the present invention provides a method of treating an immune disorder (e.g., an autoimmune disorder), a cardiovascular disorder (e.g., atherosclerosis, hypertension, thrombosis), an infectious disease (e.g., Ebola virus, Marburg virus), or diabetes. In one such embodiment, the method further comprises administering to the individual an effective amount of at least one additional therapeutic agent described below. An "individual" according to any of the above embodiments may be a human.

[0358] In a further aspect, the invention provides methods for inhibiting angiogenesis, cell proliferation, immune function, secretion of inflammatory cytokines (e.g., from tumor-associated macrophages), tumor vasculature (e.g., intratumor or tumor-associated vasculature), and / or tumor stromal function in an individual. In one embodiment, the method comprises administering to the individual an effective amount of an anti-Axl antibody or antibody fragment to inhibit angiogenesis, inhibit cell proliferation, promote immune function, induce inflammatory cytokine secretion (e.g., from tumor-associated macrophages), inhibit tumor vasculature development (e.g., intratumor or tumor-associated vasculature), and / or inhibit tumor stromal function. In one embodiment, the "individual" is a human.

[0359] In a further aspect, the present invention provides pharmaceutical formulations comprising any of the anti-Axl antibodies or antibody fragments provided herein, e.g., for use in any of the above-described therapeutic methods. In one embodiment, the pharmaceutical formulation comprises any of the anti-Axl antibodies or antibody fragments provided herein and a pharmaceutically acceptable carrier. In another embodiment, the pharmaceutical formulation comprises any of the anti-Axl antibodies or antibody fragments provided herein and at least one additional therapeutic agent, e.g., as described below.

[0360] In each and every treatment described above, the antibody or antibody fragment of the present invention can be used alone, as an immunoconjugate, or in combination with other agents in the treatment. For example, the antibody of the present invention can be co-administered with at least one additional therapeutic agent. In certain embodiments, the additional therapeutic agent is an anti-angiogenic agent. In certain embodiments, the additional therapeutic agent is a VEGF antagonist (in some embodiments, an anti-VEGF antibody, e.g., bevacizumab). In certain embodiments, the additional therapeutic agent is an EGFR antagonist (in some embodiments, erlotinib). In certain embodiments, the additional therapeutic agent is a chemotherapeutic agent and / or a cytostatic agent. In certain embodiments, the additional therapeutic agent is a taxoid (e.g., paclitaxel) and / or a platinum agent (e.g., carboplatinum). In certain embodiments, the additional therapeutic agent is an agent that enhances the patient's immunity or immune system.

[0361] Such combination therapy as described above encompasses combined administration (wherein two or more therapeutic agents are contained in the same or separate formulations) as well as separate administration, where administration of the antibody or antibody fragment may occur prior to, concurrently with, and / or after administration of the additional therapeutic agent and / or adjuvant. The antibody or antibody fragment may also be combined with radiation therapy.

[0362] The antibody or antibody fragment can be formulated, dosed, and administered in a manner consistent with good medical practice. Factors to consider in this regard include the particular disorder being treated, the particular mammal being treated, the clinical condition of the individual patient, the cause of the disorder, the site of drug delivery, the method of administration, the scheduling of administration, and other factors known to physicians. The antibody or antibody fragment is optionally, but not necessarily, formulated with one or more agents currently used to prevent or treat the disorder in question. The effective amount of such other agents depends on the amount of antibody or antibody fragment present in the formulation, the type of disorder or treatment, and other factors discussed above. These are generally used in the same dosages and by any route of administration described herein, or at about 1-99% of the dosages described herein, or at any dosage and by any route determined empirically / clinically appropriate.

[0363] The appropriate dosage of an antibody or antibody fragment for disease prevention or treatment (when used alone or in combination with one or more other additional therapeutic agents) depends on the type of disease being treated, the type of antibody or antibody fragment, the severity and course of the disease, whether the antibody or antibody fragment is being administered for prophylactic or therapeutic purposes, previous therapies, the patient's medical history and response to the antibody or antibody fragment, and the discretion of the attending physician. The antibody or antibody fragment is suitably administered to the patient at one time or over a series of treatments. Depending on the type and severity of the disease, for example, about 1 μg / kg to 40 mg / kg of the antibody or antibody fragment may be an initial candidate dosage for administration to a patient, whether by one or more separate administrations or by continuous infusion. A typical daily dosage may range from about 1 μg / kg to 100 mg / kg or more, depending on the factors mentioned above. For repeated administration over several days or longer, depending on the condition, treatment will generally be sustained until a desired suppression of disease symptoms occurs. Such doses can be administered intermittently, for example, every week or every three weeks (e.g., the patient receives from about 2 to about 20, or, for example, about 6, doses of the antibody or antibody fragment). A higher initial loading dose, followed by one or more lower doses, can be administered. However, other dosage regimens may be useful. The progress of this therapy is easily monitored by conventional techniques and assays.

[0364] It will be understood that any of the above formulations or methods of treatment can be practiced using antibody fragments or immunoconjugates of the invention in place of, or in addition to, anti-Axl antibodies.

[0365] Improving host immune function to eradicate tumors is a topic of increasing interest. Conventional methods include (i) enhancing APCs, such as (a) injecting DNA encoding foreign MHC alloantigens into tumors, or (b) transfecting biopsied tumor cells with genes that increase the probability of tumor immune antigen recognition (e.g., immunostimulatory cytokines, GM-CSF, costimulatory molecules B7.1, B7.2), and (iii) adoptive cellular immunotherapy, or treatment with activated tumor-specific T cells. Adoptive cellular immunotherapy involves isolating tumor-infiltrating host T lymphocytes and expanding the population in vitro, for example, through stimulation with IL-2, tumor, or both. Furthermore, isolated dysfunctional T cells can also be activated by in vitro application of anti-PD-L1 antibodies. The activated T cells can then be readministered to the host. One or more of these methods can be used in combination with the administration of the antibody, antibody fragment, or immunoconjugate of the present invention.

[0366] Traditional therapies for cancer include: (i) radiation therapy (e.g., radiotherapy, X-ray therapy, irradiation), or the use of ionizing radiation to kill cancer cells and shrink tumors. Radiation therapy can be administered via external beam radiation therapy (EBRT) or internally via brachytherapy; (ii) chemotherapy, or the application of cytotoxic drugs that generally affect rapidly dividing cells; (iii) targeted therapy, or agents that specifically affect deregulated proteins in cancer cells (e.g., tyrosine kinase inhibitors imatinib, gefitinib; monoclonal antibodies, photodynamic therapy); (iv) immunotherapy, or enhancement of the host's immune response (e.g., vaccines); (v) hormone therapy, or hormone blockade (e.g., when the tumor is hormone-sensitive); (vi) angiogenesis inhibitors, or blocking blood vessel formation and growth; and (vii) palliative care, or treatments aimed at improving quality of care to reduce pain, nausea, vomiting, diarrhea, and bleeding. Analgesics such as morphine and oxycodone, and antiemetics such as ondansetron and aprepitant can allow for more aggressive treatment regimens.

[0367] In treating cancer, any of the conventional therapies previously described for the treatment of cancer immunity can be administered before, after, or simultaneously with the administration of the anti-Axl antibody or antibody fragment. Furthermore, the anti-Axl antibody or antibody fragment can be administered before, after, or simultaneously with the administration of conventional cancer therapies, such as tumor-binding antibodies (e.g., monoclonal antibodies, toxin-conjugated monoclonal antibodies) and / or chemotherapeutic agents. Dosing regimen

[0368] The present invention provides a dosing regimen for treating Axl-expressing tumors, comprising administering an anti-Axl antibody or antibody fragment of the present invention, or an immunoconjugate comprising the anti-Axl antibody or antibody fragment, as described herein, at a dose of about 0.3 mg / kg to about 2.0 mg / kg body weight, 0.4 mg / kg to about 1.8 mg / kg body weight, 0.5 mg / kg to about 1.8 mg / kg body weight, 0.6 mg / kg to about 1.8 mg / kg body weight, 0.7 mg / kg to about 1.8 mg / kg body weight, or 0.8 mg / kg to about 1.8 mg / kg body weight. The dosage regimen includes administering 0.9 mg / kg body weight to about 1.8 mg / kg body weight, 1.0 mg / kg body weight to about 1.8 mg / kg body weight, 1.1 mg / kg body weight to about 1.8 mg / kg body weight, 1.2 mg / kg body weight to about 1.3 mg / kg body weight, 0.7 mg / kg body weight to about 1.8 mg / kg body weight, 1.4 mg / kg body weight to about 1.8 mg / kg body weight, 1.5 mg / kg body weight to about 1.8 mg / kg body weight, 1.6 mg / kg body weight to about 1.8 mg / kg body weight, or 1.7 mg / kg body weight to about 1.8 mg / kg body weight for at least 2 weeks (e.g., 14 days) or 3 weeks (e.g., 21 days). More preferably, about 0.8 mg / kg body weight to about 1.8 mg / kg body weight is administered for at least 2 weeks (e.g., 14 days) or 3 weeks (e.g., 21 days). The weekly dose can be administered in a single weekly dose (once per week) or in divided doses (eg, two or more times per week).

[0369] In certain embodiments, the dosing regimen comprises administering 0.8 mg / kg to about 1.8 mg / kg body weight, 0.8 mg / kg to about 1.6 mg / kg body weight, 0.8 mg / kg to about 1.4 mg / kg body weight, 0.8 mg / kg to about 1.2 mg / kg body weight, or 0.8 mg / kg to about 1.0 mg / kg body weight for at least 2 weeks (e.g., 14 days) or 3 weeks (e.g., 21 days) of a weekly dose, which can be administered once a week (once a week) or in divided doses (e.g., two or more times a week).

[0370] In certain embodiments, the dosing regimen comprises administering an antibody-drug conjugate described herein at a dose of between about 0.3 mg / kg body weight and about 2.0 mg / kg body weight, 0.4 mg / kg body weight and about 1.8 mg / kg body weight, 0.5 mg / kg body weight and about 1.8 mg / kg body weight, 0.6 mg / kg body weight and about 1.8 mg / kg body weight, 0.7 mg / kg body weight and about 1.8 mg / kg body weight, 0.8 mg / kg body weight and about 1.8 mg / kg body weight, 0.9 mg / kg body weight and about This includes administering 1.8 mg / kg body weight, 1.0 mg / kg body weight to about 1.8 mg / kg body weight, 1.1 mg / kg body weight to about 1.8 mg / kg body weight, 1.2 mg / kg body weight to about 1.3 mg / kg body weight, 0.7 mg / kg body weight to about 1.8 mg / kg body weight, 1.4 mg / kg body weight to about 1.8 mg / kg body weight, 1.5 mg / kg body weight to about 1.8 mg / kg body weight, 1.6 mg / kg body weight to about 1.8 mg / kg body weight, or 1.7 mg / kg body weight to about 1.8 mg / kg body weight for at least 2 weeks (e.g., 14 days) or 3 weeks (e.g., 21 days). More preferably, about 0.8 mg / kg body weight to about 1.8 mg / kg body weight is administered for at least 2 weeks (e.g., 14 days) or 3 weeks (e.g., 21 days). The weekly dose can be administered in a single weekly dose (once per week) or in divided doses (eg, two or more times per week).

[0371] In some embodiments, the dosing regimen comprises administering an antibody-drug conjugate, as described herein, at 0.8 mg / kg to about 1.8 mg / kg body weight, 0.8 mg / kg to about 1.6 mg / kg body weight, 0.8 mg / kg to about 1.4 mg / kg body weight, 0.8 mg / kg to about 1.2 mg / kg body weight, or 0.8 mg / kg to about 1.0 mg / kg body weight for at least 2 weeks (e.g., 14 days) or 3 weeks (e.g., 21 days). The weekly dose can be administered weekly (once per week) or in divided doses (e.g., two or more times per week).

[0372] In certain embodiments, the weekly dose is administered as a divided dose or as a weekly dose for at least one two-week (e.g., 14-day) treatment cycle, or at least one three-week (e.g., 21-day) treatment cycle. In some embodiments, the dose is administered weekly on days 1 and 8 of a 14-day treatment cycle. Preferably, the weekly dose is administered as a divided dose or as a weekly dose for two or more 14-day treatment cycles, more preferably three or more, four or more, five or more, or even six or more treatment cycles. In some embodiments, the weekly dose is administered for no more than three, four or less, five or less, or six or fewer treatment cycles. In some embodiments, the dose is administered as a weekly dose on days 1 and 8 of a 21-day treatment cycle. Preferably, the weekly dose is administered as a divided dose or as a weekly dose for two or more 21-day treatment cycles, more preferably three or more, four or more, five or more, or even six or more treatment cycles. In some embodiments, the weekly dose is administered for no more than 3, no more than 4, no more than 5, or no more than 6 treatment cycles. Preferably, there are drug holidays between the treatment cycles.

[0373] For example, in some preferred embodiments, the administration regimen comprises administering the antibody-drug conjugate to a patient in a total weekly dose of about 0.3 mg / kg body weight to about 2.0 mg / kg body weight, 0.4 mg / kg body weight to about 1.8 mg / kg body weight, 0.5 mg / kg body weight to about 1.8 mg / kg body weight, 0.6 mg / kg body weight to about 1.8 mg / kg body weight, 0.7 mg / kg body weight to about 1.8 mg / kg body weight, 0.8 mg / kg body weight to about 1.8 mg / kg body weight, 0.9 mg / kg body weight to about The dose is 1.8 mg / kg body weight, 1.0 mg / kg body weight to about 1.8 mg / kg body weight, 1.1 mg / kg body weight to about 1.8 mg / kg body weight, 1.2 mg / kg body weight to about 1.3 mg / kg body weight, 0.7 mg / kg body weight to about 1.8 mg / kg body weight, 1.4 mg / kg body weight to about 1.8 mg / kg body weight, 1.5 mg / kg body weight to about 1.8 mg / kg body weight, 1.6 mg / kg body weight to about 1.8 mg / kg body weight, or 1.7 mg / kg body weight to about 1.8 mg / kg body weight, administered for at least 2 weeks (e.g., 14 days) or 3 weeks (e.g., 21 days). In some embodiments, the treatment cycle is 14 days or longer. In some embodiments, the treatment is 21 days or longer. The weekly dose can be administered weekly (once per week) or in divided doses (e.g., twice or more per week).

[0374] For example, in some preferred embodiments, the dosing regimen involves a total weekly dose of antibody-drug conjugate of about 0.8 mg / kg to about 1.8 mg / kg body weight, 0.8 mg / kg to about 1.6 mg / kg body weight, 0.8 mg / kg to about 1.4 mg / kg body weight, 0.8 mg / kg to about 1.2 mg / kg body weight, or 0.8 mg / kg to about 1.0 mg / kg body weight administered over at least two treatment cycles with a one-week rest period between each treatment cycle (e.g., six weekly doses over an eight-week period). In some embodiments, the treatment cycle will be 14 days or longer. In some embodiments, the treatment cycle will be 21 days or longer. The weekly dose can be administered weekly (once per week) or in divided doses (e.g., two or more times per week).

[0375] In some embodiments, the weekly dose of the antibody drug conjugate is about 0.8 mg / kg body weight administered as a single weekly administration (once per week) or in divided doses (e.g., two or more times per week). In some embodiments, the weekly dose of the antibody drug conjugate is about 0.9 mg / kg body weight administered as a single weekly administration (once per week) or in divided doses (e.g., two or more times per week). In some embodiments, the weekly dose of the antibody drug conjugate is about 1.0 mg / kg body weight administered as a single weekly administration (once per week) or in divided doses (e.g., two or more times per week). In some embodiments, the weekly dose of the antibody drug conjugate is about 1.1 mg / kg body weight administered as a single weekly administration (once per week) or in divided doses (e.g., two or more times per week). In some embodiments, the weekly dose of the antibody drug conjugate is about 1.2 mg / kg body weight administered as a single weekly administration (once per week) or in divided doses (e.g., two or more times per week). In some embodiments, the weekly dose of the antibody drug conjugate is about 1.3 mg / kg body weight administered as a weekly administration (once per week) or in divided doses (e.g., two or more times per week). In some embodiments, the weekly dose of the antibody drug conjugate is about 1.4 mg / kg body weight administered as a weekly administration (once per week) or in divided doses (e.g., two or more times per week). In some embodiments, the weekly dose of the antibody drug conjugate is about 1.5 mg / kg body weight administered as a weekly administration (once per week) or in divided doses (e.g., two or more times per week). In some embodiments, the weekly dose of the antibody drug conjugate is about 1.6 mg / kg body weight administered as a weekly administration (once per week) or in divided doses (e.g., two or more times per week). In some embodiments, the weekly dose of the antibody drug conjugate is about 1.7 mg / kg body weight administered as a weekly administration (once per week) or in divided doses (e.g., two or more times per week). In some embodiments, the weekly dose of the antibody drug conjugate is about 1.8 mg / kg body weight administered as a single weekly dose (once per week) or in divided doses (e.g., two or more times per week). In some embodiments, the weekly dose of the antibody drug conjugate will be 0.8, 0.9, 1, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, or 1.8 mg / kg of the subject's body weight.

[0376] A two-week (14-day) treatment cycle with a one-week rest period between treatment cycles can also be referred to as a three-week (21-day) treatment cycle, in which the antibody-drug conjugate is administered for two of the three weeks of the three-week treatment cycle. Similarly, a three-week (21-day) treatment cycle with a one-week rest period between treatment cycles can also be referred to as a four-week (28-day) treatment cycle, in which the antibody-drug conjugate is administered for three of the four weeks of the four-week treatment cycle. Thus, in some embodiments, a dose is administered weekly, either as a split dose or as a weekly administration, for two of the three weeks of a three-week treatment cycle, or a dose is administered weekly, either as a split dose or as a weekly administration, for three of the four weeks of a four-week treatment cycle. In some embodiments, a dose is administered weekly on days 1 and 8 of a 21-day treatment cycle, or a dose is administered weekly on days 1 and 8 of a 28-day treatment cycle. Preferably, the weekly dose is administered, either as divided doses or as a weekly administration, for two or more four-week treatment cycles, more preferably three or more, four or more, five or more, or even six or more four-week treatment cycles (e.g., 2, 3, 4, 5, or 6 consecutive treatment cycles). In some embodiments, the weekly dose is administered for no more than three, no more than four, no more than five, or no more than six treatment cycles. For example, in some preferred embodiments, the dosing regimen comprises administering, either as divided doses or as a weekly administration, a total weekly dose of about 0.8 mg / kg body weight to about 1.8 mg / kg body weight, 0.8 mg / kg body weight to about 1.6 mg / kg body weight, 0.8 mg / kg body weight to about 1.4 mg / kg body weight, 0.8 mg / kg body weight to about 1.2 mg / kg body weight, or 0.8 mg / kg body weight to about 1.0 mg / kg body weight of the antibody-drug conjugate, for two weeks out of three weeks, for at least two three-week treatment cycles.For example, in some preferred embodiments, the dosing regimen comprises a total weekly dose of about 0.8 mg / kg to about 1.8 mg / kg body weight, 0.8 mg / kg to about 1.6 mg / kg body weight, 0.8 mg / kg to about 1.4 mg / kg body weight, 0.8 mg / kg to about 1.2 mg / kg body weight, or 0.8 mg / kg to about 1.0 mg / kg body weight of the antibody-drug conjugate administered as divided doses or as a once-weekly dose, 3 weeks out of 4 weeks, for at least two 4-week treatment cycles.

[0377] In some preferred embodiments, the dosing regimen comprises a total weekly dose of about 0.8 mg / kg to about 1.8 mg / kg body weight, 0.8 mg / kg to about 1.6 mg / kg body weight, 0.8 mg / kg to about 1.4 mg / kg body weight, 0.8 mg / kg to about 1.2 mg / kg body weight, or 0.8 mg / kg to about 1.0 mg / kg body weight of the antibody-drug conjugate administered as divided doses or as a single weekly dose for 2 weeks out of 3 weeks, for 1 cycle, 2 cycles, 3 cycles, 4 cycles, or 5 4-week treatment cycles (e.g., 4 cycles of weekly administration over 6 weeks, 6 cycles of weekly administration over 9 weeks, or 8 cycles of weekly administration over 12 weeks).

[0378] In some preferred embodiments, the dosing regimen comprises a total weekly dose of about 0.8 mg / kg to about 1.8 mg / kg body weight, 0.8 mg / kg to about 1.6 mg / kg body weight, 0.8 mg / kg to about 1.4 mg / kg body weight, 0.8 mg / kg to about 1.2 mg / kg body weight, or 0.8 mg / kg to about 1.0 mg / kg body weight of the antibody-drug conjugate administered as divided doses or as a single weekly dose for 3 weeks out of 4 weeks, or for 1, 2, 3, 4, or 5 4-week treatment cycles (e.g., 6 cycles of weekly dosing over 8 weeks, 9 cycles of weekly dosing over 12 weeks, or 12 cycles of weekly dosing over 16 weeks).

[0379] After or during one or more treatment cycles (e.g., days 14-21 of the second treatment cycle or days 21-28 of the second treatment cycle), the subject can be evaluated (e.g., through clinical or diagnostic testing) to determine whether the subject should remain on the treatment schedule. For example, after or during one or more 28-day treatment cycles (e.g., 1, 2, 3, 4, 5, or 6 28-day treatment cycles), the subject can be evaluated (e.g., clinical and / or diagnostic evaluation). Depending on the evaluation, the subject can discontinue treatment, continue treatment for additional treatment cycles, or begin maintenance therapy. If the subject continues treatment, the subject can be further evaluated after one or more additional treatment cycles. Depending on the continued evaluation, the subject can discontinue treatment, continue treatment for additional treatment cycles, or begin maintenance therapy.

[0380] The present invention encompasses embodiments in which a subject remains on a weekly treatment cycle (e.g., a 2-week treatment cycle or a 3-week treatment cycle) after an evaluation indicating that the subject does not have detectable cancer, e.g., after a diagnostic test that is negative for a CD30-expressing cancer (i.e., the diagnostic test fails to detect cancer in the subject). For example, in some embodiments, the subject continues on a weekly treatment cycle for at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or more treatment cycles after such an evaluation. In some embodiments, the subject continues on a weekly treatment cycle for at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or more treatment cycles. Positron emission tomography (PET) is an example of a diagnostic test used to determine the presence and severity of cancer.

[0381] In some embodiments, a subject begins maintenance therapy after one or more, preferably two or more (e.g., 1, 2, 3, 4, 5, or 6) treatment cycles (e.g., 4-week treatment cycles). In some embodiments, a subject begins maintenance therapy after an evaluation indicating little or no detectable cancer, e.g., after an evaluation indicating the subject has experienced a complete response. As used herein, maintenance therapy refers to therapy in which the administration schedule of the antibody-drug conjugate is shortened and administered at the same or a different dosage. During maintenance therapy, the antibody-drug conjugate is preferably administered at least once per 2-week treatment period, once per 3-week treatment period, on days 1 and 8 of a 2-week treatment period, or on days 1 and 8 of a 3-week treatment period. After these maintenance therapy cycles, the subject can be further evaluated (e.g., by clinical or diagnostic tests) to determine whether the subject should continue maintenance therapy, continue their usual treatment, or discontinue treatment. In some embodiments, maintenance therapy is administered once every 2 to 4 weeks, or once every 3 to 6 weeks. The dose of the antibody-drug conjugate administered during maintenance therapy may be, for example, in the range of about 0.3 mg / kg to about 2.0 mg / kg body weight per administration, preferably about 0.6 mg / kg to about 1.8 mg / kg body weight, more preferably about 1.2 mg / kg to about 2.0 mg / kg body weight, and even more preferably about 1 mg / kg to about 1.8 mg / kg body weight, with 1.8 mg / kg being an exemplary dose.

[0382] In some embodiments, the evaluation is performed after completion of weekly treatment with an antibody-drug conjugate dose of about 0.8 mg / kg to about 1.8 mg / kg body weight, more preferably about 0.8 mg / kg to about 1.2 mg / kg body weight, in which case the subject begins maintenance therapy comprising administering the antibody-drug conjugate at a dose of about 0.3 mg / kg to about 2 mg / kg body weight, preferably about 0.6 mg / kg to about 1.8 mg / kg body weight, more preferably about 1.2 mg / kg to about 2.0 mg / kg body weight, even more preferably about 1 mg / kg to about 1.8 mg / kg body weight, or about 1.8 mg / kg, once every 2 to 4 weeks or once every 3 to 6 weeks. In some embodiments, after completing weekly treatment (e.g., 1, 2, 3, 4, or 5 treatment cycles), the subject begins a biweekly dosing schedule (e.g., treatment on day 1 of a 2-week maintenance therapy cycle), e.g., treatment on day 1 of a 2-week maintenance therapy cycle) and administers the antibody drug conjugate at a dose of about 0.4 mg / kg body weight to about 2 mg / kg body weight, about 0.6 mg / kg body weight to about 2.0 mg / kg body weight, or about 0.8 mg / kg body weight to about 1.8 mg / kg body weight (about 1.8 mg / kg is preferred). In some embodiments, after completing weekly treatment (e.g., 1, 2, 3, 4, or 5 treatment cycles), the subject begins a once every 3 weeks dosing schedule (e.g., treatment on day 1 of a 3-week maintenance therapy cycle), e.g., treatment on day 1 of a 2-week maintenance therapy cycle) and administers the antibody drug conjugate at a dose of about 0.4 mg / kg body weight to about 2 mg / kg body weight, about 0.6 mg / kg body weight to about 2.0 mg / kg body weight, or about 0.8 mg / kg body weight to about 1.8 mg / kg body weight (about 1.8 mg / kg is preferred).

[0383] The present invention relates to a method for treating a subject's disease, comprising administering a weekly dose of an antibody-drug conjugate to a subject in divided doses or once a week, for a total weekly dose of about 0.8 mg / kg to about 1.8 mg / kg of patient body weight, about 0.8 mg / kg to about 1.6 mg / kg of body weight, about 0.8 mg / kg to about 1.4 mg / kg of body weight, about 0.8 mg / kg to about 1.2 mg / kg of body weight, or about 0.8 mg / kg to about 1.0 mg / kg of body weight, every 2 to 4 weeks, preferably every 2 weeks, after 21-day administration cycles of 1, 2, 3, 4, 5, or 6 out of 3 weeks, and administering about 0.4 mg / kg to about 2 mg / kg of body weight, about 0.6 mg / kg to about 2.0 mg / kg of body weight, or about 0.8 mg / kg to about 1.8 mg / kg of body weight per dose, for two or more maintenance therapy cycles. In some embodiments, the weekly administration cycle results in 2, 3, 4, 5, 6, 7, 8, 9, or 10 or more treatment cycles, and the every two weeks administration schedule results in 2, 3, 4, 5, 6, 7, 8, 9, or 10 or more maintenance therapy cycles. In some embodiments, the weekly administration cycle results in 2, 3, 4, 5, or 6 or fewer treatment cycles.

[0384] The present invention relates to a method for treating a subject's disease, comprising administering a weekly dose of an antibody-drug conjugate, administered in divided doses or once weekly, for a total weekly dose of about 0.8 mg / kg to about 1.8 mg / kg patient body weight, about 0.8 mg / kg to about 1.6 mg / kg body weight, about 0.8 mg / kg to about 1.4 mg / kg body weight, about 0.8 mg / kg to about 1.2 mg / kg body weight, or about 0.8 mg / kg to about 1.0 mg / kg body weight, administered every 3 to 6 weeks, preferably every 2 weeks, after 1, 2, 3, 4, 5, or 6 28-day administration cycles for 3 weeks out of 4 weeks, at a dose of about 0.4 mg / kg to about 2 mg / kg body weight, about 0.6 mg / kg to about 2.0 mg / kg body weight, or about 0.8 mg / kg to about 1.8 mg / kg body weight per dose, for three or more maintenance therapy cycles. In some embodiments, the weekly dosing cycle results in 2, 3, 4, 5, 6, 7, 8, 9, or 10 or more treatment cycles, and the every three week dosing schedule results in 2, 3, 4, 5, 6, 7, 8, 9, or 10 or more maintenance therapy cycles. In some embodiments, the weekly dosing cycle results in 2, 3, 4, 5, or 6 or fewer treatment cycles.

[0385] The present invention encompasses embodiments in which a subject receives a weekly dose of an antibody-drug conjugate, administered as divided doses or as a single weekly dose, at a total weekly dose of about 0.8 mg / kg to about 1.8 mg / kg of the subject's body weight for one, two, three, four, five, or six 21-day treatment cycles, administered two weeks out of three (e.g., days 1 and 8 of a 21-day treatment cycle), followed by administration every two to four weeks thereafter. Preferably, the antibody-drug conjugate is administered at a dose of about 1.8 mg / kg body weight every two weeks for two or more maintenance therapy cycles (e.g., at a dose of about 1.8 mg / kg body weight every two weeks for two or more two-week maintenance therapy cycles). Preferably, the antibody-drug conjugate is administered at a dose of about 0.8 mg / kg body weight every two weeks for two or more maintenance therapy cycles (e.g., at a dose of about 0.8 mg / kg body weight every two weeks for two or more two-week maintenance therapy cycles).

[0386] The present invention encompasses embodiments in which a subject is administered an antibody-drug conjugate at a total dose of about 0.8 mg / kg to about 1.8 mg / kg of the subject's body weight once weekly, either as divided doses or as a weekly administration, for three weeks out of four (e.g., days 1 and 8 of a 28-day treatment cycle), for one, two, three, four, five, or six 28-day treatment cycles, followed by administration every three to six weeks. Preferably, the antibody-drug conjugate is administered at a dose of about 1.8 mg / kg body weight every three weeks for two or more maintenance therapy cycles (e.g., at a dose of about 1.8 mg / kg body weight every three weeks for two or more three-week maintenance therapy cycles). Preferably, the antibody-drug conjugate is administered at a dose of about 0.8 mg / kg body weight every three weeks for two or more maintenance therapy cycles (e.g., at a dose of about 0.8 mg / kg body weight every three weeks for two or more three-week maintenance therapy cycles).

[0387] The present invention relates to a method for treating a subject using the mAb BA301-cleavable linker-MMAE of the present invention. (n) This includes embodiments in which patients are being treated with an antibody drug conjugate, but on a schedule other than a once-weekly dosing regimen (e.g., an antibody drug conjugate at a dose of about 1.8 mg / kg body weight administered every two weeks for two or more week treatment cycles, or every three weeks for three or more week treatment cycles), and are switched to a once-weekly dosing regimen described herein for no more than one, two, three, four, five, or six treatment cycles. Following the once-weekly dosing regimen, patients can optionally begin maintenance therapy as described herein.

[0388] The antibody-drug conjugate is preferably administered as monotherapy. The term "monotherapy" means that the antibody-drug conjugate is the only anti-cancer agent administered to the subject during a treatment cycle. However, other therapeutic agents can also be administered to the subject as described herein, such as programmed death receptor-1 (PD-1) blocking antibodies, granulocyte colony-stimulating factor or analogs thereof, etc. Furthermore, anti-inflammatory or other agents can be administered to a cancer-bearing subject during monotherapy to treat symptoms associated with the cancer, rather than the underlying cancer itself, such as inflammation, pain, weight loss, and general fatigue. Preferably, subjects treated with the methods of the present invention have completed prior anti-cancer agent treatment before administering the anti-antibody drug conjugate. In some embodiments, the subject has completed prior anti-cancer agent treatment at least one week (preferably 2, 3, 4, 5, 6, 7, or 8 weeks) prior to treatment with the antibody-drug conjugate. The subject also preferably does not receive treatment with an additional anti-cancer agent for at least two weeks (preferably at least 3, 4, 5, 6, 7, or 8 weeks) after the end of the first treatment cycle with the antibody drug conjugate, preferably for at least two weeks (preferably at least 3, 4, 5, 6, 7, or 8 weeks) after the end of the final administration of the antibody drug conjugate. The methods of the invention include administering to a subject an anti-Axl antibody or antibody fragment of the invention, or an immunoconjugate comprising the anti-Axl antibody or antibody fragment, for treatment of an Axl-expressing tumor.

[0389] In some embodiments, an immunoconjugate comprising an anti-Axl antibody or antibody fragment of the invention is administered to a subject, and after the anti-Axl antibody binds to an Axl-expressing tumor cell, the antibody-drug conjugate is internalized within the cell and the drug is released. For example, the methods of the invention include administering to a subject an immunoconjugate comprising mAb BA3011-cleavable linker-MMAE for the treatment of an Axl-expressing tumor. (n) The method includes administering the antibody-drug conjugate, mAbBA3011-cleavable linker-MMAE, to the patient. (n)The antibody-drug conjugate is internalized into tumor cells, where the peptide linker is cleaved by a protease, releasing MMAE. By specifically delivering MMAE to Axl-expressing tumor cells, it is expected that further tumor cell proliferation will be suppressed and tumors will shrink.

[0390] The subject to be treated with the methods of the present invention is a subject who has been diagnosed with or is suspected of having an Axl-expressing cancer. Diagnosis can be made by methods known in the art, including, for example, tissue biopsy. Products and Kits

[0391] In another aspect of the present invention, an article of manufacture containing materials useful for the treatment, prevention, and / or diagnosis of the above-mentioned disorders is provided. The article of manufacture includes a container and a label or package insert on or associated with the container. Suitable containers include, for example, bottles, vials, syringes, intravenous infusion bags, etc. The container can be formed from a variety of materials, such as glass or plastic. The container holds the composition, either by itself or in combination with another composition effective for the treatment, prevention, and / or diagnosis of a condition, and can have a sterile access port (e.g., the container can be an intravenous infusion bag or a vial with a stopper pierceable by a hypodermic needle). At least one active agent in the composition is an antibody or antibody fragment of the present invention. The label or package insert indicates that the composition is used to treat the selected condition. Furthermore, the article of manufacture may include (a) a first container (in which the composition is contained, the composition including the antibody or antibody fragment), and (b) a second container (in which the composition is contained, the composition including an additional cytotoxic or other therapeutic agent). The article of manufacture in this embodiment of the invention may further include a package insert indicating that the composition can be used to treat a particular condition. Alternatively, or in addition, the article of manufacture may further include a second (or third) container containing a pharmaceutically acceptable buffer, such as bacteriostatic water for injection (BWFI), phosphate-buffered saline, Ringer's solution, and dextrose solution. It may further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, and syringes.

[0392] It is understood that any of the above products may contain an immunoconjugate of the invention in place of, or in addition to, an anti-Axl antibody.

[0393] Finally, the present invention also provides a kit comprising at least one antibody or antibody fragment of the present invention.Kits containing the polypeptides, antibodies or antibody fragments, or antibody-drug conjugates of the present invention are used in detecting Axl expression (increase or decrease) or in therapeutic or diagnostic assays.Kits of the present invention can include antibodies coupled to solid supports, such as tissue culture plates or beads (e.g., Sepharose beads).Kits containing antibodies for in vitro detection and quantification of Axl, for example, in ELISA or Western blot, can be provided.Such antibodies useful for detection can be provided with labels, such as fluorescent labels or radiolabels.

[0394] The kits further include instructions for their use. In some embodiments, the instructions include those required by the U.S. Food and Drug Administration for in vitro diagnostic kits. In some embodiments, the kits further include instructions for diagnosing the presence or absence of cerebrospinal fluid in a sample based on the presence or absence of Axl in the sample. In some embodiments, the kits include one or more antibodies or antibody fragments. In other embodiments, the kits further include one or more enzymes, enzyme inhibitors, or enzyme activators. In still other embodiments, the kits further include one or more chromatography compounds. In still other embodiments, the kits further include one or more compounds used to prepare samples for spectroscopic assays. In further embodiments, the kits further include a reference material for interpreting the presence or absence of Axl according to the intensity, color spectrum, or other physical attributes of the indicator. Cell membrane scoring of Axl in tumors (tumor membrane P score)

[0395] Axl is reactive in tumor cells and a subset of macrophages. In tumor cells, Axl is primarily localized to the cell membrane, but it can also be observed in the cytoplasm. Axl-expressing macrophages are often present between tumor cells / nests and within the stroma adjacent to the tumor (tumor-associated stroma or tumor stroma). Axl macrophage staining can be localized to the cell membrane or cytoplasm, but not all macrophages are labeled with Axl.

[0396] CD68 is expressed in the cytoplasm of macrophages and is the standard biomarker for identifying this immune cell type. Macrophages can be present throughout a tissue sample, but are most often noted between tumor cells (within the tumor mass) and at the tumor / stroma interface (tumor-associated stroma).

[0397] Because Axl is expressed in both tumor cells and macrophages, we use a scoring method to compare Axl and CD68 staining in serial sections of each sample. In this way, the CD68 biomarker is used to identify macrophages in tumors that are stained with Axl. That is, CD68 serial sections are used to distinguish Axl reactivity in tumor cells from macrophages. Using this method, Axl cell membrane staining is scored only in tumor cells. CD68 staining is "subtracted" from the Axl assessment to provide an Axl tumor score excluding macrophages (hereafter referred to as the "tumor membrane P score").

[0398] The approach used to score Axl and CD68 is described below. Axl and CD68 can be detected by methods including, but not limited to, immunohistochemistry (IHC) in formalin-fixed, paraffin-embedded (FFPE) tumor samples. Additionally, all samples were stained with hematoxylin and eosin (H&E) for morphological evaluation and scoring.

[0399] Axl cell membrane expression in tumors is scored semiquantitatively, with the primary scoring element being the percentage of cells stained with the appropriate differential intensity.

[0400] A percentage score is assigned to represent the penetration of cell membrane staining per sample. Percentages are estimated and reported in increments including, but not limited to, any of the following: 0, 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 96, 97, 98, 99, or 100%.

[0401] In certain embodiments of the invention, Axl-expressing tumors have a tumor membrane P-score of at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95%. Preferably, Axl-expressing tumors have a tumor membrane P-score of at least 70, at least 75, at least 80, at least 85, at least 90, or at least 95%.

[0402] Differences in the intensity of cell membrane staining are recorded using a 4-point semiquantitative scale (0, 1+, 2+, 3+), where 0 = null, negative, or nonspecific staining, 1+ = low or weak staining, 2+ = moderate or moderate staining, and 3+ = high or strong staining.

[0403] When assessing Axl reactivity in tumor cells only (Axl tumor staining excluding macrophages), consecutive slides stained with both Axl and CD68 (a macrophage biomarker) are required. Staining with CD68 is closely compared to staining with Axl in areas of the tumor. Cells staining with both Axl and CD68 are considered Axl-reactive macrophages (not tumor cells) and are excluded from the Axl score.

[0404] Axl staining in macrophages makes it difficult to score tumor cell membrane staining when positive cell types are intermingled. To fully understand tumor membrane Axl expression, excluding macrophages, by cancer indication, both standard percent score and H-score approaches can be used to capture the observed pattern of reactivity. Percentage Score Method

[0405] A percent score is calculated by summing the percentage of intensities that are ≥1+, ≥2+, or ≥3+, and therefore the score ranges from 0 to 100. Percent score ≥ 1+ = (% of 1+) + (% of 2+) + (% of 3+) Percent score ≥ 2+ = (% of 2+) + (% of 3+) Percent score ≥ 3+ = (% at 3+). H-score method

[0406] The H score is calculated by summing the percentage of cells with high expression intensity (brown staining) multiplied by the corresponding differential intensity on a 4-point semiquantitative scale (0, 1+, 2+, 3+). Thus, the score ranges from 0 to 300. H score = [(% of <1) x 0] + [(% of 1+) x 1] + [(% of 2+) x 2] + [(% of 3+) x 3] Scoring of macrophage staining - As mentioned above, CD68 is a standard biomarker for macrophages, and Axl can be expressed on this type of cell. - Using slides stained with CD68 and Axl, the relative abundance of CD68- and Axl-positive macrophages in each tumor tissue will be assessed. - Macrophages are estimated for CD68 and Axl positivity in the following areas: within the tumor mass (referred to as "tumor") and within the tumor-associated stroma or stroma interacting with the tumor (referred to as "tumor-stroma"). Tumor-stroma represents the soft tissue reaction to the tumor. Stromal reaction is outside or adjacent to the outer edge or "face" of the tumor mass. - In tumors, the percentage of cells in the tumor mass or tumor nests that are composed of CD68 or Axl-positive macrophages (0-100%) is scored. In the tumor stroma, macrophage abundance for Axl and CD68 was scored using a semiquantitative scale of 0–3, where 0 indicates no positive macrophages, 1 indicates a low density of positive macrophages, 2 indicates a moderate density of positive macrophages, and 3 indicates a high density of positive macrophages. Scoring Axl in tumor cytoplasm

[0407] The percentage of tumors showing diffuse Axl cytoplasmic staining (% positive cells) is estimated on a scale of 0–100%. The average intensity of such staining is estimated using a scale of 0–3, where 0 represents no cytoplasmic staining, 1 represents weak cytoplasmic staining, 2 represents moderate cytoplasmic staining, and 3 represents strong or high cytoplasmic staining.

[0408] - Strong Axl staining in the cytoplasm makes it difficult to discern potential membrane signals.

[0409] The following examples are illustrative, but not limiting, of the soft gelatin capsules of the present disclosure. Other suitable modifications and adaptations of a variety of conditions and parameters normally encountered in the art and obvious to those skilled in the art are within the scope of the present disclosure. [Example] Example 1: Conditionally active antibodies against Axl

[0410] Axl is a cell surface transmembrane tyrosine kinase with an extracellular domain accessible by conditionally active antibodies. This cell surface protein is highly expressed in thyroid cancer tissues and overexpressed in many other cancers, such as sarcoma, myeloproliferative disorders, prostate cancer cells, or breast cancer. Increased AXL expression is associated with tumor resistance to chemotherapy, programmed death-1 (PD-1) inhibitors, molecular targeted therapy, and radiation therapy. A conditionally active antibody against the extracellular domain of Axl protein has been developed herein.

[0411] A wild-type antibody against Axl (having the heavy chain variable region of 063-hum10F10-HC in Figure 1A and the light chain variable region of 063-hum10F10-HC in Figure 1B) was selected as the template antibody. DNA encoding the wild-type antibody was evolved using comprehensive positional evolution (CPE), a method that randomizes each position in the template antibody one at a time, to generate a mutant antibody library. Each mutant antibody in the library has only one single point mutation. The mutant antibodies in the library were generated by simultaneous screening for preferential binding affinity to Axl at pH 6.0 compared to pH 7.4, as measured by ELISA.

[0412] Simultaneously, the expression level of the mutant antibodies was optimized for higher field applications in the manufacturing process. Screening was performed in serum using the FLAG tag because of the presence of human antibodies in serum, which could cause false-positive results. The screening buffer was carbonate buffer (Krebs buffer with ringers—a standard buffer, different from PBS). The generated conditionally active antibodies were found to have higher affinity for Axl at pH 6.0 but lower affinity for Axl at pH 7.4 compared to the wild-type antibody. Some of the selected mutant antibodies (scFv) are shown in Figure 2. While activity was higher at pH 6.0 than at pH 7.4, the activity ratio between pH 6.0 and pH 7.4 was at least 11-fold (Figure 3).

[0413] Furthermore, all of these conditionally active activities have high expression levels as shown in Table 4 below, where the column "Clone" indicates the antibody and the expression level "mg / ml" is shown in the second column.

[0414] These antibody clones were sent to the service provider at the required expression levels ("order amount", expected expression level). However, the actual expression levels of these antibodies ("delivered amount") were significantly higher than the expected expression levels. [Table 4]

[0415] The conditionally active antibody showed no aggregation in buffer, as demonstrated in Figure 4 using the BAP063.9-13-1 antibody as a template. The BAP063.9-13-1 antibody was analyzed by size exclusion chromatography. In Figure 4, only one peak was detected, demonstrating that the antibody exhibited little or no aggregation.

[0416] The conditionally active antibodies were also assayed using surface plasmon resonance (SPR) to measure the on- and off-rates for Axl. SPR assays are known to measure the on- and off-rates for conditionally active antibodies. SPR assays were performed in the presence of bicarbonate. The in vivo on- and off-rates (in animals and humans) of conditionally active antibodies are critical characteristics for conditionally active antibodies.

[0417] The conditionally active antibodies were observed to have higher binding affinity at pH 6.0 and lower binding affinity at pH 7.4 compared to the negative control (BAP063 10F10, which has similar binding affinity at both pH 6.0 and pH 7.4) (Figure 5). Furthermore, increasing the temperature from room temperature to 60°C did not significantly alter the ELISA assay results (Figure 5). The ELISA assay also showed that these conditionally active antibodies were highly selective at pH 6.0 compared to pH 7.4 (Figures 6A-6B show one antibody as an example).

[0418] The conditionally active biological antibodies are summarized in Table 5. Two of these antibodies were expressed as scFvs (BAP063.9-13.3 and BAP063.9-48.3). Incubation of the antibodies at 60°C for 1 hour did not change the affinity of most of the antibodies ("thermostability").

[0419] Conditionally active antibodies can be used according to the present invention to detect Axl protein on the surface of CTCs. [Table 5] Example 2: pH-dependent binding affinity of anti-Axl antibodies

[0420] Some of the anti-Axl antibodies of the present invention were tested in buffers at different pH levels. One type of buffer was KREBS buffer containing 1% bovine serum albumin (BSA). The KREBS buffer was titrated to have a pH ranging from 5 to 7.4. The binding affinity of the antibodies for Axl was measured using an ELISA assay (OD450), and the results are presented in Figure 7. Two control antibodies (BAP063-3831 and BAP063-3818) were not conditionally active because their binding affinity was not significantly affected by changes in pH. On the other hand, the anti-Axl antibodies of the present invention were conditionally active because their binding affinity for Axl was pH-dependent (Figure 7). Example 3: Cell killing by anti-Axl antibodies

[0421] The cell-killing activity of the anti-Axl antibodies of the present invention was tested using A549 cells. The results are shown in Figures 8A-8E. The cell-killing activity was measured at two pH levels: 6.0 and 7.4, representing the pH in the tumor microenvironment and normal physiological pH, respectively. The percentage of cell killing at various antibody concentrations is shown in Figures 8A-8E.

[0422] The two tests yielded consistent cell-killing results. The negative control (anti-Axl humanized WT) showed similar cell-killing activity at pH 6.0 and pH 7.4 for A549 cells (Figure 8A). In contrast, the anti-Axl antibodies of the present invention showed significantly higher cell-killing activity at pH 6.0 compared to pH 7.4, particularly at low antibody concentrations where the antibody did not saturate A549 cells (Figures 8B-8E). Example 4: Binding affinity of anti-Axl antibodies to cyno-Axl

[0423] The binding affinity of the anti-Axl antibodies of the present invention to cyno-Axl was measured and compared with that of human Axl (hAxl) in two different buffers at pH 6.0 and 7.4. The results are shown in Figures 9A-9D. Cyno-Axl is an Axl protein from a non-human primate, i.e., the cynomolgus macaque.

[0424] The control (BA-3831-WT) showed similar binding affinity to both human Axl (hAxl) and cynomolgus monkey Axl (cyno-Axl) at both pH 6.0 and 7.4 in the two buffers (Figure 9A). The anti-Axl antibodies of the present invention showed similar binding affinity profiles for hAxl and cyno-Axl in one of the two buffers, i.e., lower binding affinity to cyno-Axl at pH 7.4 compared to pH 6.0 (Figures 9B-9D). The difference in binding affinity between pH 6.0 and pH 7.0 in the other buffer was not significant. Example 5: Cytotoxicity of anti-Axl antibodies conjugated to duomycin

[0425] Duomycin is cytotoxic because it inhibits cell growth by halting protein synthesis. One of the anti-Axl antibodies of the present invention, BAP063.9 4007, was conjugated to duomycin. Two control antibodies, BAP063humWT and B12 (anti-B12 antibody), were used in this study, both of which were also conjugated to duomycin.

[0426] Several cell lines were treated with three duomycin-conjugated antibodies (BAP063.9 4007, BAP063humWT, and B12) at pH 6.0 and 7.4 (Figures 10A-10H). The duomycin-conjugated antibody BAP063.9 4007 of the present invention exhibited significantly higher cytotoxicity against the cell lines DU145 (prostate cancer cells), MDA-MD-231 (breast cancer cells), PL45 (pancreatic cancer cells), and A549 (adenocarcinoma cells) at pH 6.0 compared to the cytotoxicity against the same cells at pH 7.4. Example 6: Anti-Axl antibodies conjugated to model toxins

[0427] The anti-Axl antibodies of the present invention were conjugated to a model toxin (e.g., gemcitabine) to produce conditionally active antibody-drug conjugates (CAB-Axl-ADCs). The CAB-Axl-ADCs were first tested to confirm that their conditional cell-killing activity was not altered by the drug conjugation process. This test showed that the CAB-Axl-ADCs killed significantly more cells at pH 6.0 than at pH 7.4 (Figure 11).

[0428] The CAB-Axl-ADC was then injected into mice bearing MiaPaCa2 xenograft tumors at a dose of 1 mg / kg twice a week for 3 weeks. Several controls were used in this study, including naked CAB (anti-Axl antibody without conjugation), vehicle, toxin alone (unconjugated gemcitabine), control ADC, and affinity-matched anti-Axl ADC (AM ADC). The study showed that CAB-Axl-ADC (CAB ADC) and AM ADC provided significantly greater tumor size reduction compared to the control (Figure 12). Unconjugated anti-Axl antibody did not reduce tumor size. This study showed that anti-Axl antibodies conjugated to toxins were as effective as affinity-matched antibodies in reducing tumor size. Example 7: Serum concentrations of anti-Axl antibody drug conjugates in cynomolgus macaques

[0429] The anti-Axl antibody drug (duomycin) conjugate (CAB-ADC) of the present invention was injected into male and female cynomolgus macaques at three doses: 0.1, 1, and 10 mg / kg. Naked anti-Axl antibody was used as a control. An affinity-matched antibody drug conjugate (AM-ADC) was also used as a control. Serum concentrations of the antibody were measured over a one-week period (168 hours, see Figures 13A-13B). The CAB-ADC persisted in monkey serum longer than the AM-ADC control (Figure 13B). There was no significant difference between male and female monkeys (Figures 13A-13B). Example 8: Toxicity of anti-Axl antibody drug conjugates in cynomolgus macaques

[0430] The toxicity of the CAB-ADC of the present invention was tested in cynomolgus macaques. Aspartate transaminase (AST) and alanine transaminase (ALT) are used by the Food and Drug Administration (FDA) as indicators of drug liver toxicity. Serum AST and ALT levels were measured in both male and female monkeys (Figures 14A-14B). Three days after administration of 10 mg / kg, vehicle (PBS) did not alter serum AST or ALT levels, while the matched antibody-drug conjugate (AM) showed significantly elevated AST and ALT levels. The CAB-ADC showed significantly reduced AST and ALT levels compared with the AM control. This indicated that the anti-Axl antibody-drug conjugate of the present invention has significantly reduced liver toxicity compared with the matched antibody-drug conjugate AM.

[0431] The anti-Axl antibody-drug conjugate of the present invention was also found to cause less inflammation in monkeys (Figure 15). The lymphocyte counts in the blood of monkeys after injection of CAB, AM, and PBS were summarized. Compared to AM, which caused significant inflammation, the anti-Axl antibody-drug conjugate of the present invention (CAB-ADC) caused only mild inflammation in monkeys. Example 9: In vivo experiments in mice

[0432] Mice were implanted with one of two tumor cell lines (LCLC103H or DU145) that developed into tumors. Tumor size was measured after treatment with the antitumor drug monomethyl auristatin E (MMAE). For mice that received LCLC103H, mice were treated with a single dose of vehicle (as a negative control), CAB anti-Axl antibody conjugated MMAE ADC (CAB Axl-MMAE), or non-CAB anti-Axl antibody conjugated MMAE ADCC (non-CAB Axl-MMAE) (Figure 16A). Tumors in mice treated with ADC shrank, while tumors in mice treated with vehicle continued to grow.

[0433] Additionally, mice receiving DU145 were treated with vehicle (negative control) or CAB anti-Axl antibody conjugated MMAE ADC (CAB Axl-MMAE) at two different concentrations (6 mg / kg and 10 mg / kg). Tumor volume was measured over time. Tumors continued to grow in the negative control group (vehicle), whereas tumor growth slowed in mice treated with the ADC (Figure 16B). Example 10: Tumor Membrane P Score procedure

[0434] For immunohistochemical (IHC) staining of Axl (a cell surface receptor tyrosine kinase), Lifespan Biosciences monoclonal Mouse IgG clone 7E10 (Cat # LS-B6124) was used for the detection of Axl in formalin-fixed, paraffin-embedded (FFPE) tissues.

[0435] For IHC staining of CD68, a standard mouse monoclonal antibody (clone KP1) from Dako (Cat # M0814) was used to detect macrophages (Table 13). The IHC procedure was performed using the TechMate staining platform with the following protocol:

[0436] Step 1: FFPE tissue blocks were sectioned at 4-5 μm thickness and mounted on positively charged capillary gap slides. Slides were baked (60°C, dry heat) before use. Slide preparation

[0437] A microtomy was performed, and four to five micron (4-5 μm) sections were mounted on Fisher Biotech 22-230-900 Probe-On Plus microscope slides.

[0438] b. Bake the slides at 60°C (dry heat) for at least 1 hour and cool at room temperature for at least 15 minutes before beginning step 2.

[0439] Step 2: Tissue sections are dewaxed using organic solvents (xylene, 100%, 4 times) and then passed through a descending alcohol series (100%, 70%, 30% ethanol) to distilled water to ensure adequate tissue hydration and proper binding of primary antibodies and other detection reagents. Dewaxing / antigen pre-acquisition a. Four changes of room temperature (25°C) anhydrous xylene for 5 minutes each [do not stir]. b. Add two changes of room temperature (25°C) absolute alcohol for 2 minutes each [do not stir]. c. Two changes of 70% alcohol at room temperature (25°C) for 2 minutes each [do not agitate]. d. Apply two changes of 30% alcohol at room temperature (25°C) for 2 minutes each [do not agitate]. e. Rinse with two changes of room temperature (25°C) distilled water [a minimum of 16 in-out dips]. f. Slides immersed in distilled water at room temperature (25°C) (proceed to antigen capture)

[0440] Step 3: After dewaxing the tissue sections, antigen retrieval was performed using a steam heat-induced epitope retrieval (SHIER) solution drawn into the capillary gap formed between paired microscope slides using a commercially available steamer (≥97°C for 20 minutes) as the heat source (see Ladner et al., Cancer Res. 60:3493-3503, 2000, for a description). Steam Heat Antigen Acquisition a. Preheat the commercial steamer to over 98°C. b. Heat-induced antigen / epitope retrieval (Black & Decker HS1000 steamer or equivalent) was performed using SHIER 2 (Dako S1700, citric acid-based, pH 6.0-6.2) for Axl and SHIER 1 (QualTek, citric acid-based, pH 5.6-6.1) for CD68 at 98°C for ≥20 min. Up to 10 slides were placed in a TechMate reagent tray containing exactly 10 mL of antigen / epitope retrieval solution, paired with a clean blank slide, and the reagent was drawn up onto the tissue with a capillary. c. After collection, allow to cool for 5 minutes, then insert the slide pair firmly into the TechMate slide holder and drain the SHIER 1 / SHIER 2 with an absorbent wick pad. d. Wash twice manually using capillary action (drain draw) with Tris-buffered saline containing 0.02% v / v Tween-20 detergent (TBST, prepared by QualTek as a 20X stock solution per SOP MFB003 and used as a 1X solution after dilution with distilled / deionized water [store at 4°C]).

[0441] Step 4: Samples were subjected to IHC analysis using the TechMate instrument platform and the MIP program (without enzyme digestion) or the MIPE program (with digestion with 1:40 dilution of Proteinase K) according to the general procedure outlined in Table 6. Sequential antibody detection is employed in IHC with high specificity for the antigen or primary antibody. The location of the primary antibody is finally visualized by application of a colorimetric dye (DAB), which precipitates an insoluble reaction product at the antigen site in the presence of horseradish peroxidase (HRP). To evaluate cell and tissue morphology, hematoxylin (blue stain) is used to counterstain the nuclei. [Table 6] immunohistochemistry

[0442] Mouse Polink2+HRP reagent (Golden Bridge International [GBI]; Cat #: D37-110) is stored at 2-8°C for ready use, and all following steps are automated at room temperature (25°C) on a TechMate running the QualTek MIPE Procedure. Reagent exchange (washing, incubation) is performed by capillary action (drain-draw) using a highly absorbent wick pad (drain) and TechMate reagent tray (draw). a. Wash three times with TBST. b. TBST for Axl and Proteinase K digestion for CD68 (1:40 dilution, Dako, Cat #:S3020) 10 min. c. Wash three times with TBST. d. Goat Blocking Reagent (QML), 15 min e. Wash once with TBST. f. Axl (1:1500) antibody clone 7E10 (LifeSpan BioSciences Cat #: LS-B6124) or CD68 (1:7500) antibody clone KP1 (Dako Cat #: M0814), freshly diluted from a 1:10 working stock (kept at 4°C, also in RMB) in QualTek Reagent Manufacturing Buffer (RMB: 0.01M phosphate, 0.151M NaCl, 1% w / v BSA, 0.1% v / v ProClin 300, 0.2% v / v Tween-20, 1% v / v normal goat serum, pH 7.2, formulated by QualTek per SOP MFB002) for 1 hour. g. Wash five times with TBST. h. Mouse Polink2+ Secondary (part of GBI kit Cat #: D37-110), 25 minutes. i. Wash twice with TBST wash buffer. j. Peroxidase block (3% USP HO, ~0.02% v / v Tween-20), 3X 2.5 min (7.5 min total), with time to drain the reagent. k. Wash three times with TBST. l. Mouse Polink2+ HRP conjugated polymer (part of GBI Kit Cat #: D37-110), 25 min Wash 5 times with m.TBST. n.GBI (Cat#.C09-12) DAB Chromogen (reagent made fresh at the end of polymer incubation using 40 μl of DAB Chromogen concentrate per 1 mL of provided substrate buffer), 3 times for 5 minutes (15 minutes total), with one TBST wash in between and draining the reagent. Wash 4 times with TBST p. Hematoxylin counterstain (1:5), 1 min q. Wash six times with TBST. r. Immerse the slide in distilled water at room temperature (25°C) (transfer to the cover slip section).

[0443] Step 5: Slides were unpaired, washed in distilled water, dehydrated in an alcohol series (70%, 95%, 100% ethanol) and organic solvents (xylene, 100%, 4 changes), and permanently covered with CytoSeal (or equivalent) for interpretation and storage. Slides were examined under a microscope and staining was assessed.

[0444] To unmask the Axl epitope in FFPE tissue, we used SHIER 2 (citrate-based, pH 6.0-6.2) solution. To unmask the CD68 epitope, we used SHIER 1 (citrate-based, pH 5.6-6.1) solution. After heat-induced epitope retrieval, the process was automated using a TechMate Instrument (Roche Diagnostics) running QML workmate software v3.96. This automated platform uses a capillary gap process to perform all reagent exchanges, including counterstains, with buffer washes between. All steps were performed at room temperature (25°C).

[0445] Working dilutions of primary and negative control antibodies were prepared using Reagent Manufacturing Buffer with Goat Serum [RMB; QualTek's Santa Barbara lab (QML-SB)]. Target recognition of Axl and CD68 at the antigen-primary antibody interaction site on FFPE sections was performed using reagents from the GBI Labs Polink-2 Plu...

Claims

1. A pharmaceutical composition for treating an Axl-expressing tumor, comprising: The pharmaceutical composition comprises mAbBA301-cleavable linker-MMAE as an active ingredient. n and a pharma- ceutically acceptable carrier, The pharmaceutical composition is adapted to provide, via intravenous infusion, a dosage of the active ingredient of 1.8 mg / kg of body weight of a human subject; mAbBA301 is an antibody or antibody fragment having a heavy chain variable region comprising hcCDR1 of SEQ ID NO: 14, hcCDR2 of SEQ ID NO: 15, and hcCDR3 of SEQ ID NO: 16, and a light chain variable region comprising lcCDR1 of SEQ ID NO: 17, lcCDR2 of SEQ ID NO: 18, and lcCDR3 of SEQ ID NO: 19; A pharmaceutical composition, wherein n is an integer from 1 to 4, inclusive.

2. 2. The pharmaceutical composition of claim 1, wherein the heavy chain variable region comprises SEQ ID NO:20 and the light chain variable region comprises SEQ ID NO:

21.

3. The pharmaceutical composition of claim 1, wherein the cleavable linker is mc-vc-PAB.

4. The pharmaceutical composition according to any one of claims 1 to 3, wherein the Axl-expressing tumor is a sarcoma, an adenocarcinoma, or a non-small cell lung cancer.

5. The pharmaceutical composition of claim 4, wherein the Axl-expressing tumor is a sarcoma.

6. The pharmaceutical composition of any one of claims 1 to 3, which is administered in combination with a programmed death receptor-1 (PD-1) blocking antibody.

7. The pharmaceutical composition of any one of claims 1 to 3, wherein the Axl-expressing tumor has a tumor membrane P score of at least 50, at least 55, at least 60, at least 65, at least 70, at least 75, at least 80, at least 85, at least 90, or at least 95.

8. The pharmaceutical composition of claim 7 , wherein the Axl-expressing tumor has a tumor membrane P score of at least 70.

9. The pharmaceutical composition according to any one of claims 1 to 3, which is administered in combination with a granulocyte colony-stimulating factor or an analog thereof.

10. 4. The pharmaceutical composition of claim 1, wherein the pharma- ceutically acceptable carrier is at pH 6.0 and comprises 20 mM histidine-HCl, 70 mg / mL sucrose, and 0.5 mg / mL polysorbate 80.

11. The pharmaceutical composition according to any one of claims 1 to 3, wherein n is 4.

12. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is prepared as a liquid formulation for intravenous administration.

13. The pharmaceutical composition of claim 6, wherein the sarcoma is an advanced sarcoma having a baseline tumor membrane P score of at least 70.

14. mAbBA301-cleavable linker-MMAE in the manufacture of a medicament for treating Axl-expressing tumors n and a pharma- ceutically acceptable carrier, said medicament adapted to provide, by intravenous infusion, a dose of mAbBA301-cleavable linker-MMAE n of 1.8 mg / kg of body weight of a human subject; mAbBA301 is an antibody or antibody fragment having a heavy chain variable region comprising hcCDR1 of SEQ ID NO: 14, hcCDR2 of SEQ ID NO: 15, and hcCDR3 of SEQ ID NO: 16, and a light chain variable region comprising lcCDR1 of SEQ ID NO: 17, lcCDR2 of SEQ ID NO: 18, and lcCDR3 of SEQ ID NO: 19; n is an integer from 1 to 4, inclusive.

15. 15. The use according to claim 14, wherein the heavy chain variable region comprises SEQ ID NO: 20 and the light chain variable region comprises SEQ ID NO:

21.

16. The use according to claim 14, wherein the cleavable linker is mc-vc-PAB.

17. The use according to any one of claims 14 to 16, wherein the Axl-expressing tumor is a sarcoma, an adenocarcinoma, or a non-small cell lung cancer.

18. The use according to claim 17, wherein the Axl-expressing tumor is a sarcoma.

19. The use of any one of claims 14 to 16, wherein the medicament is administered in combination with a programmed death receptor-1 (PD-1) blocking antibody.

20. The use according to any one of claims 14 to 16, wherein the Axl-expressing tumor has a tumor membrane P-score of at least 50, at least 55, at least 60, at least 65, at least 70, at least 75, at least 80, at least 85, at least 90, or at least 95.

21. The use of claim 19, wherein the Axl-expressing tumor has a tumor membrane P score of at least 70.

22. The use of any one of claims 14 to 16, wherein the medicament is administered in combination with a granulocyte colony-stimulating factor or an analogue thereof.

23. 17. The use according to any one of claims 14 to 16, wherein the pharma- ceutically acceptable carrier is at pH 6.0 and comprises 20 mM histidine-HCl, 70 mg / mL sucrose and 0.5 mg / mL polysorbate 80.

24. The use according to any one of claims 14 to 16, wherein n is 4.